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Abstract 
The long accepted model for tumor necrosis factor receptor (TNFR) 
signaling is that ligand binding causes receptors to trimerize, resulting in a 
stoichiometric change in their cytosolic domains. This model is incomplete in that 
it does not explain the importance of receptor self-interaction nor ligand/receptor 
network formation. Here, we introduce evidence for a novel TNFR activation 
mechanism based on network-induced conformational change in the receptor 
extracellular domain, which propagates through the transmembrane helices to 
bring about reorganization of the death domains. 
First, we use normal mode analysis to suggest a mechanism whereby 
ligand binding induces a conformational change in the TNFR1 extracellular domain 
which propagates through the membrane to the cytosolic domain. We validate this 
experimentally by measuring FRET using fluorophore tagged TNFR1 chimeras. 
We then characterize a scissors-like open-to-closed transition in the disulfide-
linked death receptor 5 (DR5) transmembrane dimer that couples the extracellular 
and cytosolic conformational changes. Using quantitative confocal image analysis, 
we show that DR5 ligand/receptor networks form in both the absence and 
presence of membrane cholesterol, but in the absence of cholesterol fail to induce 
signaling. These networks differ in that they do not contain disulfide-linked DR5 
dimers and we run molecular simulations to offer an explanation. We then show 
that oxidation strengthens the methionine-aromatic interaction, a highly stabilizing 
motif found in many proteins including TNFR1 and DR5, using biophysical, 
  vi 
computational, and cell biological techniques. Lastly, we introduce mutations to the 
TNFR1 pre-ligand assembly domain to reduce its dimerization affinity and show 
that ligand binding does not directly depend on receptor self-association. Future 
work will determine the functional relevance of receptor dimerization and whether 
dimer dissociation can be exploited as a mechanism for TNFR1 signaling 
blockade. In summary, our results support a novel mechanism of TNFR activation 
that will guide the discovery and development of novel therapeutics for 
inflammatory disease and cancer. 
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Chapter 1 – Introduction 
1.1. The TNFR superfamily 
The tumor necrosis factor (TNF) superfamily is a family of ~19 structurally 
related cytokines that carry out cell signaling by binding to one or more of the ~29 
members of the TNF receptor (TNFR) superfamily (1). TNFs share a high degree 
of structural homology, but variable sequence, which allows them to target 
receptors with high affinity and specificity. TNFRs are type-I transmembrane 
proteins that mediate signal transduction for a wide range of processes including 
apoptosis (2), inflammation (3), cell survival (4), and lymphoid development (5). 
Commensurate with their role in normal signaling, TNFRs have also been 
implicated in a number of ailments, especially inflammatory diseases, infections, 
and cancer (6). 
The unifying feature of the TNFR superfamily is an extracellular domain 
(ECD) consisting of 2 or more cysteine-rich domains (CRDs), which is responsible 
for binding to protein ligands (7). Each CRD is held together by pairs of disulfide-
linked cysteines, which ascend the elongated TNFR structure like rungs of a ladder 
(8). CRDs are numbered from the N-terminus so that CRD1 is the furthest from the 
membrane followed by CRD2, CRD3, and so on, leading to the transmembrane 
domain, a single-pass α-helix that joins the ECD to the cytosolic domain. The 
presence of a death domain further classifies certain TNFRs as death receptors, 
although they do not necessarily mediate cell death. The death domain is a 
cytosolic region of approximately 80 residues that recruits intracellular adapter 
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proteins through their own death domains upon receptor activation to transduce 
further downstream signaling (9). Another group of TNFRs, named decoy 
receptors, are either secreted or membrane anchored and do not contain 
functional cytosolic domains. These modulate TNFR signaling by sequestering 
free ligand (10). The remaining members of the TNFR superfamily mediate 
signaling, though not through death domain interactions. 
This chapter serves as an introduction to two death receptors, TNFR1 and 
DR5, which are the focus of this dissertation. These are selected because 1 – they 
are prime pharmaceutical targets for modulating inflammatory and apoptotic 
signaling, respectively, 2 – their structures are well studied and characterized, 3 – 
they both demonstrate ligand-independent self-assembly, 4 – their ligand-bound 
structures are highly similar, and 5 – they both demonstrate ligand/receptor 
clustering. These elements are critical for motivating and enabling our investigation 
of the conformational dynamics of death receptors upon activation using available 
experimental and computational, biophysical, and cell biological techniques. 
1.2. TNFR1 signaling 
TNFR1 is the ubiquitously expressed (11) prototypical member of the TNFR 
superfamily (12). The default signaling pathway of TNFR1 is pro-inflammatory and 
pro-survival (13). It is activated by either of two soluble ligands, TNF (TNFα) or 
lymphotoxin-α (LTα, also known as TNFβ) which it binds with similar affinity and to 
the same effect (14, 15). Both ligands also bind to TNFR2. TNF is expressed on 
activated macrophages and lymphocytes as a type-II transmembrane protein 
before it is proteolytically cleaved to produce a soluble cytokine. Before it is 
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cleaved, membrane bound TNF also complements soluble TNF to generate 
diverse responses in both the receptor and ligand presenting cells (via outside-in 
and inside-out signaling, respectively) by binding to either TNFR1 or TNFR2 (16).  
Likewise, LTα, although a soluble protein per se, heterotrimerizes with the type-II 
transmembrane protein, LTβ, similarly expanding its range of functions (17, 18). 
The receptor conformational dynamics that lead to signaling underlie each element 
of this complex system. For the sake of this dissertation, we consider the default 
ligand/receptor signaling pathways in model experimental systems, absent 
confounding effects that may occur in situ. 
When it is activated, TNFR1 recruits adapter proteins to its cytosolic death 
domain to form a signaling complex. The death domain first sheds the inhibitory 
silencer of death domain (SODD), then binds TNFR associated death domain 
(TRADD) to the newly exposed binding interface (19). TRADD in turn binds to 
receptor interacting protein (RIP) (20) and TNFR-associated factor 2 (TRAF2) (21). 
The IKK complex then joins the signaling complex through TRAF2, is activated by 
RIP, then goes on to phosphorylate inhibitor of κBα (IκBα) (21, 22). Intact IκBα 
binds to the transcription factor, nuclear factor κB (NF-κB) and prevents it from 
entering the nucleus. When IκBα is phosphorylated and degraded (23), NF-κB is 
permitted to enter the nucleus where it binds directly to the genome and initiates 
inflammatory, pro-survival gene transcription (24). Intact IκBα can be easily 
detected by Western blot analysis, therefore IκBα degradation is commonly 
measured to monitor TNFR1 activation. Alternatively, TNFR1 mediated gene 
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transcription can be assessed quantitatively using a reporter plasmid with an NF-
κB response element. 
In certain conditions, including in some cancer cells (25), TNFR1 mediates 
caspase-dependent apoptosis. Instead of TRADD binding RIP and TRAF2, it 
recruits FAS-associated death domain (FADD) and caspase-8, which activates 
caspase-3 to trigger apoptosis (11). Because of its ability to induce apoptosis and 
true to its moniker, TNF was originally touted as a potential anti-cancer cytokine 
(26). Unfortunately, side effects due to the pro-inflammatory activity of TNF and 
LTα have prevented their systemic use as tumoricidal drugs (12). 
1.3. TNFR1 in disease 
TNFR1 is implicated in a range of inflammatory diseases including 
rheumatoid arthritis (27), TNF receptor associated periodic syndrome (TRAPS) 
(28), Crohn’s disease (29), carotid thickening, myocardial infarction (30), deep vein 
thrombosis (31), and diseases of the central nervous system including multiple 
sclerosis (32) and Alzheimer’s disease (33). These have been traced primarily to 
excessive, sustained expression of TNF (34-36), but also receptor mutation that 
results in misfolding and dysfunction (37). They been treated with great success 
by a class of biologic drugs called TNF-inhibitors that work by sequestering free 
ligand and reducing its bioavailability at sites of chronic inflammation (38). These 
drugs, which include Etanercept, Infliximab, and Adalimumab, sold as Enbrel®, 
Remicade®, and Humira®, respectively accounted for $27 billion in global sales in 
2013 and represented 3 out of the top 4 best-selling pharmaceuticals (GaBI online, 
2013). Etanercept is a TNFR2 fusion protein and Infliximab and Adalimumab are 
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both monoclonal antibodies against TNF (39). Only Etanercept binds to both TNF 
and LTα (40). 
Despite their successes, TNF inhibitors are known to increase the risk of 
serious and life-threatening side effects including infections and malignancies (41). 
We have noted that TNF and LTα are part of a complex and balanced system of 
several ligands and receptors, therefore it is unsurprising that indiscriminate 
sequestration of ligand would result in some unexpected cell responses. 
Therefore, it is desirable to treat inflammatory disease by targeting TNFR1 directly, 
leaving the normal functional relationships among LTα, LTβ, TNF, TNFR2, and 
LTβ receptor intact. TNFR1-specific inhibition using domain antibodies or peptides 
has been successful in mouse models (37, 42), however an explanation of the 
mechanism of this inhibition is lacking. Therefore, a detailed understanding of the 
biophysical events that control ligand/receptor signaling is needed to rationally 
design and improve therapies for diseases associated with TNFR1 dysfunction. 
1.4. DR5 signaling and therapeutic interest 
Whereas TNFR1 primarily signals cell survival, DR5 almost always 
mediates apoptosis. DR5 is expressed as both a short and long isoform (DR5-S 
and DR5-L, respectively) which differ by the absence or presence of 29 amino 
acids at the junction between the ECD and the transmembrane domain (43). Both 
isoforms are activated by a common ligand, TNF-related apoptosis-inducing ligand 
(TRAIL or Apo2L) (44). When stimulated, it recruits FADD and caspase-8 to its 
death domain and initiates caspase-dependent apoptosis (45). DR5 has attracted 
therapeutic interest because it selectively mediates cell death in cancer cells, 
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leaving normal cells unaffected (46). Indeed, the TRAIL/DR5 apoptotic mechanism 
seems, at least in mice, to be part of normal tumor suppression, and the loss of 
TRAIL sensitivity may mark a critical step in tumor initiation and proliferation (47). 
The idea of using DR5 as a specific mediator of tumor apoptosis has driven the 
development of non-natural DR5 agonists (45, 48) and innovative superagonists 
(49, 50) to overcome TRAIL insensitivity. However, TRAIL resistance continues to 
be an obstacle and a more detailed understanding of the biophysical events 
surrounding DR5 activation is necessary (51, 52) 
1.5. TNFR1 and DR5 structure, self-assembly, ligand-binding, and clustering 
Despite their disparate functions, TNFR1 and DR5 share a number of 
structural characteristics that make them amenable to our pairwise investigation. 
Firstly, both receptors self-associate in the absence of ligand through a pre-ligand 
assembly domain (PLAD). When treated with the amine crosslinker, BS3, and 
analyzed by electrophoretic mobility shift, unliganded DR5 migrates as a trimer 
(43). Because BS3 is membrane impermeable, this assay shows that DR5 forms 
non-covalent trimeric interactions via its extracellular domain. However, its 
transmembrane domain contains obvious dimerization features. These include a 
cysteine (C209) in DR5-L which forms a disulfide bond with an apposed DR5-L 
chain upon ligand stimulation and a GxxxG dimerization motif, exactly one helix 
turn downstream (43, 53). DR5-S also contains this GxxxG motif and is believed 
to non-covalently dimerize, however it lacks a cysteine and cannot form a disulfide 
bond (43). The functional significance of this difference is not fully understood. One 
theory speculates that the disulfide linkage disrupts the symmetric architecture of 
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otherwise non-covalent ligand/receptor networks (explained below) containing 
both DR5-S and DR5-L, thereby limiting signaling (43). Alternatively, disulfide 
bonding is proposed to enhance DR5-L activity by locking it into a signaling-
competent dimeric architecture (53). It is notable that a disulfide bond in another 
TNFR, p75 has been shown to be critical for receptor activation (54). No crystal 
structure yet exists for unliganded DR5. 
As for TNFR1, an influential publication by Chan et al. has referred to its 
preligand state as trimeric (55), however more recent studies clearly state that it is 
dimeric (56). TNFR1 was first shown to dimerize by Naismith et al. in a crystal 
structure of its extracellular domain (57). Dimerization was shown to occur through 
symmetric non-covalent interactions in CRD1. TNFR1 was later shown to self-
associate in live-cells, again by crosslinking cell surface proteins with the 
membrane impermeable amine crosslinker BS3. Unlike DR5, TNFR1 lacks any 
discernable dimerization motif in its transmembrane domain aside from a cysteine 
near its midpoint. However, as of this writing, this cysteine has not been shown to 
participate in a disulfide bond (55). 
Structures of TNFR1 both with and without ligand have facilitated 
investigation into its manner of activation. Experimental evidence (58) first led to a 
model of stoichiometrically-driven activation. That is, the ligand-induced TNFR1 
death domain trimer was hypothesized to permit binding of cytosolic adapter 
proteins, while the standalone death domain would not constitute the requisite 
TRADD binding-competent unit. The crystal structure of the LTα/TNFR1 complex 
(1tnr) seems to support this model, showing individual, non-interacting receptor 
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chains binding along the grooves between adjacent LTα protomers (8). The crystal 
structure of the TRAIL/DR5 complex (1d0g) shows these same general features 
suggesting a common manner of activation (59). 
The structure of the preligand TNFR1 dimer strikingly revealed that its 
ligand-binding and self-assembly domains do not overlap. This led to speculation 
that the TNFR1 dimer could survive ligand binding, and rather than form trimers, it 
would form an extended hexagonal network in which ligand/receptor complexes 
constitute the vertices and receptor dimers form the edges (57). This model was 
advocated by others for TNFR1 (56, 60, 61) and extended to other TNFR 
superfamily members including DR5 (43) and Fas (62). Crosslinking experiments 
confirmed the formation of high-molecular weight oligomeric complexes of TNFR1 
(55) and DR5 (43) upon ligand binding. Clustering has also been visualized by 
confocal microscopy for Fas (63-65), DR5 (43), and TNFR1 (66, 67). 
Thus, while TNFR1 and DR5 activation is ultimately triggered by ligand 
binding, the trimerization model is incomplete in that it does not explain the 
importance of receptor self-interaction or ligand/receptor network formation. 
Furthermore, it does not account for ligand-independent activation observed when 
receptors are overexpressed (19, 68, 69). 
This work introduces evidence for a novel TNFR activation mechanism 
based on ligand-induced conformational change in the receptor ECD, which 
propagates through the transmembrane helices to bring about reorganization of 
the death domains. We propose an ECD conformational change driven by 
ligand/receptor, receptor/receptor, and receptor/membrane interactions incurred 
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upon network formation. This conformational change induces a hinging motion 
through the transmembrane dimer, which reconfigures the cytosolic domains so 
that they are able to recruit adapter proteins. The studies are carried out for TNFR1 
and DR5, however due to common structural characteristics across the TNFR 
superfamily, our results may be broadly generalizable. We selected TNFR1 for 
analysis of the extracellular domain because structures exist for both its ligand-
bound and unbound states. The long isoform of DR5 was selected for studies of 
the transmembrane domain because its disulfide bond reduces the accessible 
conformational degrees of freedom and makes tractable the problem of predicting 
its structure. We hope to guide the discovery and development of novel 
therapeutics that exploit the features of this activation model to provide safer and 
more effective treatments for inflammatory disease and cancer. 
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Chapter 2 – TNFR1 Signaling is Associated with 
Backbone Conformational Changes of Receptor Dimers 
Consistent with Overactivation in the R92Q TRAPS 
Mutant 
Adapted with permission from “Lewis, A. K., C. C. Valley, and J. N. Sachs. 2012. 
TNFR1 signaling is associated with backbone conformational changes of receptor 
dimers consistent with overactivation in the R92Q TRAPS mutant. Biochemistry 
51:6545-6555.” Copyright 2012 American Chemical Society.”  
2.1. Summary 
The widely accepted model for tumor necrosis factor 1 (TNFR1) signaling 
is that ligand binding causes receptor trimerization, which triggers a reorganization 
of cytosolic domains and thus initiates intracellular signaling. This model of 
stoichiometrically driven receptor activation does not account for the occurrence 
of ligand independent signaling in over-expressed systems, nor does it explain the 
constitutive activity of the R92Q mutant associated with TRAPS. More recently, 
ligand binding has been shown to result in the formation of high molecular weight, 
oligomeric networks. Although the dimer, shown to be the pre-ligand structure, is 
thought to remain present within ligand-receptor networks, it is unknown whether 
network formation or ligand-induced structural change to the dimer itself is the 
trigger for TNFR1 signaling. In the present study, we investigate the available 
crystal structures of TNFR1 to explore backbone dynamics and infer 
conformational transitions associated with ligand binding. Using normal mode 
analysis, we characterize the dynamic coupling between the TNFR1 ligand binding 
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and membrane proximal domains and suggest a mechanism for ligand-induced 
activation. Furthermore, our data are supported experimentally by FRET showing 
that the constitutively active R92Q mutant adopts an altered conformation 
compared to wild-type. Collectively, our results suggest that the signaling 
competent architecture is the receptor dimer, and that ligand binding modifies 
domain mobilities intrinsic to the receptor structure, allowing it to sample a 
separate, active conformation mediated by network formation. 
2.2. Introduction 
Tumor necrosis factor (TNF) receptor 1 (TNFR1) is the prototypical member 
of the TNFR superfamily, a family of roughly 20 type I transmembrane receptors  
whose functions include triggering apoptosis,(2) inflammation response,(3) and 
cell survival.(4) TNFR1 is activated by binding one of two cognate ligands, TNFα 
or lymphotoxin-α (LTα, also called TNFβ) via its extracellular domain.(70) Upon 
ligand binding, a yet uncharacterized rearrangement of TNFR1 in the extracellular 
domain results in signal transduction across the membrane, causing the TNFR1 
intracellular death domain to shed the silencer of death domain (SODD)(19) and 
subsequently bind to TNF receptor associated death domain (TRADD).(71) The 
signaling cascade culminates with NF-κB activation and inflammation 
response.(72) A less common outcome occurs in certain cell types and culture 
conditions wherein TRADD recruits Fas associated death domain (FADD), 
resulting in caspase activation and apoptotic cell death.(73) However TNFR1 is 
most commonly associated with its inflammation pathway.  
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Abnormal TNFR1 activity is linked to a number of diseases including 
rheumatoid arthritis,(27) TNF receptor associated periodic syndrome 
(TRAPS),(28) Crohn’s disease,(29) carotid thickening, myocardial infarction,(30) 
deep vein thrombosis,(31) and diseases of the central nervous system including 
multiple sclerosis.(32) These diseases have been linked to a number of 
polymorphisms in the extracellular domain which cause abnormal folding, 
oligomerization, trafficking, and shedding behavior. Additionally, most mutants are 
unable to bind ligand. Notable exceptions are the R92Q and P46L mutations, 
which are termed “nonstructural polymorphisms” in that they bind ligand, traffic, 
and shed like wild-type, but exhibit abnormal, ligand-independent activity and lead 
to disease symptoms, albeit milder ones.(37) Common treatments for TNFR1 
associated inflammatory diseases include etanercept, adalimumab, and 
infliximab.(38) Each of these drugs reduces symptoms by competitive inhibition, 
capturing free ligand and rendering it unable to bind receptor. However, no current 
treatments act directly on the TNF receptor, which may reflect a lack of knowledge 
regarding extracellular signaling mechanisms involving TNFR1. Therefore, a 
detailed understanding of the mechanism by which ligand binding to TNFR1 results 
in signal transduction across the membrane may provide valuable insight into 
targeting TNFR1. 
While downstream events of the TNFR1 signaling pathway are well 
characterized, the mechanism by which ligand induces signaling across the 
membrane—i.e. ligand-independent receptor activation and ligand-induced 
reorganization in the membrane—is poorly understood. Therefore, the 
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fundamental relationship between the structure and function of TNFR1 is of great 
interest. TNFR1 is comprised of an N-terminal extracellular domain, a single-pass 
α-helical transmembrane (TM) domain, and a cytosolic death domain. Within the 
extracellular domain, two distinct regions of the receptor serve two main functions, 
pre-ligand assembly of monomeric receptor units(55) and ligand-binding of these 
pre-assembled complexes.(74) Ligand-independent assembly (Figure 2-1A) is 
driven through the membrane-distal pre-ligand assembly domain (PLAD), and 
deletion of these residues has been shown to prevent the homomeric association 
of TNFR1 monomers.(55) Ligand binding (Figure 2-1B) is driven through two 
receptor loops which provide high-affinity, high-specificity binding via a number of 
non-covalent interactions.(8) Recent evidence has suggested that in TNFR1, as 
well as other closely related proteins including TNF-related apoptosis-inducing 
ligand receptor 2 (TRAIL2, death receptor 5, DR5),(43) ligand-independent 
interactions and ligand binding occur together to generate highly organized 
network structures, (Figure 2-1C)(56) discussed further below. However, it is still 
unknown how the transition from a ligand-independent structure to a ligand-bound 
structure leads to signal transduction across the membrane. 
TNFR1 is the only member of the TNFR superfamily for which crystal 
structures exist for both its ligand unbound (Figure 2-1D) and ligand bound  (Figure 
2-1E) states, albeit the extracellular domain only. The first structure solved was 
that of the TNFR1 ectodomain in complex with its ligand, LTα (PDB ID 1tnr, Figure 
2-1E), revealing that the homotrimeric ligand binds symmetrically to three non-
interacting TNFR1 protomers, with each protomer fitting into the groove between 
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adjacent ligand chains.(8) This trimeric, axisymmetric LTα-TNFR1 complex agrees 
with previous experimental evidence for 3:3 ligand-receptor binding stoichiometry 
and is often considered to be the signaling complex.(58) The receptor itself is 
comprised of a chain of 4 cysteine rich domains (CRDs), with each CRD stabilized 
by three pairs of disulfide-linked cysteine residues.(75) The ligand contacts are 
confined to CRD2 and CRD3. More specifically, ligand-receptor interactions in the 
receptor protomer are dominated by a loop at residues 77-81 and the turn of a beta 
hairpin between residues 107-113.(8)  
A second crystal structure was later solved for the TNFR1 ectodomain pre-
ligand homodimer (PDB ID 1ncf, Figure 2-1D).(57) An anti-parallel dimer structure 
was also solved, but is not generally believed to be relevant in a native biological 
system. The dimer structure reveals that in the absence of ligand, TNFR1 self-
interacts with extensive dimer interactions in CRD1, the PLAD. In fact, only a single 
dimer interaction is found outside of the PLAD, a pair of hydrogen bonds between 
opposite Glutamines at residue 133. The significance of this pair of hydrogen 
bonds is unknown. 
Despite there being crystal structures solved for TNFR1 in both its ligand-
independent and ligand-bound forms, the relevant signaling mechanism at the 
level of receptor activation—that is, the transition from a ligand-independent dimer 
to a ligand-bound trimer—is still not known. Comparison of the two crystal 
structures, 1ncf and 1tnr, has not previously revealed any definitive tertiary 
structural difference between the ligand-independent and ligand-bound 
receptor.(57) Moreover, it is notable that the ligand binding domain and the PLAD 
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are on opposite faces of the receptor, and a structural alignment of the two crystal 
structures reveals that the homodimer can survive ligand binding without masking 
the dimerization interface or producing steric interference (Figure 2-1F). Despite 
these domains being structurally distinct, their functions have largely been 
considered intrinsically linked. Deletion of the membrane-distal PLAD prevents 
ligand binding and function, and therefore it is presumed that ligand-independent 
receptor assembly is a prerequisite for ligand binding and function.(76) However 
these studies are largely based upon receptor mutational analysis whereby entire 
protein domains are removed, which could influence the structure of ligand-binding 
regions. The structures of sequential CRDs are interdependent and folding of 
TNFR1 is highly sensitive to mutation.(37) Therefore, the relationship, if one exists, 
between the pre-ligand assembly domain and the ligand binding domain is yet 
unclear. 
Nevertheless, ligand binding and dimerization do not appear to be mutually 
exclusive. Consequently, ligand binding does not necessarily result in the 
formation of a trimer, but an extended network of ligand/receptor complexes. 
Indeed, a crosslinking study by Chan et al. shows that ligand binding results in the 
appearance of high molecular weight oligomers, rather than the expected 
trimer/trimer complex.(55) Our recent work has emphasized specific ligand-
induced receptor dimerization within the network structure of TRAIL in complex 
with DR5, a structurally homologous TNF ligand-receptor pair.(43) However, 
despite well-defined crystallographic structural data for the TNFR1 homodimer, its 
role within the TNFR1-LTα network has not yet been characterized. The model 
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proposed by our group and others is a hexagonal lattice wherein the ligand bound 
trimer forms each vertex and the receptor homodimer forms each edge (Figure 2-
1 A-C).(43, 56, 61, 62)  
 
Figure 2-1. Ligand-receptor network model. The components of the TNFR1 
hexagonal network are shown schematically with accompanying crystal structures. 
The receptor exists on the cell surface as a pre-ligand dimer (A, D). The trimeric 
ligand binds to three receptor protomers with trifold symmetry (B, E). However, this 
structure is not found in crosslinking studies, rather the ligand causes the 
formation of high molecular weight oligomers, modeled as a hexagonal lattice (C). 
The dimer of trimers subunit (i.e. a pair of ligand-bound trimers associated via the 
receptor dimerization interface) is the smallest networked unit (F). 
 
Due to the structural similarity between receptor protomers in the 1ncf and 
1tnr, an all-atom representation of such a network can be generated by structural 
alignment of the crystal structures (Figure 2-1F). The trifold symmetry of the 
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ligand/receptor complex leads to a hexagonal geometry as modeled. However, a 
conflict becomes apparent upon generation of the network through receptor-
receptor dimerization of ligand-receptor trimers (i.e. “dimer of crystal structure 
trimers”) shown in Figure 2-1F. An overlay of the crystal structures producing the 
dimer of trimers structure reveals a tilt of approximately 35˚ between adjacent 
trimers so as to prevent this network from forming on a membrane that is 
essentially planar on the scale of protein geometry. Therefore, we propose a 
ligand-induced conformational change that causes the network to become planar 
and permit its formation as observed in experimental studies. We use normal mode 
analysis, a powerful computational tool that has been used to accurately describe 
structural transitions in a variety of proteins (77-79), to explore the conformational 
dynamics involved in ligand binding of TNFR1. Our observations are supported in 
part by our experiments and should inspire additional experiments in the future. In 
the present study, we investigate the backbone conformational dynamics of 
TNFR1, how they relate to signaling, and potential connections to ligand-receptor 
network formation. 
2.3. Methods 
2.3.1 Comparison of crystal structures 
All protein coordinates were obtained from the Protein Data Bank (PDB, 
www.pdb.org, PDB ID 1ncf and 1tnr). The structural alignments and root mean 
square deviations (RMSD) were calculated using the RMSD Calculator extension 
of VMD.(80) The calculations were performed on the backbone atoms of the 
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indicated residues of both 1ncf chains (chains A and B) and the 1tnr receptor chain 
(chain R). 
2.3.2 Normal mode and RMSF calculation 
We calculated the full set of 3N normal modes for the Cα representations of  
the 1ncf and 1tnr crystal structures using the anisotropic network model tool, 
applying an exponential spring function, in LOOS.(81) The 1ncf chains were 
truncated to contain residues 14 to 150 for the purpose of symmetry, and the trifold 
symmetric 1tnr structure was kindly provided by David Banner. 
The output eigenvectors and eigenvalues were used to calculate the mean 
square residue fluctuations according to 
〈∆〉  ∝ ∑ 
 ,  [1] 
where  and  are the eigenvectors and angular frequency respectively 
of the dynamical matrix corresponding to atom  and mode . 
2.3.3 Cross-correlation calculation 
Cross-correlation maps were calculated over the first 100 non-zero 
frequency normal modes according to 
, =
∑ ⋅

 ∑ ⋅
 !
/
 ∑ ⋅
 !
/, [2] 
where  and  correspond to the eigenvectors of residues i and j 
respectively and # is the angular frequency of the kth normal mode. Convergence 
was estimated by taking the Euclidean norm of the cross-correlation matrix.  
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2.3.4 FRET 
pEYFP-N1 and pECFP-N1 vectors were a kind gift from David Thomas. The 
fluorophores had been previously mutated (A206K) to prevent dimer 
formation.(82) cDNA encoding TNFR1 was inserted at the n-terminus of the 
pEYFP-n1 and pECFP-n1 vectors using standard cloning technique. The TNFR1 
sequence was truncated immediately downstream of the transmembrane domain 
such that the cytosolic domain was replaced with EYFP or ECFP. The R92Q 
mutation was introduced using standard point-mutagenesis technique and 
sequenced for verification. 
HEK 293 cells were plated at 1:12 in a 6-well plate and transfected 48 hours 
later as follows. 0.5 µg ECFP-TNFR1 and 1.5 µg EYFP-TNFR1 were diluted into 
25 µL 20mM HEPES. A second solution of 50 µg/mL polyethyleneimine (branched, 
MW ~25000) in 20mM HEPES was prepared. The two solutions were mixed at 1:1 
by pipetting repeatedly and incubated at room temperature for 30 minutes. Cells 
were gently washed twice and resuspended in serum free DMEM. The DNA 
solution was added (50 µL total volume into each well of a 6-well plate) and the 
cells were incubated 4 hours at 37º C. The cells were then washed twice and 
incubated in serum-containing DMEM for 20 hours. Immediately prior to FRET 
imaging, cells were lifted by gentle trypsinization and replated on poly-D-lysine 
coated plates. 
Live-cell FRET imaging was conducting using a Nikon Eclipse TE200 
inverted microscope and a 40x objective fitted with a mercury lamp (XCite 120W 
Fluorescence Illumination System). Filters for excitation and emission of CFP 
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(430/24nm and 470/24nm, respectively) and YFP (500/20nm and 535/30nm, 
respectively) were controlled using an automated filter wheel (Ludl MAC6000). 
Images were acquired using MetaMorph and analyzed with ImageJ.  Energy 
transfer was measured by acceptor-selective photobleaching. Briefly, cells were 
imaged in the EYFP and ECFP channels every 20 seconds for 3 minutes. Between 
image captures, acceptor was bleached by continuous exposure through the EYFP 
excitation channel. FRET efficiency was calculated as the intercept of the linear fit 
of normalized EYFP fluorescence plotted against normalized ECFP enhancement 
with typical R2 values of around 0.90. The FRET efficiencies measured from 
individual cells were plotted against EYFP intensity and fit to a two parameter 
saturable binding curve of the form 
$ = %&'()*+['-%.]012['-%.] . [3] 
The model parameters were extracted to determine relative binding affinity 
(KD) and maximum FRET efficiency (FRETmax) of the TNFR1 dimer. 
2.4. Results 
2.4.1 Structural differences between the 1ncf and 1tnr receptor crystal structures 
To determine whether specific structural differences exist between TNFR1 
in its ligand-independent dimeric and ligand-bound trimeric states, we used VMD 
to perform a global backbone structural alignment and calculate the RMSD 
between the pre-ligand 1ncf receptors and the ligand bound 1tnr receptor. We 
calculated the backbone RMSD on all resolved residues shared among the crystal 
structures (residues 15-150) between chains A and B of 1ncf and chain R of 1tnr. 
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The pre-ligand receptor protomers differ from each other by an RMSD of 1.12 Å, 
with chain B appearing slightly more curved than chain A. The RMSD between 
1ncf chains A and B and 1tnr chain R are 1.68 Å and 1.96 Å, respectively. Naismith 
et al. originally reported the dimer structure and noted that the trimeric 1tnr receptor 
protomer solved 2 years prior by Banner et al. is slightly elongated and straighter 
compared to their pre-ligand dimer structure. Nevertheless, upon global alignment 
of all resolved residues, the structural differences between 1tnr and 1ncf appear 
to be minimal and are not consistent with our expectation of a ligand induced 
conformational change in the cytosolic domain (Figure 2-2A). However, the 
alignment algorithm results in structural deviations being distributed globally such 
that the total RMSD is minimized. If instead we assume that the dimer interface 
survives ligand binding and the PLAD remains rigid, it is reasonable to perform the 
alignment on only these residues, such that the dimer interactions remain intact. 
Moreover, we note that the B-factors of the 1ncf receptor suggest that residues 15-
100 are relatively immobile compared to residues 101-150 (see Supporting 
Information), supporting the notion that residues involved in dimeric interactions 
within the PLAD are unchanged upon ligand binding if we assume preservation of 
the dimer. We calculated a local backbone alignment and RMSD based on only 
residues 15-100. While residues 15-100 align more tightly (RMSD = 0.83 Å and 
RMSD = 0.72 Å between chain R of 1tnr and chains A and B of 1ncf, respectively), 
a structural change becomes apparent in the ligand binding and membrane 
proximal domains (Figure 2-2B). The RMSDs calculated on residues 100-150 
between chain R and chains A and B are similarly reduced (RMSD = 0.83 Å and 
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RMSD = 0.79 Å respectively), again showing that the differences between the 
ligand bound and ligand unbound structures correspond to a rigid body motion 
within the receptor protomer. Specifically, we found that in 1tnr, the ligand binding 
loop at residue 110 drops toward the membrane and that the membrane proximal 
domain rotates away from the dimerization interface. We then reconstructed the 
receptor dimer by aligning residues 15-100 of the 1tnr receptor protomer with both 
chains of 1ncf and found that the membrane proximal residues are substantially 
further apart, consistent with a conformational change in the TM and cytosolic 
domain (Figure 2-2C). These results show clearly that structural differences exist 
between TNFR1 in its dimeric state, and ligand-bound trimeric state. Whether this 
structural change is truly a consequence of ligand binding or of other crystallization 
conditions is unknown, however it does demonstrate a large degree of flexibility 
between the dimerization interface and the ligand binding and membrane proximal 
domains, which may be relevant to signaling in the full-length, membrane-
anchored receptor. 
 
Figure 2-2. Alignment of the 1ncf and 1tnr receptor protomer structures.  The 
alignment of 1ncf chain B (blue) and 1tnr chain R (yellow) shows that the global 
structural differences between the two structures are minimal (A). Alignment along 
residues 15-100 reveals a structural change in the membrane proximal residues, 
mediated by flexibility within the receptor chain (B). The structural change in the 
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membrane proximal residues becomes even more apparent when the 1tnr protomer 
is superposed onto both chains A and B of 1ncf (C). 
 
2.4.2 Comparison of the crystal structures reveals increased flexibility in the PLAD 
of the ligand-bound trimer 
To more completely characterize the backbone mobility of the TNFR1 
protomer as well as the collective motions of the tertiary structure involved in the 
transition from the ligand unbound dimer to the ligand bound trimer, we calculated 
the normal modes of both the 1ncf and 1tnr structures. To date, the dynamic 
behavior of the TNFR1 backbone has been largely disregarded and its relationship 
to signaling has not been investigated. Normal mode analysis (NMA) is a powerful 
tool used to characterize the large-amplitude structural fluctuations of a protein, 
including conformational changes that occur on time scales not accessible by all-
atom molecular dynamics. We calculated the normal modes of both structures 
using LOOS, which employs the anisotropic network model (ANM), reducing 
computational cost by coupling atoms through a single parameter energy potential 
in place of the traditional all-atom empirical force field.(81) ANM reveals the 3-
dimensional structural properties of a protein by assuming that, while residue-
specific atomic interactions guide the determination of the folded state, once folded 
the protein behaves to a large extent as an elastic solid, and molecular forces 
stabilizing the 3-dimensional geometry dominate.(83) The model is further 
simplified by reducing the treatment of residues to alpha-carbons only. While this 
appears to be an oversimplified model, normal mode analysis has been shown to 
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accurately predict structural changes in proteins in which multiple conformational 
states are known.(77, 84-86) 
The protomer chains of 1ncf were truncated for symmetry to include only 
residues 14-150. The truncated residues (11-13 and 151-155) can reasonably be 
omitted because they form incomplete domains with negligible intramolecular 
contacts and do not contribute meaningfully to the resolved portion of the tertiary 
structure. To analyze the relative residue fluctuation of the receptor protomer, we 
summed the full set of 3N-6 inverse-eigenvalue weighted normal modes according 
to Equation 1. The peaks on the resulting plot show which regions of the backbone 
tend to be more mobile, with low-frequency collective motions dominating while 
high-frequency vibrations offer negligible contributions (Figure 2-3A). The two 
crystal structures show notable differences in the mobility of various protein 
regions.  
In the all-atom representation, extensive non-covalent interactions within 
the PLAD of the 1ncf crystal structure at residues 47-49 stabilize the dimer 
interface (Figure 2-3A, Region ii). These residues are in turn stabilized by the loop 
formed at residues 23-27 (Region i), which does not form any dimer contacts, but 
is structurally coupled to the dimer interface of the PLAD. Comparing the residues 
fluctuations from the normal mode analysis of the homodimerized state (i.e. 1ncf) 
to the ligand-bound trimer state (i.e. 1tnr), both Regions i and ii are more flexible 
in the ligand-bound state due to the loss of dimeric intermolecular interactions 
across the PLAD interface. While the intermolecular side chain interactions that 
join the dimer are not present in our coarse-grained representation, the two chains 
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are near enough in the dimeric 1ncf structure that the exponentially decaying 
potential between them substantially influences the normal modes of the system. 
In the dimer state, these residues are surrounded by a larger number of close 
range interactions, and the region expectedly becomes more rigid, in agreement 
with the B-factors and justifying our treatment of the crystal structures. 
2.4.3 The ligand bound state exhibits disparate flexibility in the ligand binding 
domains 
The two predominant ligand binding domains of TNFR1 are formed by a 
loop at residues 77-81 (Figure 2-3A, Region iii) and the turn of a β-hairpin at 
residues 107-113 (Figure 2-3A, Region iv). They are coupled by a hydrogen bond 
between the backbone carbonyl of residue 80 and the backbone nitrogen of 
residue 114, which along with residue 104 transect the midpoint of the beta sheet. 
The midpoint of the beta sheet is further stabilized through a hydrogen bond 
between residues 104 and 131. Although the two ligand binding regions are 
tangentially coupled, they form two distinct and independent domains (Figure 2-3, 
Regions iii and iv), as the essential ligand binding residues of the β-hairpin are 
formed distally at residues 107-108. Furthermore, the two ligand binding domains 
target separate sets of residues within two separate protomers of the trimeric 
ligand.(8)  
In the dimer state, both ligand binding domains are flexible due to the 
absence of ligand interactions. Region iii runs along the spine of the receptor 
protomer and forms multiple intramolecular contacts, while the beta hairpin 
(Region iv) projects prominently from the structure, tethered only at its midpoint. 
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As a result, the beta hairpin is substantially more mobile. Fluctuations in residues 
77-81 are fully damped when buried by ligand binding, while Region iv remains 
somewhat flexible. If we treat the ligand as a rigid extension of the ligand binding 
domains, it is apparent that fluctuations in the β-hairpin would act to rotate the 
ligand about the rigid 77-81 loop. Conversely, this shows that the ligand can 
reorient with respect to the principal axes of the receptor by displacing Region iv 
while Region iii remains stationary. 
 
Figure 2-3. Normal mode analysis of the 1ncf and 1tnr structures. The residue 
fluctuations are shown for 1ncf (black) and 1tnr (red), summed over the full set of 
3N-6 normal modes (A). The equal-time motional correlations are shown for 
residues 105-115 for 1ncf (B) and 1tnr (C). Normalized residue mobility is shown 
schematically for the 1ncf protomer (D) and 1tnr (E), with the difference (i.e. 1ncf 
mobility subtracted from 1tnr mobility) shown in (F). Relative mobility and 
differences in mobility are indicated according to the color bar. 
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2.4.4 The transition to the ligand bound state enhances flexibility in the membrane 
proximal domains 
Approximately 22 residues leading to the TM domain are unresolved in both 
solved crystal structures and they are not believed to play a role in either ligand 
binding or dimerization.(57) The missing residues are expected to be highly 
structured, forming CRD4, which is stabilized by 3 pairs of disulfide-linked 
cysteines. The crystal structure gives coordinates for approximately half of CRD4, 
and we assume that the behavior of these residues reflects, or at least has direct 
influence on the behavior of the rest of the domain as well as the TM helix.  
The membrane proximal domains (Regions v and vii) fluctuate modestly in 
the dimer structure, and the transition to the ligand bound state causes their 
mobility to increase dramatically (Figure 2-3A, F). That ligand binding results in 
such a substantial increase in the fluctuations of the membrane proximal residues 
is by itself evidence for ligand-induced conformational change in the TM domain, 
however we sought to determine the mechanism through which ligand binding 
exerts this influence. A potential explanation is that dimerization contacts, though 
they are few and long-distance, contribute to the stability of these regions in the 
1ncf structure. However, the sole dimerization interaction outside of PLAD is a pair 
of hydrogen bonds formed symmetrically by apposed Q133 residues (Region vi), 
and the mobility at this residue is unaffected by the loss of dimer. Furthermore, we 
later show that the membrane proximal residues are flexible even where ligand-
receptor trimeric and receptor-receptor dimeric interactions are present as in the 
ligand-receptor network model (discussed below). Thus, the increased flexibility in 
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Regions v and vii appears to be an allosteric effect of ligand binding, and not a 
direct result of dimer dissociation. 
2.4.5 Motions in the 107-113 ligand binding loop and the membrane proximal 
domains are coupled  
Comparing the fluctuations of the ligand-independent and ligand-bound 
crystal structures, we have shown two striking features that coincide with the 
transition from the ligand-independent receptor dimer state to the ligand-bound 
trimeric state. First, two regions of the TNFR1 protomer, one rigid and one flexible, 
bind to the ligand at two distinct sites, and second, ligand binding causes 
dramatically enhanced flexibility in the membrane proximal domains. In order to 
determine whether these phenomena are related, and if so, how the mobilities of 
these regions are correlated, we calculated the equal-time motional correlation 
between all residues pairs of the receptor protomer (for complete cross-correlation 
analysis of TNFR1 1ncf and 1tnr structures, see Supporting Information). The 
individual analysis of low-frequency normal modes provides valuable insight into 
large scale structural changes between functional conformations, however the 
observation of correlated motions between protein domains in a single eigenvector 
does not necessarily imply that they are coupled over the full range of motion of 
the system.(87) Therefore, to understand the coupled motions of protein domains, 
it is necessary to calculate the cross-correlation over a sufficient range of normal 
modes such that the cross-correlation matrix becomes converged. We calculated 
the cross-correlation over the first 100 non-zero frequency normal modes 
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according to equation 2, using the Euclidean norm as an estimate of convergence 
(see Supporting Information). 
The cross-correlation is shown for TNFR1 residues 100-117, the mobile 
ligand binding β-hairpin, for both the 1ncf and 1tnr structures (Figure 2-3B and C, 
respectively). Qualitatively, the correlation peaks do not appear to change upon 
ligand binding. If we assume that the signaling competent unit is the dimer and that 
the ligand initiates signaling through coupled deformation of the membrane 
proximal region via the ligand-binding β-hairpin, this demonstrates that the ligand-
independent dimer is intrinsically predisposed to the same correlated motions as 
the ligand-bound trimer, and is thus capable of initiating signaling. What differs is 
the relative mobility of the ligand binding and membrane-proximal domains in each 
structure (Figure 2-3A); so while the liganded complex is flexible and may access 
the signaling conformation with ease, the pre-ligand dimer is rigid and reaches the 
signaling conformation with relatively lower frequency. This result suggests that 
the ligand-independent dimer is capable of initiating signaling, consistent with 
results showing that unliganded TNFR1 triggers NF-κB activation when 
overexpressed(19) or in the case of the constitutively active R92Q mutant.(88) 
Moreover, ligand binding to the wild type receptor changes the overall energy 
landscape thus providing access to a range of active structures that are 
inaccessible (or energetically unfavorable) in the absence of ligand. 
As mentioned above, residues 104 and 114 are structurally proximal and 
functionally related to residue 80, which is reflected by highly correlated motion 
between them (Figure 2-3B, C). Positive correlation is present between the ligand 
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binding residues of the β-hairpin and residues 77-81, however this appears to be 
an indirect effect of the strong structural coupling at the midpoint of the beta sheet. 
Positive correlation at residues 107 and 108 is greatly diminished compared with 
residues 104 and 114, suggesting that it is merely a consequence of structural 
proximity. Also, the mobility of residue 80 is abolished in the ligand bound state as 
shown in Figure 2-3A, so although the motions are somewhat correlated, they are 
negligible in magnitude and likely correspond to modest rigid body translations.  
The ligand binding β-hairpin (Region iv) and the membrane proximal 
domains (Regions v and vii) are mobile (Figure 2-3A), and their motions are highly 
anti-correlated, as shown by the negative peaks localized at residues 120 and 140 
(Figure 2-3B, C, arrowheads). That is, motion in Region iv tends to cause opposite 
motion in Regions v and vii. Recalling the structural arrangement of the immobile 
residues, the ligand binding domain and the membrane proximal domains appear 
to rotate through a rigid axis defined by residues 80, 104, 117, and 133 (Figure 2-
4). If we again consider the ligand as a rigid extension of the ligand binding 
domains and assume that the behavior of the TM domain is heavily influenced by 
that the membrane proximal residues, it follows that reorientation of the ligand 
about the principal axes of the receptor may propagate through CRD4 to generate 
a structural change in the TM domain.  
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Figure 2-4. The ligand binding region is coupled with the membrane proximal 
residues. The anti-correlated ligand binding domain and membrane proximal 
residues are highlighted. The correlation analysis suggests that Region iv and 
Regions v and vii rotate as a rigid body about the axis defined by the immobile 
residues 80, 104, 117 and 133 (black line). This reveals a mechanism by which 
ligand-induced displacement of the ligand binding β-hairpin propagates as a 
structural change in the membrane proximal domains. 
 
 
2.4.6 FRET 
Based on our normal mode analysis and comparison of the crystal 
structures, we predict that signaling is caused by a structural change in the 
receptor dimer. We experimentally tested our prediction of an active conformation 
by performing FRET measurements on ECFP and EYFP tagged chimeras of wild-
type and mutant TNFR1. We tagged TNFR1 such that the intracellular death 
domain is truncated and the fluorophore is substituted in its place. Placement of 
the fluorophore immediately downstream of the TM domain without a flexible linker 
region prevents it from sampling a wide range of geometric configurations so that 
the distance measured between fluorophores more accurately reflects changes in 
the extracellular domain propagated through the membrane. While removal of the 
death domain abolishes the native function of TNFR1 by preventing it from binding 
cytosolic adapter proteins, it allows us to directly observe how the behaviors of the 
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intracellular and extracellular domains are coupled, as we have done recently for 
a related family-member, Death Receptor 5.(43) We measured FRET by acceptor 
photobleaching where the enhancement in fluorescence by the donor fluorophore 
after selective photobleaching of the acceptor yields a quantitative measure of the 
distance between the two fluorophores (Figure 2-5A). We take the FRET efficiency 
as the theoretical maximum donor enhancement at 100% acceptor bleaching (see 
Supporting Information). 
To determine the active dimeric structure of TNFR1, we measured receptor 
energy transfer in a constitutively active mutant, R92Q, and compared the energy 
transfer to the wild type receptor. The TNFR1 R92Q mutant is known to induce 
mild inflammatory symptoms in patients with TRAPS.(37) Furthermore, it has been 
shown in vitro that the R92Q mutation causes elevated basal NF-κB activation, 
while ligand induced NF-κB activity is comparable to wild-type.(88) We observed 
measurable ligand-independent energy transfer in both wild-type TNFR1 and the 
R92Q mutant demonstrating clearly that both wild-type and mutant receptors 
oligomerize within the plasma membrane. We confirmed the dimeric nature of 
these interactions in both the wild type and R92Q mutant by plotting ECFP vs. 
EYFP intensity during photobleaching (Figure 2-5B,C). As previously 
described(89, 90) dimeric donor/acceptor interactions display a linear bleaching 
profile between lost EYFP intensity and gained ECFP intensity, while the formation 
of higher order oligomers is revealed as deviation from linearity. Our ECFP vs. 
EYFP profiles are consistent with dimeric interaction between membrane 
receptors, and more importantly, the degree of oligomerization is indistinguishable 
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between wild-type TNFR1 and R92Q. Therefore the constitutive activity observed 
in the R92Q mutant is the result of a receptor structural change rather than a 
change in receptor oligomerization. 
To determine the structural difference that exists between wild-type TNFR1 
and R92Q as propagated through the membrane, FRET efficiency was plotted as 
a function of EYFP intensity (the EYFP intensity is proportional to total receptor 
concentration) on a single cell basis (Figure 2-5D,E). The plot of FRET vs. EYFP 
intensity shows a monotonically increasing curve, which can be fit to a two-
parameter saturable binding curve as previously described.(43, 82, 90) From the 
model fit, we are able to decouple the structural properties of the receptor dimer 
from its dimerization affinity based on the extracted model parameters, where the 
FRETmax reflects the average distance between the donor and acceptor 
fluorophores and the Kd provides a measure of their affinity. Interestingly, based 
on our model fit, R92Q dimerizes with a lower FRETmax than the wild-type receptor, 
suggesting that the average fluorophore separation is greater in the mutant as 
compared to the wild type receptor (Figure 2-5F). Moreover, R92Q dimerizes with 
a lower Kd than the wild type receptor, suggesting that the mutant homodimerizes 
with greater affinity (Figure 2-5G). Though it is unknown whether the change in 
affinity is due to interactions involving the mutant or due to large scale changes in 
receptor structure, the combination of higher affinity and a change in cytosolic 
domain separation in the R92Q mutant may both contribute to its ligand-
independent activity. Because of limitations in the maximum attainable transfection 
levels, there is some degree of uncertainty in the model fits due to the scarcity of 
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data points in the plateau region at high EYFP intensity. We note that the extent to 
which our data populate the plateau regions in the scatter plots is similar to 
previously published studies using the same fitting technique.(90-92) To eliminate 
any bias resulting from the uneven distribution of data points, we have binned the 
data and refit the curves (see Supporting Information). While binning slightly 
diminishes the difference in both FRETmax and Kd between wild-type and R92Q, 
the overall effect is unchanged. Specifically, the R92Q mutation leads to a 27% or 
39% reduction in FRETmax and a 27% or 55% reduction in Kd taken from the binned 
data or raw data respectively. We also calculated the average FRET efficiency 
from cells expressing high levels of EYFP and found that, without depending on a 
model fit, the R92Q mutation leads to a significant reduction in FRET of 19%, 
consistent with our conclusion that the mutation causes separation of the cytosolic 
domains (see Supporting Information). 
 
Figure 2-5. FRET analysis of the constitutively active R92Q mutant . Energy transfer 
was measured by acceptor selective photobleaching. A single cell is shown in the 
ECFP channel before (A,i) and after (A,ii) photobleaching, and the EYFP channel 
before (A,iii) and after (A,iv) photobleaching. ECFP was plotted against EYFP during 
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the photobleach to discern the oligomeric state of the WT (B) and R92Q (C) 
receptors. FRET efficiencies of individual cells were plotted against EYFP intensity 
and fit to a two-parameter saturable binding curve for WT (D) and R92Q (E). The 
model parameters were extracted. FRETmax relates to the structure of the receptor 
dimer (F) and Kd provides a measure of the relative affinities (G). Error bars 
represent the error of the fit. 
 
 
Collectively, our FRET results suggest that the TNFR1 R92Q mutation 
results in an altered structure—an open conformation with increased separation 
between the cytosolic domains of the receptor dimer. We propose that this open 
conformation adopted by R92Q is the signal competent configuration and that the 
same conformational is enforced through ligand induced binding as predicted by 
our normal mode and crystal structure analysis described above. However, direct 
measurement of ligand induced changes in FRET is complicated by the formation 
of ligand/receptor networks. The formation of networks introduces multimeric 
donor/acceptor combinations, and it is not possible to measure the energy transfer 
in only the TNFR1 homodimer. While we predict a ligand-induced decrease in 
dimeric FRET, others have reported a ligand-induced increase in overall FRET, 
which may reflect the formation of such networks leading to an overall increase in 
energy transfer.(61) We predict that ligand binding would lead to a separation of 
the fluorophores in the receptor dimer that is subsumed within the network, 
resulting in decreased energy transfer. However, despite a reduction in dimeric 
energy transfer, the clustering of fluorophores due to network formation would 
increase overall energy transfer measured using steady state techniques (we 
estimate from the crystal structure that network formation would draw non-dimer 
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receptors within 30 Å of each other, where the Förster distance of ECFP-EYFP is 
approximately 49 Å(93)). The net effect of these two competing contributions to 
FRET complicates the analysis in the presence of ligand. We do expect that ligand-
induced networks would manifest as a non-linearity in the ECFP vs. EYFP 
bleaching profile (Figure 2-5B and 5C) due to the presence of multiple acceptors 
within the FRET distance of each donor molecule. Fluorescence lifetime imaging 
and model-based fitting algorithms are better suited for determining dimeric energy 
transfer in a complex system with many donor-acceptor pairs. 
2.5. Discussion 
Due to the structural similarity between the crystal structures of the pre-
ligand, dimeric TNFR1 and ligand-bound, trimeric TNFR1, a receptor 
conformational change has not previously been considered as a potential trigger 
for signal initiation. As a result, the widely accepted model for TNFR1 activation is 
that ligand binding causes its trimerization, thereby resulting in a reorganization of 
the cytosolic domains, and that the receptor trimer is the signaling competent 
architecture, however the precise molecular mechanism of TNFR1 signal initiation 
at the level of ligand-receptor binding is uncharacterized. Further, the current 
trimerization model does not account for ligand-independent signaling as in the 
R92Q mutant or in overexpressed systems nor does it explain the significance of 
ligand-receptor network formation. We have identified a potential conformational 
change in the receptor backbone, consistent with ligand binding and reorganization 
of the cytosolic domains. In this study, we provide evidence that the signaling 
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competent architecture is the dimer, and that ligand binding and network formation 
serve to stabilize an active dimeric conformation. 
Our results are consistent with our hypothetical model in which ligand 
binding induces a conformational change in the cytosolic domains and forms 
organized networks via dimeric receptor interactions. However the precise 
mechanism through which ligand displaces the ligand binding β-hairpin has not 
been described. Ligand binding causes TNFR1 to form networks, modeled as a 
hexagonal lattice as in Figure 2-1C. We generated a dimer of trimers model, the 
smallest networked subunit (Figure 2-1F), by structural alignment of the 1ncf and 
1tnr crystal structures and found that while networks may form without steric 
interference between dimerization and ligand binding, the resulting structure is not 
planar with respect to the membrane. The principle axes of adjacent ligands in the 
dimer of trimers are tilted at an angle of approximately 35º with respect to one 
another. Expansion of the network beyond two trimer subunits will result in further 
conflict with the membrane, forming a spiraling structure rather than the flat 
hexagonal structure, co-planar with the membrane as predicted (see Supporting 
Information). This conflict is shown schematically in Figure 2-6A (network tilting is 
shown in two dimensions for clarity). In order for the network to form, the ligand-
receptor complex must undergo a structural change so that adjacent trimer 
subunits are co-planar with each other and with the membrane. We believe this 
conformational change is consistent with the observed structural difference 
between the inactive wild type and the constitutively active R92Q mutant in the 
absence of ligand, and that the conformational change is consistent with the 
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altered mobility observed in our normal mode analysis (Figure 2-6B). This further 
suggests that the function of the receptor is dictated not by ligand-induced changes 
in death domain stoichiometry, as previously thought, but rather by a network 
stabilized conformational change in the receptor dimer. 
 
Figure 2-6. Receptor conformational change and network flattening. FRET analysis 
shows the formation of an altered conformation in the cytosolic domain in the R92Q 
mutant compared with wild type (A). We propose that the same conformational 
change is induced by ligand-receptor network formation. The ligand-receptor 
network, as generated by structural alignment of the 1tnr and 1ncf crystal 
structures, results in a steric conflict with the would-be membrane. This conflict is 
illustrated schematically in two dimensions for clarity. Adjacent ligand trimers are 
tilted at an angle of approximately 35º. To alleviate this steric conflict and grow the 
ligand-receptor network, a structural change must occur in the receptor dimer to 
allow the network to become coplanar with the membrane (B). 
 
Normal mode analysis of the dimer of trimers reveals that the essential 
motions of network flattening can be characterized by just two low-frequency 
modes (Figure 2-7). It is important to note that the analysis of individual normal 
modes does not reveal the equal-time correlated motions of protein domains, 
however individual modes can be useful in roughly describing large-amplitude 
structural changes in the protein complex. In order to flatten, the ligand trimers 
must rotate and separate at their membrane proximal end (Figure 2-7A, top), as 
well as swivel in the plane separating the two ligand trimer structures (Figure 2-
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7A, bottom). Figure 2-7A, top and bottom show the dimer of trimers structure prior 
to any displacement. The flattening motions are described by normal mode 1 and 
normal mode 3, respectively (Figure 2-7B, top and Figure 2-7B, bottom). Normal 
mode 2 corresponds to an asymmetric rotation of the dimer through an axis 
perpendicular to the membrane and does not contribute to flattening. After an 
arbitrary displacement along normal modes 1 and 3, it is apparent that the dimer 
of trimers becomes flat with respect to the membrane (Figure 2-7C, top and Figure 
2-7C, bottom show the dimer of trimers structure after displacement through 
modes 1 and 3 respectively).  
 
Figure 2-7. The normal modes of the dimer of trimers predict flattening. The dimer 
of trimers formed by structural alignment of the 1ncf and 1tnr crystal structures is 
shown from the front (A-C, top) and side-view (A-C, bottom). Both structures are 
shown prior to any displacement through the normal modes in panel A. Vectors are 
drawn corresponding to the principal axis of each ligand trimer. Porcupine plots 
illustrating the collective motions described by modes 1 and 3 are shown (B, top 
and bottom respectively). The resulting structures after arbitrary displacement 
through mode 1 and 3 are flattened to permit network extension (C, top and bottom 
respectively). 
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Normal mode analysis of the dimer of trimers model shows, as in 1tnr, that 
mobility is increased in the membrane proximal regions compared to 1ncf (Figure 
2-8). Indeed, the membrane proximal domains at Regions v and vii and the ligand 
binding loop at Region iv become the most mobile regions of the structure (Figure 
2-8B, red indicates mobile regions). Therefore, we propose that it is the change in 
the orientation of the ligand with respect to the principal axis of the receptor, 
enforced by network formation within the planar membrane, that displaces the 
mobile ligand-binding β-hairpin about the rigid ligand-binding domain at residues 
77-81. We suggest that this conformational change propagates to the membrane 
proximal region as illustrated in Figure 2-4, thereby resulting in a structural change 
in the TM and cytosolic domains. 
 
Figure 2-8. Relative mobility of the dimer of trimers model by residue. Relative 
fluctuations by residue were calculated as in Figure 2-3 for the dimer of trimers 
model. Residue mobility differs substantially compared to 1ncf (A). The relative 
fluctuation is shown schematically in (B). 
 
 
We are the first to show a higher degree of separation in cytosolic domains 
of a constitutively active, disease-related mutant as compared to the wild type 
TNFR1. As such we believe that separation of the cytosolic domains of the TNFR1 
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dimer is consistent with its activation. The mechanism coupling cytosolic domain 
separation with binding of adaptor proteins has not yet been explored and no 
structural data exists characterizing the interaction of the TNFR1 death domain 
with its cytosolic adaptor proteins. However, a crystal structure has been solved 
revealing homodimeric organization of the TNFR1 death domain.(94) Further 
studies have shown that the residues involved in homotypic death domain 
interactions are also responsible for, or overlap with residues responsible for 
binding to TRADD.(95) Therefore it is conceivable that separation of the TNFR1 
cytosolic domains – that is, transition to the active state – causes dissociation of 
the death domain dimer and allows TRADD to bind to the previously concealed 
homodimerization/TRADD binding sites. The key residues involved in SODD 
binding have not been mapped, nor has its structure been solved, therefore we 
reserve speculation on its function in TNFR1 cytosolic domain separation.  
The idea of ligand induced cytosolic domain separation as a signaling 
mechanism has been previously investigated using FRET in integrin αLβ2.(92) 
Upon ligand binding to their extracellular domains, the alpha and beta subunits of 
the receptor dimer undergo a conformational change, resulting in “swinging-out” of 
their cytosolic domains, and this structural change activates the receptor and 
initiates outside-in signaling, measured by FRET(92) intracellular tyrosine 
phosphorylation.(96) A similar mechanism has been proposed for the activation of 
p75 neurotrophin receptor (NTR), a fellow member of the TNFR superfamily. 
Ligand binding is believed to result in a scissors-like movement in the receptor 
dimer about a disulfide hinge in the transmembrane region, causing the 
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extracellular domains to join and the cytosolic domains to separate. This 
conformational change was observed using FRET and it is believed to expose 
binding interfaces for downstream signaling factors.(54) 
In our proposed model of TNFR1 activation, the signaling competent 
stoichiometric unit is the dimer. The role of the ligand in mediating the separation 
of cytosolic domains and transition to the active state is two-fold. In one respect it 
modifies the intrinsic structural fluctuations in the receptor backbone, allowing it to 
more readily sample the active conformation. This is supported by our cross-
correlation map and suggests that while the TNFR1 dimer is capable of initiating 
signaling, it is unlikely to do so due to restricted mobility in key domains. While the 
ligand-independent receptor does not form networks or experience the associated 
flattening constraint, in certain energetically unfavorable circumstances, it may be 
able to reach a signaling state as in the R92Q mutant. The ligand serves to mitigate 
this energetic barrier, allowing the ligand-bound receptor to readily adopt an active 
conformation. Second, ligand mediates network formation. The ligand receptor 
network, due to it being necessarily co-planar with the membrane, enforces and 
stabilizes the altered receptor conformation by displacing the ligand binding 
domain, which in turn causes a conformational change in the transmembrane and 
cytosolic domains. Additionally, the network may play a role in concentrating the 
signal or in stabilizing the dimer. We have shown that the R92Q mutant dimerizes 
with higher affinity that the wild type, however it is unknown whether this is a 
consequence of interactions involving the mutant itself or of its adopted active 
configuration. If the receptor dimer forms with higher affinity in its active state, it 
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follows that network enforced conformational change would also generate a 
stronger dimer, amplifying its signaling properties.  
Collectively, our results inspire a novel perspective in membrane receptor 
activation and ligand-receptor network formation. While ligand is known to induce 
network formation, we have shown that this oligomerization is not enough to 
explain the signaling event. Rather, by virtue of its formation, the network conspires 
with the planar membrane to enforce conformational change and receptor 
activation. Therefore, the relevant signaling event associated with ligand-induced 
TNFR1 activation involves a conformational change due to collaborative 
interactions between ligand-receptor, receptor-receptor, and receptor-membrane, 
which together provide an external force to overcome the energetic barrier 
between inactive and active states. 
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2.6. Supplemental Figures 
 
Figure 2-9. Backbone B-factors of chains R (black) and S (red) of the 1ncf crystal 
structures. B-factors are averaged over the backbone N, C, O, and Cα atoms. 
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Figure 2-10. Intramolecular cross-correlation maps based on the first 100 modes of 
the normal mode analysis for chain A or R of the 1ncf (A) and 1tnr (D) crystal 
structures respectively. Positive correlations are plotted in the upper left and 
negative correlations in the lower right. Positive (B) and negative (C) intermolecular 
correlations between residues A and B are plotted for the 1ncf structure. The 
Euclidean norm is plotted as an estimate of convergence (E). 
 
 
Figure 2-11. Calculation of FRET efficiency from a single cell. The FRET efficiency 
is taken as the y-intercept of the linear fit. 
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Figure 2-12. Growing the ligand-receptor network to 4 ligand-bound trimer subunits 
through structural alignment reveals substantial pitch. The dimer of trimers is 
highlighted. 
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Figure 2-13. Model fitting to the FRET data after binning (A). Data points are denser 
at intermediate EYFP intensity, and therefore this region has the strongest influence 
on the curve fit. Binning distributes the data points used for curve fitting evenly to 
remove this bias. Statistical significance (p-value < 0.05) between equivalent bins 
in the WT and R92Q measurements is denoted with (*). Average FRET efficiency 
was calculated for cells expressing high EYFP concentrations (2000 – 3000 A.U.) 
(B). Calculation of FRET efficiency without model fitting yields the same conclusion 
– that the R92Q mutation results in an increase in the FRET distance. FRETmax and 
Kd are reported as in the unbinned raw data (C and D respectively). 
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Chapter 3  – Open and Closed Conformations of the 
Isolated Transmembrane Domain of Death Receptor 5 
Support a New Model of Activation 
Adapted with permission from “Lewis, A. K., Z. M. James, J. E. McCaffrey, 
A. R. Braun, C. B. Karim, D. D. Thomas, and J. N. Sachs. 2014. Open and Closed 
Conformations of the Isolated Transmembrane Domain of Death Receptor 5 
Support a New Model of Activation. Biophysical Journal 106:L21-L24.” Copyright 
2014 Elsevier Inc. 
3.1. Prefatory note 
This study expands on my contribution to an earlier published work in the 
Sachs lab, where a complete description of methods and results can be found (43). 
The focus of that study was the supramolecular organization of TRAIL/DR5 
networks and a key finding was that the long isoform of DR5 (DR5L) forms a 
disulfide bond in its transmembrane domain upon ligand binding. This disulfide 
bond reduces the available degrees of freedom of the TM dimer and simplifies the 
problem of predicting its structure. We ran replica exchange molecular dynamics 
(REMD) simulations of the disulfide-linked dimer and analyzed the resulting low-
energy states for likely dimer conformations. Also notable is the presence of a 
GxxxG sequence, which is a known dimerization motif (97). Our simulations 
predicted a right-handed dimer in which the GxxxG motifs were in close contact. 
The following study starts with this dimer structure and explores the free energy of 
available conformations as the dimer opens and closes, with the disulfide bond 
acting as a hinge. 
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Figure 3-1. REMD predicted structure of the DR5L transmembrane domain. Adapted 
from Valley et al. (43) 
 
3.2. Summary 
It has long been presumed that activation of the apoptosis-initiating Death 
Receptor 5, as well as other structurally homologous members of the TNF-receptor 
superfamily, relies on ligand-stabilized trimerization of non-interacting receptor 
monomers. We and others have proposed an alternate model in which the TNF-
receptor dimer—which sits at the vertices of a large supramolecular receptor 
network of ligand-bound receptor trimers—undergoes a closed-to-open transition, 
propagated through a scissors-like conformational change in a tightly bundled TM 
domain dimer. Here we have combined electron paramagnetic resonance 
spectroscopy and potential of mean force calculations on the isolated TM domain 
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of the long isoform of DR5. The experiments and calculations both independently 
validate that the opening transition is intrinsic to the physical-character of the TM 
domain dimer, with a significant energy barrier separating the open and closed 
states. 
3.3. Introduction 
Death receptor 5 (DR5) is a member of the tumor necrosis factor receptor 
(TNFR) superfamily that mediates apoptosis when bound by its cognate ligand, 
TNF-related apoptosis inducing ligand (TRAIL) (98). Upregulated in cancer cells, 
DR5 is among the most actively pursued anticancer targets (99). TRAIL binds to 
preassembled DR5 trimers at their extracellular domains (ECDs), causing the 
formation of oligomeric ligand-receptor networks  that are held together by receptor 
dimers (43). In the long-isoform of DR5, this dimer is crosslinked via ligand-induced 
disulfide bond formation between two  transmembrane (TM) domain α-helices at 
Cys-209, and is further stabilized by a GxxxG motif one helix turn downstream 
(43).  
Our recent study of the structurally homologous TNFR1 showed that 
receptor activation involves a conformational change that propagates from the 
extracellular domain to the cytosolic domain through a separation (or opening) of 
the TM domains of the dimer (60). We have therefore hypothesized that the 
activation of DR5, and indeed all structurally homologous TNF-receptors, involves 
a scissors-like opening of the TM domain dimer (Figure 3-2Figure 3-1).  
Using electron paramagnetic resonance (EPR) spectroscopy, a technique 
that has been used previously to study TM helix architecture and dynamics (100, 
  53 
101), and potential of mean force (PMF) calculations (102, 103), the present study 
addresses the question of whether the isolated disulfide-linked DR5-L TM domain 
dimer occupies distinct open and closed states (Figure 3-2), and how its dynamic 
behavior contributes to the free-energy landscape of the opening transition of the 
full-length receptor.  
 
Figure 3-2. Activation model of the DR5-L TM dimer. The sequence (top) and 
positions of the disulfide bond and TOAC spin label in our previously published 
model (bottom, left) are shown. We propose an activation model (bottom, right) in 
which the transmembrane dimer pivots at its disulfide bond to reach an active open 
conformation. 
 
3.4. Results and Discussion 
The DR5-L TM domain was synthesized with TOAC, an amino acid with a 
nitroxide spin label rigidly fixed to the α-carbon (104), incorporated at position 32 
(Figure 3-2), with some minor modification to facilitate EPR measurements. 
Previous work confirmed that this peptide forms disulfide-linked dimers (e.g. via 
comparison to 2-ME treated sample) and a negligible population of higher order 
oligomers (further supported by model fitting of the EPR data below). For peptide 
work, residues were renumbered such that Thr-204 corresponds to Thr-1, and so 
on. The cytosolic Cys-29 (which we previously showed does not participate in a 
disulfide bond in cells) was replaced with serine to prevent the formation of 
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antiparallel disulfide-linked dimers, and Trp-34 was replaced with tyrosine to 
prevent intrinsic fluorescence in fluorescence studies (not published). CW dipolar 
EPR (sensitive only to spin-spin distances less than 25 Å) was used to measure 
TOAC-TOAC distances within the TM dimers and revealed an ordered Gaussian 
distribution centered at 16 Å (FWHM = 4 Å), corresponding to a closed state 
(Figure 3-3A). DEER (sensitive to spin-spin distances from 15 – 60 Å) also 
detected a short distance consistent with the dipolar EPR data, along with a longer, 
disordered component (32.9 Å, FWHM = 28 Å) (Figure 3-3B). Together, these 
measurements indicate the presence of a compact, ordered closed state and a 
broader, disordered open state. EPR on oriented membranes also indicated two 
structural states. Global fitting revealed two populations of spin label tilt angles 
(orientation of the nitroxide principal axis relative to the membrane normal): a 
narrow conformation (24°, FWHM = 20°), and a disordered conformation (50°, 
FWHM = 48°) (Figure 3-3C). This bimodal orientational distribution (Figure 3-3C) 
is remarkably consistent with the bimodal distance distribution (Figure 3-3B). 
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Figure 3-3. EPR spectra (left) of 32-TOAC-DR5 in lipid, and resulting structural 
distributions (right). (A) CW dipolar EPR spectra (left) of dimer (1 mM diamide) and 
monomer (1 mM 2-mercaptoethanol). Best fit spin-spin distance distribution was a 
single Gaussian centered at 16 ± 2 Å (right). (B) DEER waveform (left) of 32-TOAC-
DR5 dimer was best fit (right) to a 2-Gaussian distribution.  The short distance was 
constrained to agree with the CW data, since DEER has poor sensitivity for 
distances less than 20 Å. The long distance distribution is centered at 32.9 Å and is 
much broader. (C) CW EPR spectra (left) of 32-TOAC-DR5, with the membrane 
normal oriented parallel (red) and perpendicular (blue) to the field. Simultaneous 
(global) fitting of these spectra reveals narrow and broad components (right). In B 
and C, the overall distribution is plotted as black, while the closed and open 
components are plotted as green and magenta, respectively. 
 
 
We subsequently conducted a potential of mean force (PMF) calculation 
(105) using the DR5-L TM dimer starting configuration developed by our group 
previously (43), embedded in a DMPC bilayer, with the Leu-32/Leu-32 Cα distance 
(r32-32) as the reaction coordinate. Three calculations were run from independent 
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starting configurations, each using 50 windows spaced in 0.5° increments, and run 
for 20 ns at each window (totaling 3μs).  Each of the calculations yielded a similar 
result, and the mean free energy curve (Figure 3-4A) agrees remarkably well with 
our EPR measurements: a narrow distribution at the closed conformation (~16 Å, 
Figure 3-4B) separated by an ~3 kcal/mol energy barrier from a broad distribution 
of accessible open conformations (centered at ~27 Å, Figure 3-4C). The individual 
PMF plots can be found in Figure 3-5).  
In the closed state, the helices are tightly packed at the GxxxG interfacial 
motif and all the way down the juxtaposed helix faces at residues Ala-18, Leu-22, 
Ala-25, and Val-26. The tight packing is aided by kinking and twisting of the two 
helices around their common axis, increasing the interacting surface area. In the 
open conformations, the Ala-18, Leu-22, Ala-25, and Val-26 pairs are dissociated 
and, interestingly, the GxxxG motif at Gly-10 and Gly-14 remains tightly packed. 
The open state energy well is only slightly less favorable than the closed state (by 
~2 kcal/mol), and its free energy profile is relatively broad and flat. The increased 
crossing angle in the open state is facilitated by straightening of the helix kink and 
is not accommodated by a change in bilayer thickness (Figure 3-7A, B). 
The observed change in helix-helix distance (10 Å between the two minima 
in the PMF) is extremely close to that observed previously in live-cell FRET studies 
of a constitutively active form of TNFR1 (~8 Å change between states using large 
fluorescence probes at the cytosolic domains) (60). The change observed in the 
EPR data (17 Å) may be an overestimate because the measurement is made 
between TOAC spin labels that likely protrude from the two helices, depending on 
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rotational orientation. These results collectively show that activation of these 
receptors requires a small, but clearly significant conformational opening of the TM 
domains. One important note is that our EPR experiments recapitulate the 
equilibrium distribution of the two states despite there being no driving force to 
traverse the barrier between them (~3 kcal/mol in the closed-to-open transition and 
~1 kcal/mol in the open-to-closed transition, Figure 3-4). We do not interpret the 
results to mean that the dimer necessarily traverses these barriers at 4° C. Rather, 
there likely exist multiple reaction paths for dimerization of the abstracted TM 
domains. Finally, in the context of the full-length receptor, how the ligand induces 
a conformational change capable of overcoming the closed-to-open barrier 
remains an important question. 
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Figure 3-4. PMF calculation of the DR5 TM domain dimer along the Leu-32/Leu-32 
distance reaction coordinate. The PMF calculation reveals a narrow closed state 
and a broader open state separated by a free energy barrier. 
 
Whether the observed structural transition in the TM domain dimer of the 
long-isoform of DR5 is a ubiquitous conformational switch that acts over the entire 
TNFR superfamily remains unknown. Vilar et al. first proposed a similar scissors-
model for activation of p75 neurotrophin receptor, which has a cysteine at the 
center of its TM helix (54). The short isoform of DR5 lacks a TM domain cysteine, 
but does form non-covalent dimers in cells, with likely TM domain dimer contacts 
(43). Among the other closely related and structurally homologous members of the 
TNFR superfamily, TNFR1 contains a cysteine at the center of the TM domain, but 
lacks any discernible small residue motifs (e.g. GxxxG). TNFR2 lacks a TM 
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cysteine on the extracellular side, but does have a GxxxG motif positioned similarly 
to that of DR5. On the other hand, Death Receptor 4, whose functional distinction 
from DR5 has remained somewhat elusive, lacks both a cysteine and any 
recognizable small-residue hydrophobic motif.  
In summary, we have extended recent findings that point to the TM domain 
of DR5 as an essential structural component in the conformational change 
associated with activation. Our findings that the DR5-L TM domain occupies 
distinct open and closed states, separated by a substantial energy barrier, points 
the way to further studies across the TNF-receptor superfamily. 
3.5. Supplemental Methods 
3.5.1 EPR sample preparation 
For CW dipolar EPR measurements (Figure 3-3A), 32-TOAC-DR5 was 
reconstituted at 0.4 mM in DPC buffer (15 mM dodecyl phosphocholine, 50 mM 
phosphate buffer, pH 8.1), with 1 mM diamide or 1 mM 2-mercaptoethanol to 
maximize or eliminate spin-spin interactions, respectively. This environment was 
selected because prior simulation studies suggested that the hydrophobic length 
of DR5 closely matches the DPC micelle diameter, and this would favor the 
formation of the predicted closed state. The open state would be undetectable 
using CW dipolar EPR. Furthermore, DPC micelles produced the non-interacting 
monomeric spectrum under reducing conditions needed to interpret the disulfide-
bonded dimer spectrum. DR5 stock in trifluoroethanol (TFE) was dried under N2 
gas and stored under vacuum overnight to remove residual solvent. The next day, 
DPC buffer was added to the sample and thoroughly vortexed. Samples with 
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added diamide were incubated overnight at 4 °C to allow for disulfide bond 
formation, while samples with added 2-mercaptoethanol were measured by EPR 
spectroscopy after 10 minutes to prevent complete spin label reduction.  
For DEER experiments, 32-TOAC DR5-peptide was reconstituted at 700 
lipids/DR5 (mol/mol) into 2.5:2.5:1 DMPC/POPC/DHPC (mol/mol) bicelles in 50 
mM HEPES, 1 mM diamide, pH 7.0 (106). Bicelles were used to reduce 
background effects arising from the distribution of protein within the sample. 
Bicelles allow for a more homogenous (3D) protein distribution, as opposed to lipid 
vesicles which tend to produce sub-3D distributions. Briefly, lipid stocks in 
chloroform and DR5 stock in TFE were combined, dried under N2 gas, and then 
stored overnight in a vacuum desiccator. The next day, the lipid/DR5 film was 
resuspended in HEPES/diamide buffer by thorough vortexing and water bath 
sonication. The reconstituted bicelle sample was then incubated overnight at 4 °C 
to allow for disulfide bond formation. 
For oriented EPR measurements, 32-TOAC-DR5 was reconstituted at 100 
lipids/DR5 (mol/mol) into 4:1 DOPC/DOPE (mol/mol) lipid bilayers (107). This 
oriented bilayer system is well-established for protein orientation studies. Briefly, 
lipid stocks in chloroform and DR5 stock in TFE were combined, dried under N2 
gas, and dissolved in a solution of 99:1 methanol/ddH2O (vol/vol). The sample was 
deposited onto an 8x10 mm glass cover slip, and stored under vacuum overnight 
to remove solvent. The next day, the sample was transferred into a sealed glass 
desiccator containing saturated ammonium phosphate solution, and incubated just 
above the liquid surface at 42°C for 24 hours. Following this rehydration, a second 
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cover slip was placed atop the sample. The sample was gently compressed, and 
sealed in Parafilm. 
 
3.5.2 EPR Spectroscopy: 
Conventional (continuous wave, CW) EPR spectra were acquired at X-band 
(9.5 GHz) with a Bruker EleXsys E500 spectrometer equipped with the ER 4122 
SHQ (CW dipolar EPR) or TE 4101 OR (oriented EPR) resonator. Temperature 
was maintained at -73 °C (CW dipolar EPR) or 23 °C (oriented EPR) with a quartz 
dewar insert and a nitrogen gas flow temperature controller. EPR spectra were 
acquired with 2 mW (dipolar EPR) or 5 mW (oriented EPR) microwave power, 100 
kHz modulation frequency, 3 G modulation amplitude, and 120 G sweep width. For 
CW dipolar EPR, the sample was pipetted into a glass capillary and supported by 
a sample holder, while for oriented EPR, the sample on glass cover slip was 
attached to a flat cell, and rotated within the resonator to align the membrane 
normal parallel and perpendicular to the field. All EPR spectra were baseline-
corrected and then normalized to the double integral.  
Spectral simulations and least-squares fits to determine CW dipolar spin-
spin distance and probe orientation were performed as described previously (108). 
In all cases, data were fit to a model corresponding to a sum of Gaussian 
distributions (of distance or orientation). The number of components was increased 
until no further improvement in the fit was achieved. Analysis of distance 
distribution from CW dipolar EPR using Tikhonov regularization gave results 
similar to those using the Gaussian analysis. 
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4-pulse DEER (109) was performed at Q-band and 65 K on a Bruker 
EleXsys E580 spectrometer equipped with a SuperQFT-u bridge and an ER 
5107D2 resonator. The decay was analyzed using DEERAnalysis2011 (110), with 
the raw data truncated by 500 ns to remove a small artifact introduced by 
observer/pump pulse excitation overlap (111), and then background-corrected 
assuming a homogenous 2D model. The resulting waveform was fit to a two 
Gaussian model, where one component was constrained to match the mean 
distance and full-width half-maximum (FWHM) determined by CW dipolar EPR, 
while the remaining parameters (mean distance and FWHM of the second 
component, populations of both components) were varied. As with CW dipolar 
EPR, Tikhonov regularization yielded a distance distribution to that obtained by 
Gaussian analysis. 
  
3.5.3 PMF calculation and molecular dynamics 
To further characterize the observed open and closed TM dimer structures, 
we conducted molecular dynamics (MD) simulations and calculated a potential of 
mean force (PMF) using the Leu-32/Leu-32 Cα distance as a reaction coordinate. 
A starting structure of the DR5L transmembrane homodimer was previously 
generated using replica exchange molecular dynamics (43). Residues are 
renumbered such that Thr-204 in the full length protein corresponds to Thr-1 in our 
synthetic peptide, and so on. The starting configuration was rotated through the 
Cys-6 disulfide dihedral angle to generate starting configurations for 50 windows 
of the PMF calculation, varying by 0.5° each. This transformation was chosen to 
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avoid placing stress on the disulfide bond. The reaction coordinate was taken as 
the distance between the Cα atoms of Leu-32 to correlate with measured distances 
from the EPR experiments. These distances varied from 9.48 – 36.74 Å, spaced 
by roughly 0.6 Å. A 2 kcal/mol/Å2 harmonic bond was applied using the NAMD 
Colvars module to restrain the reaction coordinate at all stages of simulation. Each 
dimer configuration was inserted into an all-atom, 128 lipid DMPC bilayer using 
CHARMM-GUI, and solvated with TIP3 water at ~50:1 water:lipid ratio (112).  
NPT ensemble simulations were performed using the CHARMM 36 
parameters. Constant temperature (303 K) and pressure (1 atm) were maintained 
using the Langevin piston and Nosé-Hoover algorithms, respectively. 
Electrostatics were calculated using the particle mesh Ewald method with a 1.5 Å 
grid spacing and 4th order interpolation. Lennard-Jones interactions were cutoff at 
10 Å. Each window was minimized using NAMD 2.8 for 1000 steps, then 
equilibrated with Cα harmonic constraints of 1, 0.1, and 0.01 Kcal/mol/Å2 for 2 ns 
at each stage with a 2 fs time step. Equilibrated systems were simulated 
unrestrained (except for the harmonic bond restraining the reaction coordinate) for 
24 ns, with the final 20 ns used in the PMF calculation. The PMF was calculated 
at 300K with 100 bins using the weighted histogram analysis method (WHAM) 
algorithm developed by Grossfield (105). The simulations were performed in 
triplicate from randomly seeded velocities and the WHAM calculations were 
performed for each. The PMFs were shifted to equalize the mean free energies, 
then the mean and standard error of the 3 curves were plotted. PMFs of 
independent simulations are plotted in Figure 3-5. Error analysis for each individual 
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run was conducted using the integrated Monte Carlo bootstrapping code, with a 
decorrelation time of 0.24 ns, as calculated for Cα atoms using Loos (81). 
Helix kink angle was calculated for both chains between the principal axes 
of residues 6-20 and 22-32 over all simulation time from the three replicated 
systems, and reported in Figure 3-7A. The electron density profile was calculated 
for all atoms on centered trajectories from each of the three replicated systems, 
and the mean reported in Figure 3-7B. Both calculations were performed using 
Loos (81) on trajectories from windows 15 and 34, in which the r32-r32 bond 
distance was restrained to the minima of the closed and open states respectively. 
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3.6. Supplemental Figures 
 
Figure 3-5. Umbrella sampling histograms (left) and PMF curves (right) for 3 
independent simulations. 
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Figure 3-6. Side and top views of the TM dimer in the closed conformation (~16 Å) 
(A), at the local energy barrier (~20 Å) (B), and in the open conformation (~30 Å) (C). 
 
 
Figure 3-7. Helix kink angle and electron density.  Helix kink angle histogram (A) 
and electron density (B) calculated over all three replicated simulations. TM dimer 
opening is accommodated by straightening of the helix kink and not a change in 
bilayer thickness. 
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Chapter 4  – Death Receptor 5 Networks Require 
Membrane Cholesterol for Proper Structure and Function 
4.1. Summary 
Death receptor 5 (DR5) is an apoptosis-inducing member of the tumor 
necrosis factor superfamily whose activity has been linked to lipid rafts. Upon 
ligand binding, DR5 forms large clusters within the plasma membrane that have 
often been assumed to be manifestations of raft co-localization. However, we have 
recently shown that DR5 clusters are more than just randomly aggregated 
receptors. Instead, they are highly structured networks held together by receptor 
dimers. These dimers are stabilized by specific transmembrane helix-helix 
interactions, including a disulfide bond in the long-isoform of the receptor. The 
complex relationship between DR5 network formation, transmembrane helix 
dimerization, raft localization and receptor activity has not been established. It is 
unknown whether the membrane itself plays an active role in driving DR5 
transmembrane helix interactions or in the formation of the networks. We show 
that cholesterol depletion in cells does not inhibit the formation of DR5 networks. 
However, the networks that form in cholesterol depleted cells fail to induce 
caspase cleavage. These results suggest a potential structural difference between 
active and inactive networks. As evidence, we show that cholesterol is necessary 
for covalent dimerization of DR5 transmembrane domains. Molecular simulations 
suggest that dimerization is facilitated by increased helicity and deeper partitioning 
of Cys209 in a thicker bilayer. 
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4.2. Introduction 
Death receptor 5 (DR5) is an apoptosis-inducing member of the tumor 
necrosis factor (TNF) receptor superfamily that is activated by TNF-related 
apoptosis-inducing ligand (TRAIL) or other agonists (113-117). The TRAIL-DR5 
signaling pathway is of great therapeutic interest, as exogenous TRAIL prevents 
tumor growth and, in contrast to other apoptosis-inducing ligands such as FasL, 
does not exhibit systemic cytotoxicity (118). Thus, DR5 is widely regarded as a 
potential target in the treatment of cancer (45, 46, 119, 120)  with a number of its 
ligands, including recombinant human TRAIL and antibody agonists (as we will 
study here), currently in clinical trials (121-126) (see also clinicaltrials.gov). 
However, TRAIL resistance has proven to be a challenging barrier to the success 
of DR5-based cancer therapies (51, 52). Thus, continued efforts to understand the 
complex events involved in DR5 signal propagation, including the initiating events 
at the membrane, will be useful for understanding therapeutics currently in clinical 
trials as well as discovering novel DR5-targeted therapeutics. 
TRAIL- and agonist-induced apoptosis is initiated by the formation of large 
(~300-500 nm diameter) DR5 receptor networks in the plasma membrane (43, 63, 
127, 128). We have shown that these networks are structured lattices, modeled by 
us and others as trimeric ligand-receptor complexes held together by dimeric 
receptor junctions (one monomer from each pair of ligand-receptor complexes) 
(43, 56, 60-62). Ligand induced receptor dimerization is consistent with 
crystallographic and functional evidence showing that both intracellular protein 
  69 
domains and downstream proteins form stable and functional dimeric complexes 
(62, 129-133). We also showed that the dimeric junctions of DR5 networks are 
stabilized through interactions between amino-acids in the transmembrane 
helices, which form tight dimeric bundles in the membrane (43, 53). In the long-
isoform of DR5, a disulfide bond forms between TM helices upon activation. 
Although the short-isoform lacks the disulfide bond, both the long and short 
isoforms contain the well-established GxxxG TM helix interaction motif, which 
allows for tight packing at the interface of the two monomeric helices (97, 134).  
We have also recently suggested that the receptor dimer of TNFR1 (a 
structurally homologous member of the same superfamily as DR5), undergoes a 
conformational transition upon activation (60). This is a very different model than 
what has previously been proposed for TNF-Receptor activation. In earlier models, 
activation was thought to involve receptor trimerization and a stoichiometric 
change in the cytosolic domain that required no conformational changes (i.e. 
receptor backbone rearrangements) (8, 59). Our molecular calculations, on the 
other hand, support a model in which signal initiation is a consequence of the 
mechanical strain placed on the receptors as the network grows. More specifically, 
we have suggested that the extracellular domain of the receptor dimer pivots 
outwards on network formation, and that as a consequence the transmembrane 
dimer opens like scissors (closed in the inactive state, open in the active state) (53, 
60). This model of activation has been supported by several recent studies on 
TNFR1 (76, 135, 136). 
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Given that ligand-induced dimeric interactions of DR5 occur in part via 
transmembrane residues, it stands to reason that the membrane itself may play an 
active role in driving the dimeric interactions that promote network-formation. 
Cholesterol-rich microdomains in the plasma membrane, often referred to as lipid 
rafts, play an active role in signal transduction in a number of pathways (137-139) 
including several that involve members of the TNFR superfamily. Ligand-bound 
TNFR1 localizes to rafts, and recruits downstream signaling proteins (140, 141). 
The death receptor Fas has been shown to localize to rafts in a ligand-dependent 
manner (142), though others have observed ligand-independent raft localization 
(143). In DR5, Song et al. showed that caspase-8 cleavage in TRAIL-sensitive 
cells could be inhibited by treatment with methyl-β-cyclodextrin (MβCD) (144). 
Multiple other studies have shown that DR5 function correlates with its migration 
into lipid rafts (144-148). However, it is unknown whether localization within 
cholesterol-rich lipid microdomains is associated with receptor oligomeric 
structure, i.e. DR5 dimerization and network-formation. 
Here, we find that the extent of agonist-induced DR5 clustering is not 
diminished by cholesterol-depletion. However, cholesterol depletion greatly 
reduced the ability of DR5 to initiate caspase-dependent apoptosis. We attribute 
this to the formation of non-functional ligand-receptor networks that differ from 
functional networks by a reduction in the population of constituent disulfide-linked 
DR5 dimers. Collectively, these results offer the first evidence that membrane 
heterogeneity plays a central role in dictating the structural details and functional 
activity of DR5 networks. These results further support a model in which DR5 
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networks have a specific structure, and that lipid rafts do not simply corral high 
local concentrations of receptors, but play an essential role in driving ligand-
receptor network architecture. 
4.3. Materials and Methods 
4.3.1 Cell culture and reagents 
Jurkat cells were cultured in RPMI-1640 media (HyClone) supplemented 
with 10% FBS, 4mM L-glutamine, penicillin and streptomycin and maintained 
between 105 and 106 per mL at 37˚C and 5% CO2 in a water-jacketed incubator. 
DR5 antibody agonist (mAb631), and fluorescent secondary antibody (NL557) 
were purchased from R&D Systems. DR5 antibody for Western blots was 
purchased from Cell Signaling Technologies. 
4.3.2 Detergent resistant membrane extraction 
Detergent resistant membrane (DRM) and detergent soluble membrane 
(DSM) fractions were isolated as previously described (144, 149, 150). Briefly, 
Jurkat cells (108 cells) were treated with DR5 agonist or control, resuspended in 
550 μl TNE buffer (150mM NaCl, 2mM EDTA in 50mM Tris-HCl, pH 7.4) and 
homogenized 20 times using a 25 gauge needle. Homogenate (500 μl) was mixed 
with an equal volume of 2% Triton X-100 in TNE buffer supplemented with 
protease inhibitors (yielding a 1% Triton X-100 final concentration) and lysis 
proceeded for 30 minutes on ice. Samples were centrifuged at 10,000g for 5 
minutes at 4˚C, and post-nuclear supernatants (1 ml) were mixed with 2ml of 56% 
sucrose, transferred to a SW41 ultracentrifuge tube, and overlaid with 5ml of 35% 
sucrose and 5ml of 5% sucrose. All sucrose solutions were prepared in TNE buffer 
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(150). Step gradients were centrifuged at 39,800 rpm (271,000g) at 4˚C for 18 
hours using a SW41Ti rotor centrifuge. Gradients were fractionated into 9 fractions 
of equal volume using a Gradient Station (BioComp Instruments). Protein content 
in each fraction was measured by BCA assay (Pierce) and compared to a BSA 
standard curve. Cholesterol content in each fraction was measured using Amplex 
Red cholesterol assay (Invitrogen Life Technologies). DR5 migration into DRM 
fractions was analyzed by TCA precipitation and Western blot analysis, using 
equal volumes of each fraction. Results are from 3 independent experiments. 
4.3.3 Caspase-8 activity 
Caspase-8 activity was measured as previously described (43). Jurkat cells 
were treated with a DR5-specific antibody agonist at 1 μg/ml for 4 hours at 37˚C. 
Caspase activity was measured using CaspGLOW Red Active Caspase 8 staining 
kit (BioVision) according to manufacturer instructions. Fluorescent labeled active 
caspase-8 was detected by flow cytometry (FACSCalibur) over 50,000 cells. Data 
was analyzed using FlowJo software (Tree Star, Inc.), where identical gating 
schemes were used to determine the percentage of caspase-8 active cells. 
4.3.4 Cholesterol extraction 
To extract membrane cholesterol, Jurkat cells were washed in PBS and 
resuspended in serum-free media (RPMI-1640). Cells were treated with 5mM 
methyl-beta-cyclodextrin in serum-free RPMI for 30 minutes at 37˚C, then gently 
washed with PBS before stimulation with agonist. 
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4.3.5 Western blotting 
Jurkat cells were washed with PBS and treated with DR5-specific antibody 
agonist for 1 hour in PBS. In cross-linking experiments, cells were then treated 
with 1 mM of the amine-reactive membrane-impermeant crosslinker BS3 (Pierce) 
for 30 minutes at room temperature, then quenched with 20 mM Tris-HCl (pH 7.5) 
for 15 minutes at room temperature. Cells were pelleted by centrifugation and 
lysed in RIPA buffer (50mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% Sodium 
deoxycholate, 0.1% SDS, 1% NP-40) supplemented with protease inhibitors and 
10 mM iodoacetamide for 1-2 hours at 4˚C. Total protein concentration of lysates 
was determined by BCA assay (Pierce) and equal amounts of total protein (~80ug) 
were mixed with 4x NuPAGE sample buffer (in the absence of reducing agents), 
boiled for 10 minutes, and loaded on 4-12% Bis-Tris SDS-PAGE gel (Invitrogen). 
Proteins were transferred to nitrocellulose membrane and probed using an 
antibody against DR5 (D4E9, Cell Signaling) and anti-rabbit HRP-conjugated 
secondary antibody (GE Amersham), and detected using ECL Plus (GE 
Amersham). 
4.3.6 Confocal imaging and analysis 
Jurkat cells were untreated or treated with 5mM MβCD to deplete 
cholesterol as described above. Cell washes in subsequent steps were performed 
by centrifuging at 10g and gently resuspending in ice-cold PBS with 1% FBS. Cells 
were washed once and treated with mAb631 agonist at 5 μg/mL in PBS with 1% 
FBS for 30 minutes on ice. DR5 was removed by washing twice, and cells were 
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resuspended with 5 μg/mL NorthernLights557 in PBS with 1% FBS, then tumbled 
for 30 minutes at 4C. Cells were then washed twice, resuspended, and plated on 
poly-lysine coated 35 mm glass-bottom culture dishes (MatTek Corporation) for 
imaging. Cells were allowed to settle before taking images. 
Cells were imaged using an Olympus IX82 inverted microscope equipped 
with a FluoView FV1000 laser scanning confocal head with 543 nm laser excitation 
and 555-655 nm emission using a 100x (1.3NA) oil immersion objective lens. All 
images were acquired at the same laser intensity and resolution (1600x1600 pixel, 
0.079 um/pixel edge). 
Images were analyzed using MATLAB. Each image, containing 10–30 cells 
was first smoothed using a low-pass 2D finite impulse response filter with a 
Gaussian window. Background intensity was subtracted for each image by 
selecting a region of the field containing no cells. Each cell border was selected 
manually from the light field image, and these points fit to an ellipse. A 30 pixel 
shell along this ellipse was isolated, avoiding the inclusion of any potential 
fluorescence in the cytoplasm (some cells showed limited internalized label). 
Angular intensity was then determined along the shell in 1° bins. The peak 
positions were determined using the MATLAB ‘findpeaks’ command on an ideal 
low-pass filtered angular integration trace. The peak locations were used as 
parameters to fit the raw angular integration trace to a 1D mixed Gaussian 
distribution, which solved for the maximum intensity and standard deviation of each 
peak. 
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4.3.7 Replica exchange molecular dynamics of the long isoform DR5 
transmembrane domain 
All-atom Replica Exchange Molecular Dynamics (REMD) was run using the 
MMTSB toolset (151). DR5 is expressed as both long and short isoforms (DR5-S 
and DR5-L), where the long isoform is able to form disulfide-linked dimers, while 
the short isoform is not. We used DR5-L here to expand on our finding that disulfide 
bonding in DR5 depends on membrane cholesterol. The starting structure of the 
DR5-L transmembrane (TM) domain was an ideal helix using residues 200-239 
(SSPGTPASPCSLSGIIIGVTVAAVVLIVAVFVCKSLLWKK). The single 
transmembrane helix was duplicated to generate a dimer and the two segments 
were started ~8 Å from each other. Simulations used the CHARMM 22 
parameters(152, 153) with CMAP correction(154) and the SHAKE algorithm (155). 
The protein was centered in an implicit bilayer, modeled using the Generalized 
Born with simple switching function (156, 157). The hydrophobic thickness was set 
to 32 and 40 Å to model non-raft and raft domains, respectively, and the switching 
length was set to 0.6 Å. 16 replicates were run from 4 independent starting 
configurations at 300K – 600K using the Nosé-Hoover method to control the 
temperature(158). Each replicate was run for 10 ns (total of 640 ns for the 4 sets 
of 16 replicates) using a 2 fs time step. Replica exchange was attempted every 
1000 steps with a success rate of ~20%. Structures from the 300K window were 
used for analysis. 
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4.4. Results 
4.4.1 DR5 signal transduction in response to agonistic antibody is raft-dependent 
TRAIL induction causes DR5 to migrate into cholesterol-rich, detergent 
resistant membrane (DRM) fractions and when the membrane is cholesterol-
depleted by MβCD treatment, DR5 signaling via caspase-8 activation is inhibited 
(144). This study uses the agonistic antibody, mAb631 in lieu of TRAIL to trigger 
DR5 signaling. Thus we first determined that the effects of mAb631 and TRAIL 
induction of DR5 with respect to its raft/non-raft behavior are consistent. Jurkat 
cells were treated with agonistic antibody, lysed, and separated by sucrose 
gradient ultracentrifugation as described in Materials and Methods. Activation by 
agonistic antibody causes DR5 to relocate from high density fractions to lower 
density, cholesterol rich fractions (Figure 4-6), consistent with DR5 behavior in 
response to TRAIL. We then investigated whether agonist-induced, DR5 
dependent caspase-8 activation depends on DR5 migration to DRM fractions. We 
treated cells with MβCD to deplete membrane cholesterol, thereby preventing DR5 
relocation to cholesterol-rich membrane fractions, then treated cells with agonistic 
antibody and measured caspase-8 activation. Jurkat cells with membrane 
cholesterol (i.e. not treated with MβCD) efficiently activate caspase-8 upon the 
addition of DR5 agonist (Figure 4-1, compare gray and black distributions). Pre-
treatment with MβCD results in a reduced ability of these cells to activate caspase-
8 (Figure 4-1, compare gray and black distributions). 
  77 
 
Figure 4-1. Membrane cholesterol is required for efficient activation of caspase-8 by 
DR5. Jurkat cells were pre-treated with either control (A) or MβCD (B), followed by 
no treatment or α-DR5 (grey distribution and black line, respectively), and caspase-
8 activity was measured using Red-IETD-FMK and flow cytometry. Plotted is a 
histogram of caspase-8 activity level showing the ligand-dependent activation of 
caspase-8 and reduced activity in cells pre-treated with MβCD. (C) The activation of 
caspase-8 is quantified using identical gating schemes on each population, and the 
results are plotted as fold activation of caspase-8. 
 
4.4.2 Ligand-receptor networks form in the absence and presence of membrane 
cholesterol 
DR5 agonistic antibody has been established to induce DR5 network 
formation (43), and we have confirmed above that it drives the co-localization of 
the receptor to cholesterol-rich membrane fractions. However, there is no clear 
evidence that lipid rafts induce DR5 network formation or vice versa. Ligand-
receptor networks are routinely identified using confocal fluorescence microscopy, 
as in this study, in order to quantify cluster size and number (43, 63, 127). Jurkat 
cells were pre-treated with MβCD (or control), to extract membrane cholesterol, 
and cells were subsequently treated with DR5 antibody agonist. Receptor-bound 
agonist was labeled with fluorescent secondary antibody and imaged using 
confocal microscopy to quantitatively determine the extent of network formation in 
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the membrane with and without MβCD treatment (Figure 4-2). Treatment of Jurkat 
cells with MβCD has been shown to deplete cholesterol within 30 minutes in a 
dose-dependent manner and extracts cholesterol preferentially from the plasma 
membrane, since it is not believed to enter live cells (159). Cell cholesterol content 
was measured using the Amplex Red assay to confirm ~50% cholesterol depletion 
in MβCD treated cells. We measured 0.45 μg cholesterol per μg lysate in untreated 
vs. 0.19 μg cholesterol per μg lysate in MβCD treated cells, a reduction of 58%. 
Removal of cholesterol much beyond 50% has been shown to cause substantial 
cell death in Jurkat cells (160). Images were taken in 3 separate experiments and 
the mean and standard error of each measurement were calculated. 
In both untreated and MβCD treated cells, stimulation with labeled mAb631 
resulted in punctate staining along the cell membrane indicating ligand-receptor 
clustering (Figure 4-2a,b) as has been shown previously in DR5 and other 
members of the TNFR superfamily (43, 65, 128, 160-163). To determine the 
number and size distribution of these DR5 networks we fit the angular intensity 
trace to a 1D mixed Gaussian distribution (Figure 4-2c). The total integrated label 
intensity reports the total ligand bound per cell, while the total number of peaks in 
each cell reports the number of independent networks, and the heights and widths 
of the individual Gaussians were used to determine network size.  Quantitative 
analysis revealed no significant differences in the extent of network-formation in 
untreated and MβCD treated cells. Total fluorescence per cell was determined by 
taking the area-under-the-curve (AUC) of the raw angular intensity trace. The AUC 
in the untreated and MβCD treated cells were 1.49x105 ± 3.8x104 and 1.17x105 ± 
  79 
2.06x104, respectively (Figure 4-2d), indicating that cholesterol depletion did not 
inhibit mAb631 binding. The average number of clusters per cell was 38.2 ± 0.85 
and 39.3 ± 0.95 in the control and MβCD treated cells respectively (Figure 4-2e). 
Peaks were counted as any bin along the angular integration with higher intensity 
than both neighboring bins, and therefore, any fluorescence above background is 
counted. The Gaussian integral of each of the networks, calculated as 3|5|√7 
where 3 is the height of the curve peak and 5 is the standard deviation, reveals the 
distribution of cluster sizes (Figure 4-2f). DR5 in both the control and MβCD treated 
cells formed networks with integrated intensity varying widely between ~10 and 
2x104 (intensity units) with equivalent distributions. Error bars are calculated from 
triplicate experiments and reported for every eighth bin for clarity. Lastly, we plotted 
the distribution of network widths (calculated as 4 × 5 to represent the arc length 
in degrees containing 95.4% of the labeled receptor) (Figure 4-2g). Again, both 
control and MβCD cells behaved the same, with network sizes centered at 10°. 
Assuming a cell of radius 3 μm, a 10° arc spans 524 nm, which is on the same 
scale as the Fas networks measured by Siegel et al. (63). To conclude, treatment 
with MβCD does not prevent agonist binding, and no difference in average network 
size is discernible in cholesterol depleted vs. control cells, strongly suggesting that 
mAb631-DR5 clustering is not raft dependent. 
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Figure 4-2. Ligand-receptor cluster formation does not require membrane 
cholesterol. Jurkat cells were treated with mAb631 and labeled with fluorescent 
secondary antibody. Shown are Jurkat cells under transmitted luminescence (a), 
ligand-receptor clusters illuminated by fluorescently labeled agonist antibody (b), 
and the angular fluorescence intensity trace for the cell shown (c). The raw trace is 
shown in black and the Gaussian fit in blue. The total ligand bound (d), number of 
clusters per cell (e), and distribution of SPOTS sizes are invariant between 
untreated and MβCD treated cells. 
 
4.4.3 Membrane cholesterol is required for dimerization of DR5 in response to 
ligand 
We have shown previously that upon the addition of antibody agonist DR5 
forms disulfide-linked dimers that are subsumed within ligand-receptor networks 
(43). Figure 4-3 repeats this result, and is expanded to assess whether extraction 
of membrane cholesterol has any effect on ligand-induced DR5 dimerization. 
Jurkat cells were pre-treated with MβCD (5mM) or left untreated, and cells were 
subsequently washed and treated with DR5 antibody agonist, cross-linked, and 
lysed. Equal amounts of total protein were run on non-reducing SDS-PAGE and 
DR5 dimerization and oligomerization were analyzed by Western blot (Figure 4-
  81 
3a). As can clearly be seen in the control cells, the ligand-induced DR5 dimer band 
disappears upon cross-linking (compare lane 2 to 4), because the dimer becomes 
part of the larger crosslinked network. The dimer band is present in the 
uncrosslinked sample (lane 2) because it is held together by a disulfide bond 
between TM helices via Cys-209, as previously shown (43). The networks can be 
seen clearly as high molecular weight species larger than 260 kDa, and are 
induced by addition of ligand in both untreated and MβCD treated cells (lanes 4 
and 8). 
Cells pre-treated with MβCD have a markedly diminished ability to form DR5 
dimers (Figure 4-3a, b). To better evaluate the extent to which MβCD inhibits 
disulfide-linked dimerization of DR5, we ran the agonist treated and untreated 
samples with and without MβCD, then densitometrically quantified the amount of 
dimer using ImageJ. The Western blot in Figure 4-3b shows a smaller reduction in 
dimerization than that in Figure 4-3a, however quantification reveals significant 
differences between dimerization in untreated vs. MβCD treated cells (from 7 
independent experiments). In cells containing cholesterol, the addition of ligand 
causes a four-fold increase in the dimeric population of DR5. After pre-treatment 
of Jurkat cells with MβCD, ligand causes only a 2.5-fold increase in DR5 
dimerization (Figure 4-3c). Therefore, while depletion of membrane cholesterol 
does not alter the formation of large DR5 networks, it does influence the covalent 
structure of DR5 dimers subsumed within these oligomers. 
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Figure 4-3. Extraction of membrane cholesterol inhibits ligand-induced DR5 dimer 
formation. Jurkat cells were pre-treated with either control or MβCD, as indicated, 
to extract membrane cholesterol. Cells were subsequently washed and treated with 
α-DR5 agonist and lysed. Lysates were analyzed via non-reducing SDS-PAGE and 
Western blot using an antibody against DR5. Agonist-bound DR5 formed oligomeric 
networks in both untreated and MβCD treated cells (a, lanes 4 and 8). Asterisks 
indicate non-specific bands. Disulfide-linked dimerization of DR5 via Cys209 
occurred only in untreated cells (a, lane 2).Shown is the dimeric form of DR5 at 
approximately 85kd from a separate experiment (b).Quantification of DR5 dimer 
bands shows a significant increase in DR5 dimerization upon treatment with ligand, 
and that pre-treatment with MβCD diminishes DR5 dimerization (c). 
 
4.4.4 Molecular simulations suggest that membrane thickness controls DR5-L TM 
domain helical stability and Cys209 partition depth 
We have shown that migration to DRM fractions is necessary for ligand-
induced DR5-L covalent dimerization, however the biochemical and structural 
features of lipid rafts that promote disulfide-bond formation are unknown. To further 
explain this finding, we ran REMD simulations to explore differences in the 
preferred low-energy conformations of the DR5-L TM dimer in a thick (40 Å, 
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corresponding to cholesterol-rich) vs. a thin (32 Å, corresponding to cholesterol-
depleted) bilayer. We have previously simulated the disulfide-linked TM dimer to 
predict the structure and dynamics of the covalent dimer (43) however, here we 
simulated two un-bonded monomers. We hypothesized that disparate bilayer 
thicknesses would give rise to differences in monomer-monomer interactions, tilt, 
and helicity, and suggest the basis by which the thicker membrane promotes 
disulfide-bond formation. REMD is a powerful computational tool that allows a 
system to rapidly overcome free energy barriers and access low-energy 
conformational states while preserving ergodicity, however our results should be 
interpreted with the caveat that the accessible conformational space of the isolated 
TM domains, absent explicit membrane molecules, differs from that of the intact 
protein in situ. 
We previously observed the formation and stability of the tightly packed 
GxxxG dimerization motif (97, 134) in the disulfide linked DR5 TM domain dimer, 
one helical turn downstream of Cys209 (43). This motif is likewise stable in the 
non-bonded dimer in both the 32 Å and 40 Å bilayers (Figure 4-4). We expect that 
the presence of this motif stabilizes the dimer and thus promotes disulfide bond 
formation. Interestingly, the occurrence of the motif is more frequent in the thicker 
bilayer (Figure 4-4A). It should be noted that while this bilayer thickness 
dependence was clearly observed in two of the four starting configurations, the 
difference was less convincing in the other two (Figure 4-7). 
We then investigated three other possible thickness dependent differences: 
helix tilt, helicity, and partition depth. Because our simulation of the isolated TM 
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domain is able to access conformations that may not be sampled by the full-length 
protein or are otherwise not pertinent to the TM domain dimer (e.g. those in which 
the two helices are non-interacting), for the remainder of the analysis we compared 
only those structures in which the GxxxG interface was present (Figure 4-4a, 
boxed) The overall trends were the same if we considered all structures generated 
by the simulations. Bilayer thickness-dependent helix tilt and helical content due 
to hydrophobic mismatch (mismatch between the bilayer thickness and 
hydrophobic length of the TM domain) are often cited as determinants of TM 
domain behavior. We observed low tilt angles in both the 32 Å and 40 Å bilayers 
with little evidence of dependence on thickness (average tilt of 19˚ and 23˚ 
respectively, Figure 4-7). We then used the DSSP algorithm (164, 165) to calculate 
peptide secondary structure to determine whether bilayer thickness influenced 
helicity. We found that the same residues were helical in both bilayers, however 
helicity was increased by ~40% throughout the hydrophobic length of the peptide 
in the thicker bilayer (Figure 4-4b). The most obvious explanation for an increase 
in helicity is that the interfacial (N-terminal), partially solvent-exposed residues in 
the thinner bilayer become more stably folded in the thicker bilayer in order to 
minimize their free energy. This offers an explanation for how the thicker bilayer 
favorably positions the two Cys209 residues for disulfide bond formation (by 
stabilizing them in the helices on the same helical face as the GxxxG motif). 
The DR5 TM domain notably contains a Trp at residue 237 which partitions 
to the switching region of the bilayer (corresponding to the headgroup/acyl chain 
region of an explicit bilayer). Trp residues are well-known to anchor TM helices in 
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this region (166-170). As shown in Figure 4-4c,d, Trp237 partitions to the switching 
region in both systems. This causes Cys209 to partition to the switching region of 
the 32 Å bilayer, but draws Cys209 deeper into the low-dielectric region 
(corresponding to the bilayer interior) of the 40 Å bilayer. Immersion of these 
interfacial residues in the hydrophobic region of the bilayer may promote their 
folding into a stable helix. Additionally, a hydrophobic environment has been 
theorized to dramatically reduce the energy barrier of disulfide-exchange (171), 
and burial of Cys209 in the bilayer may enhance the rate of disulfide bond 
formation in rafts. Thus, a combination of increased helicity and hydrophobic 
immersion of Cys209 in thicker bilayers may explain the increased propensity to 
form disulfide-linked dimers. 
 
Figure 4-4. Membrane thickness affects DR5-L TM domain helical stability and 
Cys209 partition depth. The DR5-L transmembrane dimer was simulated using 
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REMD. The average GxxxG distance was plotted to identify the likely dimer 
conformation (< 6 Å, dashed box). This dimer conformation was sampled in both 
the 40 Å (black) and 32 Å (blue) implicit bilayers representing raft and non-raft 
domains respectively (a). Subsequent analysis is conducted on only these frames. 
The fraction of frames with helical secondary structure shows increased helix 
stability in the 40 Å bilayer (b). A snapshot of the simulated peptide in its GxxxG 
dimer configuration is shown with C209 shown in red, the G(213)xxxG(217) motif 
shown as blue spheres, and W237 shown as a red sphere (c). Trp237 (Cα atom) 
partitions directly outside the switching region in both the 40 Å (black) and 32 Å 
(blue) bilayers. Cys209 (sulfur atom) partitions at the switching region in the 32 Å 
bilayer (blue), but deep within the low dielectric region in the 40 Å bilayer (black) 
(d). The positions of the switching regions of each bilayer are shown as dashed 
horizontal line. 
 
4.5. Discussion 
Raft-dependent activation has been previously observed in a number of 
TNF receptors including DR5 (144) when induced by TRAIL. We have shown that 
raft-dependence is similarly a feature when DR5 is activated by agonistic antibody. 
Previously, Song et al. showed that DR5 in non-rafts (in TRAIL insensitive cells) 
triggered the NF-κB pathway rather than the apoptotic pathway (144). We did not 
investigate whether mAb631 induces NF-κB activation in cholesterol-depleted 
cells, however ongoing work will investigate this possibility. If mAb631 does 
activate the inflammatory pathway in cholesterol-depleted cells, it would suggest 
that DR5 clusters that are not stabilized by disulfide bonding recruit different 
cytosolic machinery that activates the NF-κB pathway, either by favoring a different 
dimer structure or by altering the dimerization kinetics of the TM domain. 
An additional possibility that we have not directly addressed is whether the 
depletion of cholesterol (elimination of rafts) prevents the co-localization of the 
receptor with the intracellular signaling machinery (the death inducing signaling 
complex, or DISC). In the case of Fas-induced apoptosis, the components of the 
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DR5 DISC are not constitutively present in the rafts (142), and they have been 
shown to co-immunoprecipitate with DR5 in both rafts and non-rafts (144). 
Therefore, the available evidence suggests that co-localization of the DISC and 
DR5 is not purely raft-driven. Nonetheless, our data cannot fully rule out this 
possibility. 
Raft-driven disulfide-bond formation has also been observed in the TM 
domain of the influenza A M2 protein (172). The TM domain of M2 resembles that 
of DR5-L with respect to its secondary structure, presentation of an extracellular 
cysteine, and propensity to form disulfide bonded multimers. Most importantly, the 
extent of dimerization of the M2 TM helix via disulfide bonding was shown to 
directly depend on both bilayer thickness (varied by changing the lipid chain length) 
and cholesterol concentration (which is also known to increase bilayer thickness) 
(173, 174). Specifically, Cristian et al. maximized disulfide-bond formation of the 
28.5 Å long M2 peptide in a 26.5 Å POPC bilayer (172). This translates to an angle 
of 21.6°, effectively the same as our measured angles for DR5-L. Furthermore, 
their result predicts that disulfide bond formation would be maximized in a thick, 
~40 Å bilayer for DR5-L, a 43 Å TM domain measured from Cys209 to W237. This 
biophysical result is consistent with our finding in cells that lipid rafts, which are 
both thicker and more enriched in cholesterol than non-rafts, drive DR5-L disulfide-
linked dimerization.  
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Figure 4-5. Updated activation model for DR5 incorporating bilayer structure. 
Instability in the transmembrane helix inhibits covalent dimerization of DR5 via 
Cys209 in non-rafts (a). Translocation to lipid rafts draws the cysteines into the 
bilayer interior, stabilizing the TM helices and driving disulfide bond formation (b). 
 
To conclude, our findings are further evidence that signaling by DR5 is 
driven by the formation of highly-organized networks in which structure is guided 
by not only receptor-receptor and ligand-receptor interactions, but also receptor 
interactions with the lipid membrane. Specifically, our results show that network 
formation does not depend on the local lipid microenvironment. However, in order 
for networks to be functional, at least in the case of the long isoform, the DR5 
transmembrane domain must undergo raft-dependent dimerization via Cys209. In 
non-rafts, instability in the transmembrane helix inhibits covalent dimerization of 
DR5-L. When the receptor translocates into lipid rafts, the cysteines are drawn into 
the bilayer interior, stabilizing the TM helices and driving disulfide bond formation 
(Figure 4-5). The disulfide-linked DR5 dimer, subsumed within the ligand-receptor 
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network that is immersed in a lipid raft, can then undergo a transition to the active 
state as our previous results suggest (53, 60). 
 
4.6. Supplemental Figures 
 
Figure 4-6. Agonistic antibody causes relocalization of DR5 into cholesterol-rich 
membrane regions. (A) Jurkat cells were treated with DR5 agonist (α-DR5) or left 
untreated, triggering DR5 migration from high-density DSM fraction to low density 
DRM fraction upon stimulation with agonist. DR5 isoforms are indicated by 
arrowheads. (B) Cholesterol concentration in each fraction shows cholesterol 
enrichment in DRM fraction 3, suggesting the presence of cholesterol-rich lipid 
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rafts, in control and agonist treated samples (gray and black bars, respectively). (C) 
Total protein content measured in each fraction in the absence and presence of 
agonist (grey and black bars, respectively). 
 
 
 
 
Figure 4-7. Plots of GxxxG distance for REMD simulations from each of the 4 
starting configurations (A-D). Tilt angles of the GxxxG dimer conformations in the 
40 and 32 Å bilayers (E). 
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Chapter 5  – Oxidation Increases the Strength of the 
Methionine-aromatic Interaction 
5.1. Prefatory note 
This chapter builds on a previous publication in the Sachs Lab that studied 
the prevalence and importance of the methionine-aromatic interaction, especially 
where it serves as a critical element of the binding interfaces that join TRAIL to 
DR5 and LTα to TNFR1(43). As a middle author of that paper, I contributed 
immunoprecipitation and functional data that showed that abolishing either 
component of these methionine-aromatic motifs resulted in substantial reduction 
in LTα/TNFR1 binding and signaling. That publication left a lingering question – 
what happens to the methionine-aromatic motif when methionine is oxidized? – 
The LTα/TNFR1 system was well suited to address this question as the methionine 
was in the ligand and could be modified without subjecting the cell to cytotoxic 
levels of oxidative stress. Thus, we ran the same experiments, oxidizing LTα 
instead of mutating it. This led to the multi-disciplinary, in-depth investigation of 
oxidation of the methionine-aromatic motif that follows. 
 
Figure 5-1. The met-aromatic interaction in LTα/TNFR1. Mutation of the aromatic-
containing residue within the structurally homologous loop in TNFR1 disrupts 
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interaction with its cognate ligand, LTα, measured by immunoprecipitation. Whole 
cell lysates show equal expression of wild type and mutant receptor (left). Cells 
were treated with various concentrations of LTα ligand, wild type and mutant. 
Mutation of the sulfur-containing methionine residue within LTα ligand disrupts the 
function, shown by degradation of IκBα at various concentrations of ligand (right). 
Adapted from Valley et al. (43). 
5.2. Summary 
Oxidation of methionine disrupts the structure and function of a range of 
proteins, but little is understood about the chemistry that underlies these 
perturbations. We show, using quantum mechanical calculations, that the strength 
of the methionine-aromatic interaction motif, a driving force for protein folding and 
protein-protein interaction that has emerged in recent years, is increased by 0.5 – 
1.4 kcal/mol when methionine is oxidized and no hydrogen bonds are formed. We 
performed thermal denaturation experiments on model peptides to show that 
oxidation of the motif stabilizes the interaction by 0.5-0.6 kcal/mol. We also find 
that non-hydrogen bonded interactions between dimethyl sulfoxide and aromatic 
groups are prevalent in both the Protein Data Bank and Cambridge Structural 
Database, and are enriched over dimethyl sulfoxide/aliphatic interactions. We 
confirm the biological relevance of these findings through a combination of cell 
biology, electron paramagnetic resonance spectroscopy and molecular dynamics 
simulations on 1) calmodulin structure and dynamics and 2) lymphotoxin-α/TNFR1 
binding. Thus, the methionine aromatic motif is a determinant of protein structural 
and functional sensitivity to oxidative stress. 
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5.3. Introduction 
The methionine-aromatic motif is now recognized as a promiscuous, highly 
stabilizing non-covalent interaction that forms between methionine thioether 
sulfurs and the aromatic rings of nearby (~5 Å) tyrosine, tryptophan, and 
phenylalanine residues(175-180). Methionine-aromatic interactions are present in 
~33% of protein structures (Protein Data Bank (PDB) as of 2012), and the majority 
of those structures have more than five instances of the motif. The motif is 
significant because it is substantially stronger than a purely hydrophobic contact, 
suggesting that it plays a unique role in stabilizing both protein structure and 
ligand-receptor binding(175), and potentially expanding on the evolutionary 
significance of methionine as a member of the amino-acid library.  
Methionine-aromatic interactions were first detected in a small 
bioinformatics study that found alternating sulfur-containing and aromatic amino 
acids in eight protein structures(179, 180). An analysis of 36 protein structures in 
1985(177) and our exhaustive analysis of the PDB (as of 2012) confirmed that 
methionine-aromatic interactions are enriched compared to aromatic interactions 
with non-sulfur-containing amino acids(175). A search of the Cambridge 
Crystallographic Structural Database (CSD) similarly found an abundance of 
sulfur-aromatic (S/Ar) interactions between the C-S-C divalent sulfur motif and 
aromatic groups(176). The interaction free energy between methionine and 
phenylalanine has been studied experimentally(181, 182). One such study 
measured the Met-Phe interaction (-0.65 ± 0.15 kcal/mol) in a thermal unfolding 
experiment of a synthetic helical peptide with phenylalanine and methionine at 
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positions i and i+4 respectively(182). Quantum calculations by Pranata revealed 
an interaction energy of 1-3 kcal/mol at a range of 4-6 Å between dimethyl sulfide 
(DMS) and benzene(178). Our own quantum calculations confirmed these results, 
and expanded the analysis to include DMS interactions with phenol and indole, 
recapitulating the methionine-tyrosine and methionine-tryptophan interactions, 
respectively, and identified that dispersion interactions are the major contributors 
to stability(175). 
In addition to forming highly stabilizing interactions with aromatic residues, 
methionine is uniquely important because it is susceptible to oxidative 
modification(183). Oxidation is widely studied in the context of diseases ranging 
from inflammatory diseases (such as Crohn’s disease(34), rheumatoid 
arthritis(184) and irritable bowel syndrome(185)) to pulmonary fibrosis(186, 187) 
and cancer(188, 189) among others. In oxidizing environments, the methionine 
thioether can undergo modification with the addition of one or two sulfonyl oxygens 
to become methionine sulfoxide (MetOx) or sulfone, respectively(183). Elevated 
levels of methionine sulfoxide have been detected in diseased tissues, but 
methionine sulfone is rare(190). Methionine sulfoxidation is known to regulate the 
activity of certain proteins, while in other cases, methionine-rich domains protect 
critical amino acids from oxidation by removing free radicals and regulating the 
local redox environment(191).  
Despite this functional significance, the specific molecular mechanism 
through which proteins sense and respond to oxidative modification of methionine 
residues has not been fully characterized. It has been posited that polarization of 
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the methionine thioether by oxidation could weaken the methionine-aromatic 
interaction by ablating the hydrophobic contribution(192), but this has never been 
tested experimentally. In the present study we will show the opposite to be true – 
that oxidation of methionine strengthens its interaction with aromatic residues, and 
that this has the potential to disrupt native conformation and alter protein function. 
Importantly, we show that the interaction is strengthened even in the absence of a 
hydrogen bond between the sulfoxide oxygen (acceptor) and donor hydrogens (on 
Tyr or Trp). Through quantum mechanical calculations, we show that the 
interaction between the dipole moment of dimethyl sulfoxide (DMSO) and the 
aromatic ring quadrupole moment is the main contribution to the increased stability 
of the motif. 
We start by analyzing both the PDB and the CSD to identify and 
characterize interactions between DMSO (a small molecule analog to MetOx) and 
aromatic groups in the crystal structures of proteins and small molecules. DMSO 
has previously been shown to solubilize tryptophan more readily than leucine, 
alanine, and glycine(193), so we expected to find that it specifically interacts with 
aromatic sidechains. We then performed quantum mechanical calculations on 
model compounds to determine the strength of the sulfoxide-aromatic interaction, 
and assessed the potential contribution of hydrogen bonding on the motif in a 
variety of solvent environments. We then isolated and determined the strength of 
the specific interaction between unoxidized and oxidized methionine and the 
sidechain of phenylalanine by extending a previously described helix unfolding 
experiment and performing a double mutant cycle analysis(182).  
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We investigated the effects of site-specific methionine oxidation on the 
methionine-aromatic interaction in two biologically important proteins. First, using 
a combination of electron paramagnetic resonance (EPR) spectroscopy and 
replica-exchange molecular dynamics (REMD) simulations, we probe the effects 
of oxidation on the structure of calmodulin (CaM). CaM is one of the best-
documented examples of a protein whose function is modulated by methionine 
oxidation. The nine methionine residues are targets for reversible oxidation, which 
serves as a mechanism through which the cell senses and responds to oxidative 
stress by modulating metabolism and energy utilization(194-197). Published data 
suggests that methionine oxidation can perturb local secondary structure, induce 
conformational disorder, and disrupt key hydrophobic interactions(198-201). 
Methionine oxidation in CaM has been shown to induce global structural 
changes(202) and impair the ability of CaM to regulate the ryanodine receptor 
calcium channel(203-205), the plasma membrane Ca2+ ATPase(202, 206-209), 
and other targets(210, 211). Here we provide evidence that interactions between 
methionine and aromatic side chains play a crucial role in CaM structure, 
correlating with functional changes induced by oxidation.  
Second, we investigate lymphotoxin-α (LTα) binding to tumor necrosis 
factor receptor 1 (TNFR1), which we showed is stabilized by a methionine-
aromatic interaction between M120 of LTα and W107 of TNFR1(175). TNFR1 is a 
type-I transmembrane protein that is activated by its ligand, LTα, and initiates the 
pro-inflammatory NF-κB pathway(12). Given that LTα has been implicated in a 
number of diseases that are also associated with local oxidative stress(34, 184-
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189), and because the extracellular environment at sites of chronic inflammation 
and tumor is oxidative(212), it is critical to understand the impact of oxidation on 
the ligand’s binding and potency in activating TNFR1. Tumor necrosis factor (TNF) 
is a ligand that binds to the same receptor targets and is similar in sequence, 
structure, and function to LTα, but notably lacks methionine residues. This provides 
a biologically relevant model system in which to directly investigate the effect of 
methionine oxidation on the methionine-aromatic motif. We find that oxidation of 
M120, which is indispensable for ligand-receptor binding via its interaction with 
W107, unexpectedly interferes with ligand activity and binding. Further 
investigation suggests this to be a result of competing interactions between 
oxidized M120 and nearby intramolecular tyrosine residues. 
5.4. Results 
5.4.1 DMSO-aromatic interactions are prevalent in small molecule and protein 
crystal structure databases 
To find examples of sulfoxide-aromatic interactions, we searched the PDB 
and CSD for occurrences of DMSO molecules near aromatic rings (Figure 5-2). 
The PDB is a repository containing crystal structures of proteins and the CSD is 
the analogous repository for organic and metal-organic small molecules. We 
analyzed a non-redundant subset of the PDB comprised of all structures containing 
at least one DMSO molecule. Structures sharing >90% sequence identity were 
represented by a single structure with the highest score as ranked according to 
RCSB PDB quality factor algorithm. Redundant structures were excluded, as they 
do not represent truly independent data points for the purposes of our informatics 
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study. Our search yielded 205 unique structures containing a total of 872 DMSO 
molecules. A representative example showing a tyrosine aromatic ring and DMSO 
is shown in Figure 5-2a. There is a clear enrichment of aromatic residues 4-7 Å, 
with a maximum at 5Å, from DMSO sulfurs as compared to all amino acids or the 
aliphatic amino acids, closely resembling the radial density function for methionine 
in our previous study(175) (Figure 5-2b). 451 (51.7%) DMSO molecules were 
found within 7 Å of the center of the nearest aromatic residue. Only 32 of these 
(7.1%) are in position to accept a hydrogen bond from either tryptophan or tyrosine. 
Thus, hydrogen bonding does not play a substantial role in DMSO-aromatic 
bonding in the PDB. Our search of the CSD similarly found an ~50% enrichment 
of DMSO-aromatic contacts (representative example, Figure 5-2c) compared to C-
CH2-C-aromatic pairs (Figure 5-2d), which were used previously as non-interacting 
control to show the enrichment of the Met-aromatic motif(176). Again, only a small 
percentage of the CSD instances of DMSO/phenol or DMSO/indole pairs were in 
position to form a hydrogen bond (<14%). 
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Figure 5-2. Structural informatics search of the CSD and PDB. A representative 
snapshot of a DMSO-aromatic interaction taken from the PDB (PDB: 4KAD) (a). The 
radial distributions of all amino acids and aromatic amino acids is plotted relative 
to DMSO, showing a clear enrichment of aromatic residues 4-7 Å from DMSO (b). 
We compare to the radial density of all amino acids and the aliphatic amino acids, 
Leu, Ile, and Val, relative to DMSO. A representative snapshot of a DMSO-aromatic 
interaction taken from the CSD (CSD: AWUHEF) (c). The radial density of aromatic 
groups relative to DMSO sulfur shows an enrichment around 4-7 Å (d). We compare 
to the radial density of aromatic groups relative to C-CH2-C motifs, which are non-
interacting. 
 
We then parsed the frequency of methionine-aromatic interactions in the 
PDB <7 Å between DMSO and the center of phenylalanine, tyrosine, and 
tryptophan individually. Figure 5-3a shows that the interaction is more prevalent 
with Tyr and Trp than with Phe when normalized by the relative abundance of each 
of these amino acids in our non-redundant, DMSO-containing subset of the PDB. 
This trend is not explained by relative solvent accessibility, as Trp and Phe have 
similar solvent accessibilities, while that of Tyr is somewhat higher(213). We 
calculate a 1.3 and 1.4 fold preference for tyrosine and tryptophan over 
phenylalanine, respectively, translating to a ~0.3 kcal/mol increase in Met-Tyr and 
Met-Trp stability compared to Met-Phe. Therefore, these database results suggest 
that, even though hydrogen bonding is not common in the interaction motif, DMSO 
interacts more favorably with tyrosine and tryptophan than with phenylalanine. This 
has similarly been observed in cation-π interactions in proteins, where the more 
electron rich Pi systems of tryptophan and tyrosine relative to phenylalanine make 
them more attractive to positively charged ligands(214). 
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5.4.2 Quantum calculations reveal that oxidation strengthens the sulfur-aromatic 
interaction  
The interaction energy between the reduced (DMS) and oxidized (DMSO) 
models of methionine with the model aromatic compounds benzene, phenol, and 
indole was calculated with full geometry optimizations using the Møller-Plesset 
perturbation theory at the second order (MP2) in gas phase as described in the 
Quantum Calculations Methods section. The results corrected for basis set 
superposition error are reported in Table 5-1 and the corresponding structures are 
shown in Figure 5-7. Uncorrected interaction energies and M06-2X data are shown 
in Table 5-4. The data show that upon oxidation of DMS to DMSO the complex 
with benzene is 0.9 kcal/mol more stable. To understand the origin of this 
stabilization we first tested the possible contribution of dispersion interactions, 
which we previously found contributed to the increased stability of the complex 
between DMS and benzene when compared to its sulfur-free analog, 
propane(175). The results (Table 5-5) show that the dispersion energy contribution 
for DMS/benzene is -8.4 kcal/mol, and for DMSO/benzene it is -8.2 kcal/mol. The 
change in dispersion energy contribution is small (0.2 kcal/mol) and is more 
stabilizing for the DMS/benzene interaction than for the DMSO/benzene. 
Therefore dispersion interactions are not the source of the stronger interaction 
energy in the oxidized complex. Rather, the stronger interaction can be explained 
in terms of the interaction between the dipole moment of DMSO and the aromatic 
ring quadrupole moment. The calculated dipole moment for DMS is 1.8 Debye, 
while in DMSO the enhanced polarization due to the presence of oxygen results in 
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a dipole moment of 5.0 Debye roughly aligned along the S=O bond. Furthermore, 
both DMS and DMSO maximize dispersion interactions with the benzene ring by 
aligning the Me-S-Me moiety over the ring plane; as a result, in the DMS/benzene 
complex the orientation of the small dipole of DMS is orthogonal to the benzene 
quadrupole moment, while in DMSO/benzene the angle between the S=O bond 
and the ring is approximately 120°, which is well poised for a favorable 
dipole/quadrupole interaction. The Natural Bond Orbital (NBO) charge analysis for 
the complex and isolated species (see Table 5-6 and Figure 5-9) supports this 
explanation, showing a large positive charge (+1.19 e) on the sulfur that can 
interact with the π electron cloud, balanced by a negative charge (-0.96 e) on the 
oxygen that is pointing away from the benzene ring (see Figure 5-7).  
 Benzene Phenol Indole 
DMS -2.4 -4.9 -4.7 
DMSO -3.3 -10.6 -10.0 
Table 5-1. Interaction energies for DMS or DMSO with benzene, phenol and indole.  
Results in kcal/mol are computed for fully optimized structures at the MP2/6-
311+G(d,p) level and corrected for basis set superposition error. The corresponding 
structures are reported in Figure 5-7. 
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Figure 5-3. Relative frequency of DMSO interactions with phenylalanine, tyrosine, 
and tryptophan corresponds to interaction energy. The fraction of DMSO molecules 
participating in a methionine-aromatic interaction with each aromatic residue is 
plotted. These values are normalized against the abundance of each aromatic group 
in the PDB subset analyzed and shows enrichment of interactions with tyrosine and 
tryptophan compared to DMSO-phenylalanine interactions (a). Interaction energies 
calculated at the MP2/6-311+G(d,p) with CP-corrections for the complexes between 
benzene, phenol, and indole and DMSO. The structures exclude hydrogen bonding 
and are calculated using ensembles of configurations from the simulations as 
described (b). 
Table 5-1 shows that for phenol and indole the change in interaction energy 
upon oxidation of DMS to DMSO (-5.7 and -5.3 kcal/mol, respectively) is of larger 
magnitude than for benzene. Such a large change cannot be explained in terms of 
enhanced dipole/quadrupole interactions, and is a result of specific hydrogen bond 
interactions between the negatively charged DMSO oxygen and the hydrogen of 
the phenol hydroxyl group or the indole amine (see Figure 5-7). To determine the 
relevance of hydrogen bonding in sulfoxide-aromatic interactions in a range of 
environments, we ran molecular dynamics simulations of DMSO and phenol, or 
indole in hexane, ethyl acetate (EtOAc), or TIP3P water using the adaptive biasing 
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force (ABF) module in NAMD. We found (see Figure 5-10) that DMSO hydrogen 
bonded substantially with phenol and indole in hexane. Thus, in this nonpolar 
environment we expect the contribution of the hydrogen bond to outweigh the 
increased interaction energy of the S/Ar motif. Importantly, in EtOAc (a polar non-
protic solvent with dielectric constant of 6, fairly representative of the interior of a 
protein), hydrogen bonding occurred much less frequently. Therefore, the S/Ar 
motif plays a relevant role in the stabilization of the complex in this environment. 
Finally, in water hydrogen bonding between DMSO and the aromatic residues was 
essentially absent and replaced by solvation of the DMSO sulfonyl group and the 
aromatic hydrogen donor by water. This last simulation mimics the conditions of 
residues on the surface of a protein, which are often involved in protein-protein 
interactions(215).  
To disentangle the energy contribution due to specific hydrogen bonding 
from that of sulfur-aromatic interaction, we performed quantum mechanical 
calculations on two ensembles of configurations from our simulations in EtOAc. 
Benzene and DMS systems were also run to compare to the results of our full 
optimization calculations. As discussed above, the EtOAc intermediate dielectric 
constant (~6) and its capability of accepting hydrogen bonds allows the complexes 
between DMSO and phenol/indole to sample both hydrogen-bonded and non-
hydrogen-bonded conformations with similar probability. Therefore, by separating 
the structures that contained only sulfur-aromatic interactions from those that were 
hydrogen-bonded (see Methods), we analyzed two ensembles of conformations 
that are good mimics of the interactions on the surface of a protein and in its 
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hydrophobic core. The results reported in Table 5-2 and Figure 5-3b for ensembles 
of structures explicitly sampled in EtOAc solvent are in good agreement with the 
data from the full optimization reported in Table 5-1, and together indicate that (a) 
in the absence of hydrogen bond, oxidation of DMS to DMSO strengthens the 
sulfur-aromatic interaction by 0.5 - 1.5 kcal/mol, and (b) in hydrogen bonded 
structures (rare in proteins) the stabilization of the complex can be as strong as 8 
kcal/mol.  
 Benzene Phenol Indole 
DMS -0.9 -1.0 -1.3 
DMSO Non H-bonded -1.4 -2.2 -2.7 
DMSO H-bonded  -9.0 -7.5 
Table 5-2. Interaction energies in EtOAc. Interaction energies in kcal/mol of DMS or 
DMSO with benzene, phenol, and indole in EtOAc. 
 
5.4.3 Evaluation of Oxidation in a Model Peptide Scaffold 
To experimentally assess the database findings and quantum results, we 
used thermal denaturation of peptide constructs that were designed based on a 
previously reported 15-residue peptide scaffold. Thus, our approach recapitulates 
and expands on the first published experiments that were used to assess the 
strength of the S/Ar interaction (see Methods)(182). In that study, in which 
oxidation was not addressed, the Met-Phe pair was found to interact (∆Gint) with 
0.65 kcal/mol, establishing the baseline for our investigation of the oxidized 
methionine-aromatic interaction (which we denote as SOx/Ar). The peptides used 
here are the same as in that study: a phenylalanine is placed at position 9 and a 
methionine (or methionine sulfoxide) residue is placed at position 13 (Table 5-8). 
The peptide scaffold was originally designed such that the strength of the 
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interaction at these i, i+4 sites determines the thermal stability of the peptide 
secondary structure.  
As shown in Table 5-3, our experiments reproduced the original S/Ar result 
for Met-Phe (∆Gint=0.62 kcal/mol). Then, upon oxidation of the methionine, the data 
shows that the interaction between methionine and phenylalanine is doubled 
(strengthened by 0.62 kcal/mol). To obtain these results, we performed the same 
thermal unfolding experiment as done previously, monitoring the secondary 
structure of the peptide scaffold by circular dichroism (CD)(182). Two aspects of 
our approach differed from the original study. First, we performed a double mutant 
cycle to isolate the methionine-aromatic interaction from possible interference due 
to neighboring residues (Figure 5-12). This approach solidifies our reported 
interaction free energies, and is especially important in the case of oxidized 
methionine because of the increased likelihood of hydrogen bonds and 
electrostatic interactions with the other residues in the peptide. 
Peptide ΔGInt (kcal/mol) 
Phe-Met 0.62 ± 0.09 
Phe-Met (ox) 1.24 ± 0.09 
Table 5-3. Determined ΔGInt for Phe-Met and Phe-MetOx at 0°C. ΔGInt in kcal/mol 
determined through double mutant cycle analysis for Phe-Met and Phe-MetOx. ΔGInt 
was determined at 0°C where the strongest α-helical character was present. 
 
Second, we followed Greenfield(216) by fitting the temperature-
dependence of each CD spectrum (Figure 5-13) to the Gibbs-Helmholtz equation 
(GHE, Figure 5-14). We justify applying a two-state approximation and hence using 
the GHE by: 1) observation of complete reversibility (overlap) in the heating and 
cooling curves (Figure 5-15); and 2) the presence of a molar ellipticity isodichroic 
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point in all constructs(217) (Figure 5-13, inset). Additionally, principal component 
analysis(218) of the CD spectra yielded only two components that dominated the 
CD spectra (Figure 5-16 and 0), again consistent with the two-state assumption. 
Together with the addition of the double mutant cycle, the fact that we obtained 
nearly identical values for the Met-Phe energy as in the original study (compare 
0.62±0.09 to 0.65 kcal/mol) reinforces the robustness of our approach. Thus, our 
peptide study lends experimental support to the conclusions drawn from the 
quantum calculations: oxidation increases the strength of the methionine-aromatic 
interaction. 
5.4.4 Oxidation of calmodulin transforms structure by establishing a new Met-
aromatic contact  
In order to test the impact of the increased strength of the SOx/Ar motif in 
proteins, we first investigated the effects of methionine oxidation in an already well-
characterized protein, CaM. The C-terminal helix of CaM has a high methionine 
content and is sensitive to oxidative stress in vivo, which alters the protein’s 
structure and function(202, 203, 206, 208, 209, 219). In the crystal structures of 
CaM, both in its calcium-bound (halo, 3CLN)(220) and unbound (apo, 1CFD)(221) 
forms, a C-terminal methionine forms an S/Ar interaction with F141 (M144 in apo 
(Figure 5-4a) and M145 in halo). It has been speculated previously that oxidation 
at M144 and M145 might destabilize the protein by altering an important, nearby 
hydrogen bond between Y138 and E82 that connects the short C-terminal helix to 
the central linker(202, 222). No specific molecular mechanism for this effect has 
been proposed or tested.  
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Based on our results above, one possibility is that oxidation of M144 and/or 
M145 increases the likelihood of an SOx/Ar interaction with Y138, which would be 
manifest in a spatial rearrangement within the C-terminal domain that should be 
observable by EPR. As M144/145 and Y138 are on opposite ends of a short helix, 
such an interaction would require helical unwinding, an effect that has been 
observed using NMR(207). Replica exchange molecular dynamics simulations 
(REMD) of the isolated, Ca2+-free (apo) C-terminal peptide fragment (residues 
136-146) of CaM were used to guide the design and interpretation of experimental 
EPR measurements on full-length protein. We simulated both the unoxidized and 
doubly oxidized (at M144 and M145) forms. Because of the expectation of helical 
unwinding, a computational investigation of full-length CaM is hampered by 
limitations in sampling efficiency. Thus, while the peptide fragment is an 
abstraction of the real system, it is nevertheless a useful tool because it 
accelerates the sampling of relevant conformational space. Furthermore, the 
simulations were useful in 1) establishing V136 and T146 as appropriate sites for 
spin-labels to test the impact of oxidation on the full-length protein; and 2) providing 
molecular scale details unavailable from EPR that correlate distance changes to 
the potential presence of an SOx/Ar motif. 
In the simulation of the unoxidized peptide, an S/Ar interaction formed 
between Y138/M144 or Y138/M145 only 3.3% of the time. On the other hand, an 
SOx/Ar interaction formed 22.7% of the time when both M144 and M145 were 
oxidized (Figure 5-4b, Figure 5-17). In only 1.2% of these interactions did a 
hydrogen-bond form (Figure 5-18). As can be seen in Figure 5-4b, the SOx/Ar 
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interaction with Y138 leads to a spatial rearrangement that brings together 
residues V136 and T146. The distribution of the distance between the Cα atoms 
of those two residues is shown in Figure 5-4c. Likewise, the frequency of the native 
interaction between M144 and F141 is also increased upon oxidation (49% vs. 
12% of frames, Figure 5-19). Thus, oxidation increased the total percentage of 
simulated frames in which an S/Ar interaction occurs by 3.7-fold (72% vs. 15%). 
Based on Boltzmann’s law, this change reflects a roughly 1.6 kcal/mol increase in 
the free energy of the interaction upon oxidation. This value compares well to the 
results of our peptide experiment (0.62 kcal/mol, Table 5-3) and supports the 
underlying conclusion of increased interaction strength upon oxidation of the S/Ar 
motif, even absent hydrogen bonds. It is important to note that the simulations of 
the short, unoxidized peptide fragment sample unfolded conformational states that 
are not represented by the crystal structure (where residues 138-146 are helical) 
and may not be accessible in a simulation of the full-length protein. Nonetheless, 
the emergence of a second population of states containing the SOx/Ar motif (with 
Y138)—only in the oxidized simulation—motivated experiments to explore whether 
this subpopulation exists in the full-length protein when oxidized. 
 
Figure 5-4. REMD and EPR measurements of CaM. Structure of unoxidized apo-CaM 
fragment (residue 136-146, PDB:1CFD) where F141 interacts with M144 (a) 
compared to a representative structure of the Y138 aromatic interacting with 
oxidized M144 (b) from REMD. Distance distribution calculated between Cα atoms 
of T136/V146 from REMD (c) and best-fit models of the distance distribution from 
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dipolar EPR spectroscopy at submicromolar [Ca2+] with maleimide spin labels at Cys 
residues 136 and 146 (d). 
 
To test the effects of oxidation of CaM’s C-terminal helix in the full-length 
protein, we used dipolar EPR spectroscopy to detect intramolecular structural 
perturbations at submicromolar [Ca2+]. The intramolecular distance distributions 
detected by EPR are shown in Figure 5-4d. As shown in Figure 5-19, the EPR 
spectrum of the unoxidized protein was best fit to a single broad Gaussian distance 
distribution, centered at 13.7 Å, with a width of 6.5 Å. After methionine oxidation, 
the data were best fit to a two-population model in which one population is centered 
at a similar distance to that observed in the absence of oxidation (14.0 Å), except 
that the width is narrower (3.7 Å), and there is a new population at shorter distance 
(8.9 Å) with an even narrower width (2.5 Å). In several respects, this confirms the 
predictions from MD simulations (Figure 5-4c): the long-distance population 
becomes narrower, and a new well-ordered short distribution emerges. The EPR 
distances and widths are slightly greater than those predicted by MD simulation, 
as expected since our MD simulations report the distances between Cα atoms, 
while EPR distances are between nitroxide groups at the ends of flexible side 
chains. EPR spectra do not directly detect Cα-Cα distances, but changes in such 
distances have been shown to correlate well with EPR data(223). The 
convergence of the simulated and experimental results strongly suggests that 
upon oxidation of CaM a new SOx/Ar interaction forms between either M144/Y138 
or M145/Y138. Work still remains to definitively show that this minor component in 
the overall accessible conformational space (Figure 5-4c and Figure 5-4d) is 
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responsible for disruption of the Y138/E82 hydrogen bond and alters the protein’s 
function. 
5.4.5 Oxidation of LTα stabilizes intra-molecular Met-aromatic interactions, 
diminishing binding and ablating function 
We investigated the effects of oxidation on the bioactivity and binding of LTα 
and TNF in live cells. We have previously shown that the interaction between LTα 
and TNFR1 is stabilized by a methionine-aromatic interaction via M120 of LTα and 
W107 of TNFR1. Mutation of M120 to alanine interrupts ligand binding, resulting 
in a >10 fold loss in ligand function(175). Thus, we hypothesized that the increased 
strength of the S/Ar interaction upon oxidation should stabilize binding via the 
M120/W107 interaction. Western blot analysis (Figure 5-5a) showed that untreated 
LTα and TNF efficiently induced downstream signaling, as has been definitively 
established. Surprisingly, LTα pretreated with H2O2 failed to induce IκBα 
degradation.  
In order to isolate the impact of oxidation of M120 on LTα function and 
binding, we mutated the methionines at residues 20 and 133 to remove their 
susceptibility to oxidization (see Methods for details). This mutant ligand—denoted 
here as M120 or MOx120 when oxidized—triggered IκBα degradation in the 
unoxidized form to the same extent as wild-type (indicating that two other mutated 
methionine residues, M20 and M133, are not important for activity). Site-specific 
oxidation (MOx120) rendered LTα inactive (Figure 5-5a). Co-immunoprecipitation 
experiments explain this loss in function as a result of lost binding of the MOx120 
ligand to TNFR1 (Figure 5-5b). Thus, we conclude that oxidation of LTα inhibits its 
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activity by disrupting the critical M120-W107 methionine-aromatic interaction, 
thereby preventing binding to TNFR1. 
 
Figure 5-5. Oxidation of LTα, but not TNF ablates its interaction with TNFR1. 
Western blot analysis of IκBα degradation in response to treatment with oxidized 
(+) and unoxidized (-) LTα and TNF (a). LTα bioactivity is ablated after exposure to 
oxidative stress. This effect is not observed in TNF, where oxidized and unoxidized 
ligand trigger IκBα degradation to the same extent. Exposure to oxidative stress 
similarly prevented M120 LTα from triggering IκBα degradation. Co-
immunoprecipitation of TNFR1 with oxidized (+) and unoxidized (-) ligands (b). LTα 
efficiently pulls down TNFR1 when untreated. Treatment of LTα under oxidative 
stress causes dramatic reduction in the amount of receptor bound. TNF is again 
unaffected by oxidative stress. The LTα M120 mutant again behaves the same as 
wild-type, indicating that oxidation of M120 is responsible for the loss of binding. 
 
To explore the molecular basis for this loss in binding, and to explain this 
apparent contradiction (decreased binding despite increased S/Ar interaction 
strength), we used molecular dynamics simulations and quantum calculations. 
Analysis of the ligand/receptor crystal structure (1TNR) revealed aromatic residues 
in the ligand (Y96 and Y122) that are near to and on the same chain as M120 
(Figure 5-6a). Given their spatial proximity, it is likely that M120 forms S/Ar contacts 
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with either or both of these tyrosines. MD simulations of the unbound ligand 
showed this to be the case in approximately 70% of the simulated frames (the 
M120-Y122 interaction was approximately twice as frequent as the M120-Y96 
interaction). Oxidation of M120 increased the interaction strength of M120 with 
Y96—again using the Boltzmann equation we calculate an increased affinity of 
0.35 kcal/mol. This value is lower than that described above for CaM, but once 
again is consistent with our general conclusion that oxidation strengthens S/Ar 
interactions. Interestingly, there was no oxidation-induced change in the frequency 
of M120/Y122 contacts. These data raise the possibility that Y122 and Y96 interact 
differently with M120 under oxidative conditions. We confirmed that hydrogen 
bonding was not a major factor in the interaction (Figure 5-20). We again used the 
simulations to generate an ensemble of configurations for quantum energy 
calculations. A snapshot from the oxidized ensemble is shown in Figure 5-6b. As 
was the case with our calculations on the non-hydrogen-bonded ensemble of 
DMS/DMSO-phenol configurations, oxidation increased the strength of the S/Ar 
interaction by 1-2 kcal/mol (Figure 5-6c).  
We hypothesized that the strengthened MOx120/Y96 interaction could lock 
the ligand in a configuration that prevents MOx120/W107 interaction, thereby 
interrupting binding. To test this, we first needed to show that the addition of a 
sulfonyl oxygen to M120 in the crystal structure binding configuration does not itself 
destabilize the binding pocket by steric overlap or electrostatic repulsion. We first 
simulated the unoxidized crystal structure of the ligand-receptor complex. Figure 
5-6d highlights the stability of the M120/W107 interaction, and shows the 
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infrequent instances of M120 interaction with either Y122 or Y96. We then started 
a simulation of the ligand-receptor complex in a configuration in which the 
MOx120/Y122 pair was pre-formed (using a configuration generated from the 
unbound ligand simulation). Y96 was allowed to remain in its receptor backbone 
binding position. The binding cavity organization reverted to that of the crystal 
structure configuration after 50ns (Figure 5-6d) and was stable throughout the 
remainder of the simulation (Figure 5-21). Therefore, we conclude that loss of 
ligand-receptor binding is not caused by intrinsic steric clashes with MOx120 that 
disrupt the binding pocket. We also conclude that MOx120/Y122 interactions do not 
prevent MOx120/W107 interactions and ligand binding.   
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Figure 5-6. Molecular dynamics simulations of LTα with M120 oxidized show that 
competitive interaction of M120 with Y96/Y122 prevents its interaction with W107. 
In the receptor bound state, Y96 is folded upward so that it interacts with the 
backbone of the receptor, allowing M120 to form a stable methionine-aromatic 
interaction with W107 (a). When Met120 is oxidized, it draws Y96 downward so that 
it protrudes into the binding pocket (b). The histogram of the interaction energy 
between M120 and Y96/Y122 calculated from 128 structures taken from the MD 
simulations shows enhanced interaction due to oxidation. The histogram was 
smoothed with the Gaussian kernel-smoothing function “density” of the program 
“R” (c). The bond occupancy of the M120-Y96/Y122 (black) and M120-W107 (gray) 
interactions is shown for 3 systems: the unmodified crystal structure (1TNR), the 
M120-Y122 interacting configuration, and the M120-Y96 interacting configuration 
(d). M120 interacts stably with W107 in 1TNR. In the M120-Y122 interacting system, 
M120 interacts somewhat more with Y96/Y122, but still primarily with W107. In the 
M120-Y96 interacting system, the bond occupancy is reversed - that is, M120 
interacts primarily with Y96/Y122 and the W107 interaction is blocked. A snapshot 
of the Y96 interacting system with Y96 blocking the M120-W107 interaction is shown 
(e). 
 
We then started a second oxidized ligand-receptor simulation, this time with 
a pre-formed MOx120-Y96 pair.  We observed two distinct effects of oxidation, both 
of which are consistent with loss of receptor binding. In two of the three chains (of 
the symmetric ligand trimer), MOx120 remained stably bound to Y96, preventing it 
from forming the critical S/Ar motif with W107 (Figure 5-6d) and also preventing 
Y96 from binding the receptor backbone. In these cases, the MOx120/Y96 pairing 
(Figure 5-6e), along with the surrounding binding pocket, remained stable 
throughout the simulation. In the remaining chain, Y96 released from MOx120, and 
in this process disrupted the binding pocket while ejecting the receptor. 
Collectively, the results suggest that increased stability of the MOx120/Y96 pair 
prevents the critical M120/W107 interaction and destabilizes the bound state. 
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5.5. Concluding Remarks 
Oxidative stress plays a prominent role in a number of normal and 
pathological biological functions. However, the precise chemical and physical 
mechanism through which oxidative modification of proteins influences their 
structures and functions is largely unknown. We have shown that oxidation of 
methionine strengthens the methionine-aromatic interaction motif, independent of 
hydrogen bonding, by at least 0.5 kcal/mol and up to 1.5 kcal/mol. In the vast 
majority of instances in the PDB and CSD as well as the two proteins studied here 
in detail, the aromatic group does not form a stable hydrogen bond with the 
sulfoxide due to solvation of both the donor and acceptor by water. Hydrogen 
bonding may further enhance the interaction in hydrophobic and aprotic 
environments, however we do not observe that in our two test cases where the 
motif is solvent exposed. In LTα-TNFR1 and CaM, we have shown that competing 
interactions between methionine sulfoxide and nearby aromatic residues 
contributes to the modulation of protein structure and function. 
To conclude, non-covalent interactions are the cornerstone of biological 
molecular recognition events. For bioactive small-molecule development, which 
exploits these interactions, sulfur is the third most commonly incorporated 
heteroatom in pharmaceuticals next to nitrogen and oxygen.(224) The sulfoxide-
aromatic interaction provides a new handle for tuning affinities of small molecules 
for chemical probe and therapeutic development as well as altering protein 
function. Moreover, the dynamic nature of methionine oxidation provides a 
reversible switch that can be employed for introducing responsive molecules to 
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changes in redox environment. The energy range of these altered interactions 
corresponds to twofold to tenfold change in the equilibrium constant, which 
together with the ambivalent character of sulfoxide functional groups, the dynamic 
nature of their formation, and their prevalence in biology and pharmaceutics, offers 
medicinal chemists and chemical biology a useful tool to probe biological systems. 
5.6. Methods 
5.6.1 Structural bioinformatics analysis of the Protein Data Bank 
A non-redundant (sequence identity <90%) subset of the Protein Data Bank 
(PDB) containing DMSO molecules was analyzed using the Biopython toolset and 
a custom Python script adapted from our previous study(175). Distances were 
defined between the DMSO sulfur and the center of the aromatic ring. Distance 
data were collected up to a cutoff of 20 Å. Hydrogen bonds were defined as having 
a heavy-atom donor to sulfonyl oxygen distance of < 3.5 Å. For the radial density 
function (RDF), the distance from a DMSO to its nearest aromatic group was 
binned and divided by shell volume. Each RDF was normalized by the relative 
population of amino acids in the analyzed PDB files (divided by 9.25% for F, Y, W, 
22.47% for L, I, V, and by 100% for all amino acids). The resulting plots were 
normalized by the mean value at the long distance, non-interacting region of the 
“All Amino Acids” RDF to shift the bulk density to 1 and to cast the y-axis as an 
enrichment factor. 
5.6.2 Structural bioinformatics analysis of the Cambridge Structural Database 
Searches were executed in the Conquest program of the Cambridge 
Structural Database (CSD version 5.35, 2014 release), and structural analyses 
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were performed using the Mercury program (v 1.5). The distance was defined as 
in the PDB. C-CH2-C was used as a non-interacting analog to C-S-C, following the 
previous CSD analysis by Zauhar, et al.(176) The sulfur (or carbon in control) atom 
to aromatic distance was constrained to 0-10 Å. For the radial density function 
(RDF), the distances from each DMSO (or C-CH2-C) to all aromatic groups were 
binned and divided by shell volume, then normalized by the total number of 
contacts. The resulting RDFs were shifted to 1 as in the PDB analysis, by 
normalizing to the value at the flat region of the C-CH2-C RDF. A total of 20630 
DMSO-aromatic pairs were found in 840 structures and 3093875 C-CH2-C-
aromatic pairs were found in 72745 structures. 
5.6.3 ABF simulations of DMSO and aromatic groups in three solvents 
Simulations were performed using the Adaptive Biasing Force (ABF) 
module in NAMD 2.9 using the CHARMM 36 generalized forcefield. The adaptive 
biasing force (ABF) module was used so that the system could overcome free 
energy barriers and fully sample all conformational states. Parameters for DMS 
were adapted from those for ethylmethylsulfide. The distance between the DMSO 
thioether and the center of mass of the 6-membered ring of phenol, or indole was 
used as the reaction coordinate of the mean force calculation. The system potential 
along the reaction coordinate was negated by the adaptive biasing force to 
simulate a flat free energy landscape. Each system was solvated in a ~45 Å3 
periodic box of TIP3P water, hexane, or ethyl acetate, for a total of 18 systems. 
The adaptive biasing potential was applied between 2.5 and 14 Å with a binwidth 
of 0.1 Å and simulations were carried out for at least 7.5 x 106 steps. All other 
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simulation parameters were set as in our traditional MD (see Molecular dynamics 
simulations of LTα and TNFR1 methods). The calculated PMF was not used in our 
analysis. 
5.6.4 Quantum calculations 
The interaction energy between model compounds was investigated with 
quantum mechanical calculations performed in the gas phase. The reduced and 
oxidized states of methionine were modeled by dimethyl sulfide (DMS) and 
dimethyl sulfoxide (DMSO), respectively; the side chains of phenylalanine, 
tyrosine, and tryptophan were modeled by benzene, phenol, and indole. The 
interaction energy between compounds A and B was defined as: 
$:;<= = $:;>?@AB
C − $: − $; (1) 
All energies were obtained from fully unrestrained structure optimizations 
carried out with Gaussian 09(225) at the MP2/6-311+G(d,p) level and account for 
basis set superposition error(226). Additional data computed at the M06-2X/6-
311+G(d,p)(227) level are reported in Table 5-4. These two levels of calculation 
were chosen because we previously showed that they bracket the interaction 
energy calculated at the CCSD(T)/6-311+G(d,p) level(175). Notice that for each 
complex several minima were characterized, and the data is reported only for the 
lowest energy one. 
The dispersion energy contribution to the complex formation was calculated 
as in Ref. (175) by taking the difference between the interaction energy (eq 1) 
computed at the MP2 and Hartree-Fock (HF) levels. In both cases the same basis 
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set was employed, and the HF energies were calculated as single point on the 
MP2 optimized structures. 
The effect that the variety of conformations adopted in solution has on the 
interaction energy was investigated by averaging the interaction energies of 128 
structures randomly sampled from the minimum (sulfur – aromatic distance 
between 4 – 6 Å) of the ABF simulations in ethyl acetate described below. Upon 
removal of the solvent, the instantaneous interaction energy was calculated at the 
MP2/aug-cc-pVDZ level using eq. 1 without any additional structure optimization. 
A similar procedure was employed to investigate the interaction energy 
between the side chains of M120, Y96, and Y122 in LTα. From the MD simulations 
described below, 128 structures were randomly selected and the average 
interaction energy calculated at the MP2/aug-cc-pVDZ level as: 
$EFGHIJHF<= = $EFGHIJHF>?@AB
C − $EFG − $HIJ − $HF (2) 
The side chains were truncated at the Cβ-Cγ bond and the missing valence 
was saturated with a hydrogen atom. Upon removal of the rest of the protein and 
the solvent and without any further optimization, the interaction energy was 
calculated at the MP2/aug-cc-pVDZ level and corrected for the basis set 
superposition error. 
For the calculations on the ethyl acetate simulations described above, the 
Natural Bond Orbital(228) (NBO) charges were calculated and averaged over all 
128 structures. The NBO localization scheme was tested along Mulliken(229) 
localization over a number of different basis sets of increasing size. Because the 
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results showed a strong dependence of the Mulliken charges on the basis set 
size(230) while NBO charges did not, the NBO localization scheme was preferred. 
5.6.5 Peptide Synthesis  
To study the appropriate pair sequences in a peptide chain, the un-oxidized 
amino acid Met or oxidized Met was inserted into the sequence: a) Tyr-Gly-Gly-
Ser-Ala-Ala-Glu-Ala-Aromatic-Ala-Lys-Ala-Met-Ala-Arg-NH2, b) Tyr-Gly-Gly-Ser-
Ala- Ala-Glu-Ala-Aromatic-Ala-Lys-Ala-Met (ox)-Ala-Arg-NH2. The peptides were 
assembled on Fmoc-PAL-PEG-PS resin by Fmoc chemistry using a PE 
Biosystems PioneerTM protein synthesis system. Single Met oxidation was 
accomplished by incorporation of Fmoc-Met (ox)-OH during synthesis. Standard 
N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate N-oxide (HA TU)/ N,N- 
diisopropylethylamine (DIEA) (1/2.4 eq.) activation, in 1-methyl-2-pyrrolidinone 
(NMP), was applied. Fmoc deprotection was achieved with 20% piperidine in NMP. 
The final release of the peptides, with removal of the side chain protecting groups, 
were accomplished by exposure of the peptide-resin to 82.5% trifluoroacetic acid 
(TFA), 5% phenol, 5% thioanisol, 2.5% 1,2-ethanedithiol, 5% water (Reagent K). 
The peptides were precipitated with cold methyl-t-butyl ether, vortexed, 
centrifuged, decanted, and dried over argon. The dried peptides were dissolved in 
degassed water and purified by high-performance liquid chromatography (HPLC) 
using a reversed- phase C8 HPLC column. Peptide elution was achieved with a 
linear gradient from 0 to 34% B (95% acetonitrile / 5% water / 0.1% TFA) in 40 min 
at a flow rate of 2.5 mL/min with detection at 280 nm using a System Gold 
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Beckman Coulter system. The HPLC fractions were collected and analyzed by 
mass spectrometry (MS).  
5.6.6 Peptide Scaffold Design 
The peptide scaffold utilized for defining the energetic impact of oxidation 
on Met-Aromatic interaction had a number of specific design elements. The helical 
content was optimized to reside within a range that enabled sensitive detection of 
its change by CD. The capping box motif at the N-terminus is the sequence 
Ser/Thr-X-X-Glu/Gln and is a helix stop signal(231). This stop signal has Ser or 
Thr as the N-cap and a Glu or Gln residue at position i+3, specifically; the 
sequence Ser-Ala-Ala-Glu is the capping motif in each of the peptides of the 
double mutant cycle. To this capping box, the N-terminus had a tyrosine added for 
concentration determination. The C-terminus was blocked by changing the COO- 
to a CONH2 to mediate this effect of dipole destabilization and to increase helical 
propensity(232). 
5.6.7 Electrospray ionization (ESI)-MS 
The peptides were analyzed on a LC/MSD ion trap (Agilent). ESI-MS 
spectra were acquired in positive ion mode. The solvent contained 40 % 
acetonitrile and 0.1 % formic acid. 10 to 30 µL sample were directly injected at a 
flow rate of 10 µL/min with a source temperature of 300 ˚C. The applied spray 
voltage was 3500 V, and the skimmer voltage 40 V. MS scans were acquired over 
an m/z range of 200 to 2000. The scan for the native mass 1499.69 Da of the 
sequence Tyr-Gly-Gly-Ser-Ala-Ala-Glu-Ala-Phe-Ala-Lys-Ala-Met-Ala-Arg, shows 
the single charged ion with m/z 1500.0 and the double charged ion m/z 750.7. The 
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scan for the Met(O)-Phe sequence pair (1515.69 Da) shows the singly charged ion 
with m/z 1515.7, the double charged ion m/z 758.4, and the triple charged ion m/z 
505.9. The observed masses for the respective molecular ions agree with the 
theoretical peptide scaffold design. 
5.6.8 Circular Dichroism Spectroscopy 
All peptides were stored in tetrafluoroethylene (TFE) after synthesis, which 
was removed by evaporation using Nitrogen gas prior to use. To ensure complete 
removal of the TFE, the sample was then put under vacuum for one hour. The 
dried peptide was re-constituted in 10mM KH2PO4, 100mM KCl at pH 7.5, and 
prepared for CD data collection. All CD experiments were performed on a Jasco 
J-815 CD Specrometer (Annapolis, MD) using a 0.1cm quartz cuvette using 150μM 
peptide concentration for all samples. Concentrations of the peptide samples were 
determined using a Nanodrop Spectrometer. Data points were collected from 200 
to 260nm in 1nm increments from -2°C to 60°C for FM and FM (ox) For YA, FA, 
AM, AM (ox) and AA, one data point was collected at 222nm at each 0.5°C or 2°C 
change as temperature increased from - 2°C to 60°C. Cooling melts were also 
collected on all peptides as temperature decreased from 60°C to -2°C. All collected 
data points were averaged from 3 acquisitions of the recorded ellipticity. 
5.6.9 Analysis of CD data 
To extract the free energy of interaction from the temperature dependence 
of the CD, spectra were collected from the lowest experimentally accessible 
temperature (-2oC) to a temperature beyond which there were no observable 
changes in spectral shape for all peptides (60oC). The spectra are given in Figure 
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5-13. Following Greenfield(216), we used the signal, K, at 222nm to report on 
changes in peptide structure. This wavelength was chosen because it reflects 
helical content and is also the wavelength at which the overall change in ellipticity 
is greatest across the temperature ramp. Following the same rationale we used 
previously(233), the CD signal is given by: 
K = K<=L + NKO<LB/1 + N (3) 
where K<=LB is the value at 222nm recorded at -2oC, and KO<LB is the value 
at 222nm recorded at 60oC. Because N = Q∆R/&(, we rewrite this equation as: 
KS = K<=LB + Q∆TUVKO<LB/1 + Q∆TUV. (4) 
We then fit the temperature dependent data, KS, by substituting the 
Gibbs-Helmholtz equation into equation 4, 
 
∆W = ∆X(@ Y1 − SS@Z + ∆AS − S@ − Sln
S
S@, 
(5) 
 
and varying the three parameters: enthalpy (∆X(@), heat capacity change (∆A), 
and transition temperature (S@). 
Data for Phe-Met and Pet-Met(ox) are given for each replica in Figure 5-14. 
By varying the concentrations of the peptide in each of its three replicates, the 
measured signal varies for each replica. The three replicates are globally fit 
simultaneously, an approach that improves the stringency of the parameter fits for 
each peptide. The free energy is then extracted from the fit at the desired 
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temperature (T=0oC in this case). The change in free energy for each leg of the 
double mutant cycle is reported in Figure 5-12. 
5.6.10 Double Mutant Cycle 
To construct a double mutant cycle, peptides were synthesized in which the 
aromatic residue and Met (or MetOx) was replaced first individually, then 
concurrently by the neutral residue alanine (Ala). The difference in ΔG between 
the Met-aromatic (oxidized or un-oxidized) and its respective singly substituted 
construct, or between the singly substituted construct and the doubly mutated 
construct gives a ΔΔG. The difference of the respective ΔΔG values produces a 
ΔΔΔG, which indicates whether the specific interaction is contributing to the 
stabilization of structure. ΔΔΔG is simplified here as ΔGint to match the free energy 
of interaction reported in the reference(182) (the two expressions are 
thermodynamically equivalent, although Vigeura et al. did not use a double mutant 
cycle). If ΔGint equals zero, the interaction observed is not contributing to the 
structural stability; if greater than zero, the interaction is stabilizing; and if less than 
zero, destabilizing(234-236). 
5.6.11 Principal Component Analysis 
Principal component analysis for each of the FM, FMOx, FA, AM, AMOx, and 
AA peptides data sets was carried out with the “prcomp” function of the program 
R (v. 3.2.1). For each data set only one of the three replicates was used. To 
increase the sensitivity of the analysis, we focused on the isodichroic point region 
by analyzing only the wavelengths between 200 nm and 210 nm (11 data points), 
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while the entire temperature range was included in the analysis. The correlation 
matrix was calculated between the mean-centered vectors of wavelengths: 
C_ij=T_i (λ_1,λ_2,…,λ_N )⋅T_j (λ_1,λ_2,…,λ_N ) 
The results reported in Figure 5-16 and 0 show that the first two principal 
components describe 94% or more of the total variance, which is consistent with 
the assumption that the change in molar ellipticity is dominated by only two sources 
of signal. 
5.6.12 Replica exchange molecular dynamics of calmodulin 
The replica exchange molecular dynamics (REMD) simulation was 
performed in NAMD 2.9 using the CHARMM22 potential parameters(237). Eleven 
residues of the last helix (136-146) of CaM (3CLN.pdb) were used in the all-atom 
point-charge force field in vacuum without change neutralization(220). Eight 
replicas with temperatures exponentially spaced from 300K to 600K (300, 331.23, 
365.7, 403.77, 445.8, 492.2, 543.43, 600 K) were used with the initial velocities of 
the atoms generated by the Maxwell-Boltzmann distribution and a timestep of 1 fs. 
The first 106 steps were performed without attempting exchanges to equilibrate, 
then exchanges were attempted every 1000 steps (1 ps) with an acceptance rate 
~20%. Coordinates were taken every 100,000 steps (100 ps). 78,810 frames were 
taken for the unoxidized peptide and 74,400 frames for the oxidized peptide, 
corresponding to a total simulation time per replica of 985 and 930 ns, respectively. 
Only the replicas at 300 K were used in the analysis. Methionine-aromatic 
interactions were identified as having a distance of <7 Å and an angle less than 
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60°, consistent with previous definitions(175, 176). Hydrogen bonds were cutoff at 
<2.5Å from hydrogen to acceptor. 
5.6.13 Dipolar EPR spectroscopy of spin-labeled calmodulin. 
A mammalian CaM mutant, with V136 and T146 both mutated to Cys, was 
prepared by site-directed mutagenesis (QuikChange II kit, Agilent, Santa Clara 
CA), confirmed by DNA sequencing, expressed and purified as described 
previously(211), and dialyzed overnight at 4°C against 10mM NaCl, 10mM Tris 
(pH 7.0). Spin-labeling with maleimide spin label (MSL, N-(1-oxyl-2,2,5,5-
tetramethyl pyrrolidinyl) maleimide, Toronto Research Chemicals, Canada) was 
carried out by incubating 120 µM CaM with 480 µM MSL in CaM buffer (10 mM 
NaCl, 10 mM Tris, 5 mM EGTA, pH 7.0) for two hours at 22o C (followed by 
overnight dialysis against CaM buffer to remove unreacted label), resulting  in 
complete labeling of the two Cys, as shown by mass spectrometry. To oxidize 
methionine side chains, spin-labeled CaM was incubated in 500 mM hydrogen 
peroxide for 30 min, followed by dialysis into CaM buffer. As shown previously 
under similar conditions(211), mass spectrometry verified that all of the nine 
methionine residues of CaM were oxidized. X-band (9.5 GHz) EPR spectra of 200 
µM CaM (in CaM buffer plus 10% glycerol) were acquired at 200o K with a Bruker 
ER500 spectrometer, using 1 G modulation amplitude and sub-saturating 
microwave power (0.63 mW). EPR spectra were analyzed to determine the 
distribution of distances between the two spin labels, as described previously(108). 
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5.6.14 Ligand preparation and treatment 
Plasmids encoding LTα and TNF expressing an N-terminal FLAG tag, 
downstream from an inducible T7 promoter were subcloned using standard cloning 
techniques. Plasmids were transformed into chemically competent BL21 bacteria, 
plated on LB agar plates, and cultured in LB to an OD600 of ~0.5. Cultures were 
then cooled to 18°C, induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside, 
and grown for 18 hours. The bacteria suspension was centrifuged, then lysed by 
sonication in ice-cold PBS. The lysate was column purified using anti-FLAG M2 
Affinity Gel (Sigma) according to the manufacturer protocol, dialyzed exhaustively 
against MilliQ H2O, and then lyophilized. FLAG-LTα, as prepared in our laboratory, 
contains 4 methionine residues, of which M120 and M133 potentially play 
structural and functional roles in the ligand-receptor complex. M133 is buried 
between two folds of a β-sheet, and its precise functional role, if any, has not been 
established. For the LTα-M120 mutant, we mutated M133 to valine and M20 to 
alanine in order to match the homologous residues found in Bos Taurus LTα, which 
shares 73% sequence identity and 81% sequence similarity (Sequence 
Manipulation Suite), but lacks methionines except for its N-terminus. TNF, which 
also binds to and activates TNFR1 with similar potency(15) was used as a control. 
 Oxidative stress was applied by dissolving 8 μg of ligand in buffer 
containing 10 mM HEPES, 100 mM KCl, 1 mM MgCl, 1 mM CaCl, then adding 100 
mM H2O2 to a total volume of 100 uL. The oxidation reaction was allowed to 
proceed for 18 hours at room temperature, then stopped by removing H2O2 in 2 
sequential stages using Zeba 7KDa molecular weight cutoff spin columns. 
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Removal of H2O2 was confirmed by Amplex red assay, and the residual 
concentration of H2O2 was determined as insufficient to induce autophagy. We 
measured tryptophan fluorescence to confirm that oxidation does not lead to gross 
unfolding of LTα, finding no shift in the emission spectrum when excited at 280 nm 
(Figure 5-22). 
5.6.15 Western blot analysis of IκBα 
HEK 293 cells were maintained in DMEM supplemented with 10% FBS, 
penicillin/streptomycin, and 2 mM L-glutamine. Confluent cells were split at 1:12 
into 6-well plates and used for experiments on day 3. Untreated and oxidized 
ligands were added to cells to final concentrations of 200 ng/mL and 20 ng/mL for 
LTα and TNF respectively, and incubated for 20 minutes at 37 °C. Cells were then 
washed once and gently sheared from the plate with ice-cold PBS, then 
centrifuged and resuspended in radioimmunoprecipitation assay (RIPA) lysis 
buffer. Cell lysates were normalized to equal protein concentrations, and 60 μg 
were loaded onto 4-12% Bis-Tris gradient gels for Western blot analysis. IκBα was 
detected using horseradish peroxidase (HRP) conjugated rabbit α-IκBα (Cell 
Signaling Technology, #9242) and α-Rabbit IgG (Amersham). 
5.6.16 Co-immunoprecipitation 
Co-immunoprecipitation was performed using anti-FLAG M2 agarose 
beads (Invitrogen) according to the manufacturer instructions. Briefly, HEK 293 
cells were split at 1:12 into 15 cm plates and transfected with 8 μg of plasmid 
encoding TNFR1 (pCMV6-XL5-TNFR1) on day 1 by calcium phosphate 
transfection. On day 3, cells were lifted by shearing, washed once, and 
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resuspended in ice-cold PBS at ~106/mL. LTα and TNF were added at 12 and 25 
ng/mL respectively, and the cells were incubated for 30 minutes at 4 °C while 
rocking. Cells were then washed 3 times in ice-cold PBS and resuspended in RIPA 
lysis buffer, then analyzed by Western blot. TNFR1 was detected using rabbit α-
TNFR1 (Abcam, ab19139) and α-rabbit secondary, as described above. 
5.6.17 Molecular dynamics simulations of LTα and TNFR1 
We carried out molecular dynamics simulations of oxidized or unoxidized 
LTα in its unbound state and unoxidized in complex with TNFR1 using the structure 
solved by Banner et al. (1TNR) as the starting configuration(8). Two additional 
systems, Y122 interacting config. and Y96 interacting config., were constructed in 
which M120 began bound to Y122 or Y96, respectively, while all other residues in 
the 1TNR crystal structure were left essentially unchanged (minor manipulation 
and steepest descent minimization was required to resolve overlap in the binding 
pocket). The starting configurations of M120, Y96, and Y122 in these systems 
were taken from the oxidized ligand simulation. Each system was solvated in a box 
of at least 40,000 water molecules modeled as TIP3P(238) and the charge was 
neutralized by adding K+ and Cl- ions. The isothermal-isobaric (NPT) ensemble 
was used along with the CHARMM36 force field(153, 239, 240) at a temperature  
of 303 K and 1 atm pressure, which were maintained using the Langevin piston 
and Nosé-Hoover(158) algorithms. Parameters for MetOx were provided by 
Krzysztof Kuczera(241) and adapted for use in the CHARMM36 force field. Long-
range electrostatics were calculated using the particle mesh Ewald method (242) 
with a 1.5 Å grid spacing and 4th order interpolation. Lennard-Jones interactions 
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were switched off at a cutoff distance of 10 Å. Each system (except the Y96 and 
Y122 interacting configurations) was minimized using NAMD 2.8(237) for 1000 
steps, then equilibrated with Cα harmonic constraints of 1, 0.1, and 0.01 
kcal/mol/Å2 for 2 ns at each stage. Dynamic trajectories were propagated with the 
r-RESPA algorithm (243) with a 2 fs time step and the RATTLE algorithm (244) 
was applied to all covalent bonds involving hydrogen. The ligand-receptor system 
was simulated for ~35 ns and distance and angle analyses were averaged over 
the entire trajectory. The ligand-only systems were simulated for a total of ~430 
ns. The first 150 ns (including relaxation) were excluded from structural analyses 
to allow re-equilibration of the ligand after removal of the receptor chains. The Y96 
and Y122 interacting systems were equilibrated with great care before running 
unrestrained dynamics. Each was minimized to resolve steric clashes, then 
equilibrated according to the scheme shown in Table 5-9. Distances and angles 
were calculated from the thioether sulfur of M120 to the centers and normal vectors 
of the aromatic groups of Y96, Y122, and W107. Methionine-aromatic interaction 
cutoffs were defined as in the CaM simulations. 
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5.7. Supplemental Figures 
 
Figure 5-7. Minimum energy structures. The minimum energy structures for the 
complex between DMS or DMSO and benzene, phenol, and indole, calculated from 
full optimizations at the MP2/6-311+G(d,p) level. 
Figure 5-8.  
 Benzene Phenol Indole 
Complex M06-2X MP2 M06-2X MP2 M06-2X MP2 
DMS -4.6 (-4.0) -6.0 (-2.4) -8.3 (-7.3) -9.3 (-4.9) -7.3 (-6.3) -9.5 (-4.7) 
DMSO -6.2 (-4.9) -7.3 (-3.3) -16.0 (-14.4) -16.0 (-10.6) -13.6 (-12.1) -15.5 (-10.0) 
Table 5-4. Interaction energies for DMS and DMSO with benzene, phenol, and 
indole. Computed interaction energies in kcal/mol for the complexes of benzene, 
phenol, and indole with DMS and DMSO (structures are shown in Figure 5-7). M06-
2X and MP2 data are reported for structures fully optimized at the corresponding 
levels of theory with the 6-311+G(d,p) basis set. Hartree-Fock data are reported for 
benzene only as single point energy calculations on the MP2 optimized structures. 
Interaction energies corrected for basis set superposition error are reported in 
parenthesis.  
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 MP2 HF Dispersion Energy 
DMS -6.0 2.4 -8.4 
DSMO -7.3 0.9 -8.2 
Table 5-5. Dispersion energy interactions. Dispersion energy interactions are 
calculated in kcal/mol for the complexes of benzene with DMS and DMSO as the 
difference between the MP2/6-311G(g,p) interaction energies and the HF/6-
311+G(d,p) calculated as single point on the MP2 minima. 
 DMSO/Benzene DMS/Benzene DMSO DMS Benzene 
O -0.96  -0.96   
S 1.19 0.19 1.18 0.20  
C -0.77 -0.70 -0.76 -0.70  
H 0.22 0.21 0.22 0.21  
H 0.22 0.21 0.21 0.19  
H 0.21 0.19 0.21 0.19  
C -0.76 -0.70 -0.76 -0.70  
H 0.22 0.21 0.22 0.21  
H 0.21 0.19 0.21 0.19  
H 0.21 0.19 0.21 0.19  
C -0.20 -0.20   -0.20 
C -0.21 -0.21   -0.20 
C -0.20 -0.19   -0.20 
C -0.20 -0.21   -0.20 
C -0.21 -0.20   -0.20 
C -0.20 -0.20   -0.20 
H 0.21 0.20   0.20 
H 0.20 0.20   0.20 
H 0.21 0.20   0.20 
H 0.21 0.20   0.20 
H 0.20 0.20   0.20 
H 0.21 0.20   0.20 
Table 5-6. NBO Charges analysis of the benzene complexes with DMS and DMSO, 
and of the isolated species based on the MP2/6-311+G(d,p) electron density. 
 
 Gas EtOAc Water 
DMS -4.7 -3.9 -3.6 
DMSO -6.2 -5.1 -4.7 
ΔEint -1.5 -1.2 -1.1 
Table 5-7. Effects of solvation on quantum mechanical interaction energy. The 
effect of solvation on quantum mechanical interaction energies has been tested for 
the complex of benzene with DMS and DMSO. The interaction energy in kcal/mol for 
the complexes optimized in gas phase at the M06-2X level was calculated in the gas 
phase and with single point PCM calculations to describe the effect of solvation in 
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EtOAc and water. The basis set employed was 6-311+G(d,p). The ΔEint entry shows 
that the effect of solvation is less than 0.4 kcal/mol. 
 
 
Figure 5-9. NBO average charges for the ABF simulations. NBO charges were 
computed as the average for the 128 structures for the simulations of DMS/DMSO 
and benzene in EtOAc using the MP2/6-311+G(d,p) electron density. In red the 
charges for benzene/DMS are reported, and in black for benzene/DMSO. 
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Figure 5-10. Fraction of structures in which the DMSO sulfonyl accepts a hydrogen 
bond from the aromatic. Structures were extracted from the ABF simulations of 
DMSO and aromatic amino acid analogs in three solvents. The fraction of structures 
that are hydrogen bonded (H-acceptor distance < 2.5Å) along all sulfur-aromatic 
distances is plotted. Hydrogen bonding occurred in nearly all configurations that 
were in range in hexane (a, b), fewer configurations in EtOAc (the frequency of 
hydrogen bonding was reduced by ~60%) (c, d), and almost none of the 
configurations in TIP3P water (e, f). EtOAc is able to accept hydrogen bonds from 
the aromatic group and TIP3P is able to donate and accept hydrogen bonds, which 
results in the lower prevalence of bonding between the DMSO and aromatic group. 
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Figure 5-11. Histogram of distances from each DMSO atom to the center of the 
aromatic ring. Non-hydrogen-bonded DMSO-aromatic pairs from the ABF 
simulations were analyzed and show no strong bias for the methyl groups to 
interact with the aromatic ring. Benzene (a), phenol (b), and indole (c). 
 
 
Peptide Abbreviation Construct Sequence 
Phe-Met FM YGGSAAEA-F-AKA-M-AR-NH2 
Phe-Met (ox) FM(ox) YGGSAAEA-F-AKA-M (ox)-AR-NH2 
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Phe-Ala FA YGGSAAEA-F-AKA-A-AR-NH2 
Ala-Met AM YGGSAAEA-A-AKA-M-AR-NH2 
Ala-Met (ox) AM(ox) YGGSAAEA-A-AKA-M (ox)-AR-NH2 
Ala-Ala AA YGGSAAEA-A-AKA-A-AR-NH2 
Table 5-8. All peptides used in CD thermal studies , their appropriate abbreviation 
and their sequences. Only residues 9 and 13 were varied, and these positions are 
shown in bold. 
 
 
Figure 5-12. Double-mutant cycle. Thermodynamic double mutant cycle of FM (a) 
and FM(ox) (b) peptides. Nomenclature is: Wild-type peptide (FM and FM(ox)), singly 
mutated peptide (FA, AM and AM(ox)) and doubly mutated peptide (AA). F, M and A 
represent phenylalanine, methionine (un-oxidized or oxidized) and alanine, 
respectively. Free energy of each peptide denaturation is represented as ΔG at each 
step in the cycle. ΔΔG values are determined by the difference in ΔG denaturation 
values of peptides at 0°C, which were used to determine the ΔΔΔG. For simplicity, 
and as described in the Methods, we assign the nomenclature ΔGint to reflect the 
change in interaction free energy between Met/Phe and Met(ox)/Phe (SOx/Ar- S/Ar = 
1.24 - 0.62 = 0.62 kcal/mol). Thus there is a doubling of the strength of the interaction 
upon oxidation. Error was calculated through a total differential approach, where 
the derivatives of the GHE with respect to ΔH, ΔCp and Tm were calculated. The 
error for each thermal denaturation ΔG is the sum of the products of each derivative 
and their respective individual error values. Error was then calculated with ΔG 
values for each side of the thermodynamic cycle for ΔΔG and ΔGInt. 
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Figure 5-13. Combined spectra of one peptide observed from 200 to 260nm at 
increasing temperatures from -2°C to 60°C. Crossing of all spectra at ~202nm 
indicates isodichroic point seen in inset plot. 
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Figure 5-14. Representative data sets and global fits for three replicas of Phe-Met 
(Left, solid squares) and Phe-Met (ox) (Right, solid circles). For each peptide, a black 
solid line represents the global fit to all three datasets using the Gibbs Helmholtz 
equation, as described in Methods. The fitting parameters are, for Phe-Met: ∆HTm = 
26.0 ± 0.7 kcal/mol, ∆CP = 0.2 ± 0.2 kcal/mol°C and Tm = 18.3 ± 0.3 °C; and for Phe-
Met(ox) are: ∆HTm = 27.1 ± 0.1 kcal/mol, ∆CP = 0.21 ± 0.02 kcal/mol°C and Tm = 21 ± 
1°C were determined for Phe-Met (ox) peptide. Raw ellipticity signal varies for each 
peptide sample set due to variations in each individual peptide experiment (~150µM 
concentration). Free energy values were extracted from the global fit at T=0°C and 
are presented in Figure 5-12. 
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Figure 5-15. Overlaid heating and cooling melt curves for FM, FM(ox), FA, AM, AM(ox), 
and AA peptides. Heating curves are represented by a black solid line, and cooling 
curves are represented by a red dashed line. Ellipticity displayed as a fraction of 
unfolded peptide. FM heating and cooling melt (a), FM(ox) heating and cooling melt 
(b), FA heating and cooling melt (c), AM heating and cooling melt (d), AM(ox) heating 
and cooling melt (e), and AA heating and cooling melt (f). 
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Figure 5-16. Principal Component Analysis. The variance for all principal 
components is shown as gray bars, and the cumulative percent variance is shown 
as red lines for all peptides. 
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FM PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 
σ 29.55 19.16 6.30 1.99 1.40 0.85 0.62 0.59 0.37 0.27 0.00 
Var Prop. 0.68 0.29 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cum. Prop. 0.68 0.96 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
FMx PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 
σ 17.12 15.89 5.03 1.62 1.46 0.93 0.67 0.55 0.36 0.32 0.00 
Var Prop. 0.51 0.44 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cum. Prop. 0.51 0.94 0.99 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
FA PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 
σ 10.00 5.69 0.66 0.46 0.36 0.29 0.23 0.21 0.18 0.14 0.00 
Var Prop. 0.75 0.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cum. Prop. 0.75 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
AM PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 
σ 24.56 23.44 1.30 0.87 0.59 0.52 0.42 0.31 0.23 0.16 0.00 
Var Prop. 0.52 0.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cum. Prop. 0.52 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
AMx PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 
σ 22.72 15.39 0.65 0.39 0.36 0.25 0.21 0.20 0.12 0.12 0.00 
Var Prop. 0.68 0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cum. Prop. 0.68 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
AA PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11 
σ 38.38 28.45 2.60 1.19 1.07 0.80 0.47 0.42 0.27 0.19 0.00 
Var Prop. 0.64 0.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Cum. Prop. 0.64 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Principal Component Analysis. The details of PCA for each peptide are shown as 
standard deviations, proportion of variance, and cumulative proportion of variance. 
 
 
Figure 5-17. S/Ar interactions in CaM simulations. The fractional occupancy of the 
unoxidized (black) and oxidized (gray) methionine aromatic interaction involving 
either M144 or M145 from the REMD simulation. 
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Figure 5-18. Hydrogen bonding of MOx144 and MOx145 with Y138 in the calmodulin 
simulations. The histogram shows that only a small fraction of Met-aromatic 
interactions involve a hydrogen bond. The methionine-aromatic distances were 
binned, and then the fraction of structures that were hydrogen bonded in each bin 
was plotted. 
 
Figure 5-19. Distribution of distances in CaM, from MD simulation , between 
sulfoxide and center of aromatic ring of Y138-M144 (a) and Y138-M145 (b). (c). A 
snapshot from MD simulation showing the interaction between Y138 and M145.  (d) 
EPR spectra (200 G scan width, inset shows expanded view of a 50-G portion of the 
low-field spectra) of CaM spin-labeled at V136 and Y138, showing residuals to fits. 
(e) Distribution of distances from fits. For unoxidized CaM, residuals show that the 
a b
Distance (Å) Distance (Å) 
c
Unoxidized 
Oxidized 
Unoxidized 
Oxidized 
d e
  143 
2-Gaussian fit is no better than the 1-Gaussian fit, which is thus shown in Figure 5-
4.  For oxidized CaM, the 2-Gaussian fit is superior and is thus shown in Figure 5-4. 
 
 
Figure 5-20. Hydrogen bonding in the molecular dynamics simulations of LTα. The 
fraction of frames in which hydrogen bonding occurs for the range of methionine-
aromatic distances. The methionine-aromatic distances were binned, then the 
fraction of structures that were hydrogen bonded in each bin were plotted. In all 
three simulations, the fraction of structures that are hydrogen bonded is small. 
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Figure 5-21. RMSD of the binding pocket for the MOx120-Y122 interacting 
configuration. The RMSD is shown for the binding pocket (all ligand and receptor 
residues within 15 Å of MOx120) for the 3 ligand chains. All three binding pockets 
are stable. 
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Figure 5-22. Tryptophan fluorescence of LTα after exposure to oxidative stress. LTα 
was left untreated or oxidized as in cell experiments, and its fluorescence emission 
spectrum was measured after ~18 hours. The unfolded control sample was 
dissolved in 8M urea for several hours before measuring its emission spectrum. 
Fluorescence emission wavelength scans from 300 – 400 nm were taken on a Varian 
Cary Eclipse Fluorescence spectrometer at an excitation wavelength of 280 nm and 
a scan rate of 30 nm/min. Excitation and emission slits were set to 5 nm. The 
emission spectra were normalized between 0 and 1. Total unfolding in 8M urea 
causes tryptophan residues to become exposed to polar solvent, resulting in a red-
shifted emission spectrum (red). Exposure of LTα to oxidative stress does not 
result in red-shifting of the emission spectrum (blue) compared with the untreated 
LTα spectrum (green), indicating that the ligand is stably folded. 
 
Stage Receptor Ligand Steps 
 Backbone Sidechain Backbone Sidechain  
1 1 1 1 1 106 
2 0.1 1 1 1 106 
3 0.01 1 1 1 106 
4 0 1 1 1 106 
5 0 0.1 1 1 106 
6 0 0.01 1 1 106 
7 0 0.005 1 1 106 
8 0 0 1 1 106 
9 0 0 0.1 1 106 
10 0 0 0.01 1 106 
11 0 0 0 1 106 
12 0 0 0 0.1 106 
13 0 0 0 0.01 106 
14 0 0 0 0.005 106 
15 0 0 0 0 106 
Table 5-9. Relaxation schedule for the MOx120-receptor complex simulations. 
Restraint spring constants are given in kcal/mol/Å2. 
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Chapter 6 – Rationally selected mutations in the TNFR1 
preligand assembly domain ablate self-interactions but 
preserve ligand binding 
6.1. Introduction 
Tumor necrosis factor receptor (TNFR) 1 is the prototypical member of the 
TNFR superfamily. When activated, it triggers pro-inflammatory signaling via a 
well-characterized signaling cascade that culminates in activation of NF-κB (72). 
TNFR1 exists on the membrane as self-associated homodimers (55), which are 
bound and activated by its cognate ligands, TNF and LTα (58). Members of the 
TNF receptor superfamily are notable for having extracellular domains comprised 
of multiple cysteine-rich domains (CRDs). TNFR1 in particular contains 4 CRDs, 
each consisting of 3 pairs of disulfide-linked cysteines (75). CRD1 is also known 
as the preligand assembly domain (PLAD) and is responsible for receptor self-
association (55), while ligand binding occurs through CRD2 and CRD3 (8). The 
long standing model for activation holds that homotrimeric ligand binds to TNFR1 
to bring together 3 receptor chains. The TNFR1 cytosolic death domains are 
consequently trimerized, and with this stoichiometry, are then able to bind 
intracellular adapter proteins. However, this model does not explain the 
significance of preligand receptor dimers, nor does it explain overexpression-
induced activation (19) and spontaneous activation in disease mutants (37). 
The trimerization model also does not suggest a role for ligand/receptor 
clusters that form on the cell membrane, modeled by us and others as organized 
lattices (43, 56, 57, 60-62). Structural analysis indicates that the TNFR1 PLAD and 
  147 
ligand-binding  interfaces are distinct and distant from each other. Thus the 
receptor homodimer survives ligand binding to produce a hexagonal network of 
receptor-receptor edges linked by trimeric ligand/receptor vertices. 
We have recently uncovered evidence for an alternative mechanism of TNF 
receptor activation involving conformational change of the receptor dimer (60). In 
our proposed model, ligand/receptor, receptor/receptor, and receptor/membrane 
interactions combine to produce a reconfiguration of the extracellular domain upon 
ligand/receptor network formation. The signal mechanically propagates through 
the cell membrane by hinging of the transmembrane helices (53) to expose the 
cytosolic death domains and allow them to bind adapter proteins. This model does 
not require receptor trimerization to form the signaling apparatus, permitting ligand-
independent activation. 
In light of the evidence that receptor dimers initiate signaling, we 
hypothesized that disruption of dimers by mutagenesis in the PLAD would inhibit 
ligand-independent TNFR1 activity. TNFR1 inhibition is an active area of 
therapeutic interest. Currently available therapies acting on the TNFR1 pathway, 
including Etanercept, Adalimumab, and Infliximab, work by sequestering TNF or 
LTα and reducing its bioavailability (245). However, these drugs can cause 
significant life-threatening side-effects and are not always effective (246, 247). 
Deng et al. previously targeted receptor dimerization to ameliorate inflammatory 
signaling due to abnormal TNFR1 activity using a soluble PLAD peptide (27). 
However, sPLAD also prevented ligand binding and the study did not decouple 
loss of signaling due to reduced receptor self-association and ligand blockade, a 
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critical distinction if we are to engineer a novel therapeutic strategy for TNFR 
inhibition.  
Chan et al. performed a mutagenic analysis of the TNFR1 dimerization 
domain in their seminal study of the TNFR1/2 preligand assembly domains (55). 
Among their mutants, KY19/20AA and K32A were found to disrupt receptor self-
association. However, these mutations affect amino acids (Y20 and K32) that are 
buried and form extensive intra-protomeric contacts, especially joining CRD1 to 
CRD2. Thus, they cannot be reasonably expected to preserve the native protein 
fold. Indeed, both mutants showed reduced binding to the conformation-selective 
monoclonal antibodies MAB225 and Clone 4.12. Deletion of the PLAD in its 
entirety (residues 1-55) was likewise found not to dimerize or bind ligand and 
several have noted that this modification is not expected to result in wholesale 
conformational disruption due to its apparent stability as an isolated module (248-
251). The PLAD deletion mutant did have an intact binding epitope for MAB225, 
but not Clone 4.12. However the epitopes of these antibodies were not known so 
deletion of residues 1-55 may have either removed or deformed the antibody 
epitope. Branschadel et al. have alternatively argued a scaffold role for CRD1, 
wherein non-covalent contacts between CRD1 and CRD2 are necessary to 
preserve the ligand-binding interface of CRD2 and CRD3 (76). 
Proper folding of TNFR1 has more recently been shown to be highly-
sensitive to point mutations in CRD1 and elsewhere. Lobito et al. showed the 
formation of disulfide-linked oligomers (an indication that intramolecular disulfide 
bonds are not forming correctly) in the H22Y, C33G, T50M, C52F, C88R, and 
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R92P mutants associated with TRAPS. Mutation of any cysteine obviously results 
in a mismatch of disulfide pairs and misfolding is not surprising. H22 and T50, like 
Chan’s Y20 and K32 mutations, project into the protein core and make intra-
molecular contacts. R92Q is notable for folding correctly and retaining its ability to 
bind ligand, but R92P disrupts both. 
This study mutates rationally selected amino acids in the PLAD to ablate 
receptor dimers. We hypothesize that TNFR1 signaling can be inhibited in a 
manner not dependent on ligand-blockade, by reducing dimerization affinity of the 
receptor. Future studies will target receptor dimerization by small-molecule 
inhibition. 
6.2. Materials and Methods 
6.2.1 Plasmid preparation and transfection 
All plasmids encoding TNFR1 were generated using standard cloning 
technique. The pEXFP-n1-TNFR1 constructs were prepared previously(60) and 
pCMV6-XL5 TNFR1 was purchased from Origene. All mutations were introduced 
by Quikchange mutagenesis and sequenced to ensure the correct sequence. pGL-
NF-κB and pRL-CMV were purchased from Promega. FLAG-LTα was expressed, 
purified, and dialyzed in our lab as described previously(43). 
Transient transfection was carried out using the calcium phosphate method. 
HEK293 cells, maintained in DMEM with 10% FBS, 4mM L-Glutamine, and 
penicillin/streptomycin were plated at ~20% confluence in 12-well, 6-well, or 10 cm 
plates. Transfectant volume and total DNA was scaled according to culture 
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volume. The following day, cells were transfected by adding 50 μL transfection 
mixture with 1 μg total DNA to every 1 mL of media. 
6.2.2 FRET 
HEK293 cells were transfected with 0.5 μg pECFP-TNFR1ΔCD and 1.5 μg 
pEYFP-TNFR1ΔCD in a 12-well plate. The following day, cells were lifted with 
TrypLE, resuspended in phenol red-free DMEM, and plated on poly-D-Lysine 
coated plates. Cells were allowed to settle at room temperature for 1 hour before 
imaging. Live-cell FRET imaging was performed on a Nikon Eclipse TE200 
inverted microscope and a 20x objective configured as in our previous study (60) 
with minor modifications detailed here. Cells were imaged in the EYFP and ECFP 
channels every 15 s for 5 min. Between image captures, acceptor was bleached 
by continuous exposure through the EYFP excitation channel. Image analysis was 
carried out in ImageJ. FRET efficiency of each cell was determined as the intercept 
of the linear fit of normalized EYFP fluorescence plotted against ECFP 
enhancement. FRET efficiencies were plotted against EYFP intensity of individual 
cells and fit to a two-parameter saturable binding curve. 
6.2.3 Co-immunoprecipitation 
Co-immunoprecipitation was performed using anti-FLAG M2 agarose 
beads (Invitrogen) according to the manufacturer instructions. 1 μg pCMV6-XL5-
TNFR1 and 9 μg pCDNA3.1 (for correct total DNA) were transfected into HEK293 
cells in a 10 cm plate. After 48 hours, cells were lifted by gentle shearing, washed, 
and then resuspended in ice-cold PBS, then transferred to 1.5 mL centrifuge tubes. 
FLAG-LTα was added at 20 ng/mL and incubated for 30 minutes at 4 °C. Cells 
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were then washed 3 times in ice-cold PBS and resuspended in RIPA lysis buffer. 
Co-immunoprecipitated samples were incubated with M2 agarose beads overnight 
with rocking at 4 °C. TNFR1 was detected by Western blot using rabbit α-TNFR1 
(Abcam, ab19139). 
6.2.4 NF-κB luciferase reporter assay 
HEK293 cells were transfected one day after seeding in a 6-well plate with 
0.1 μg pCMV6-XL5-TNFR1, 0.1 μg pRL-CMV, 1 μg pGL4.32-(NFκB)-RE, and 0.8 
μg pCDNA3.1. After 48 hours, cells were lifted with TrypLE, resuspended in phenol 
red-free DMEM, and seeded in octuplicate into 384-well plates. Firefly and renilla 
luciferase was measured using the Promega Dual-Glo kit according to the 
manufacturer instructions. 
6.3. Results 
6.3.1 Analysis of the TNFR1 dimerization interface 
We first analyzed the crystal structure of the TNFR1 extracellular domain 
dimer (1ncf) to select residues that stabilize interactions between protomer chains, 
but are not expected to play a substantial architectural role within the protomer. 
Such residues are found in CRD1 with sidechains that project away from the 
protein core and are within 5 Å of reactive atoms on the opposite chain (Figure 6-
1). We first identified 4 residues that satisfied these criteria. Glutamine is a 
potential hydrogen bond donor or acceptor and Q17 is in range of the backbone 
or sidechains of K35 and G36 and the sidechain of E54 of the opposite protomer. 
K19 is positively charged and can potentially form a salt bridge with D49. H34 
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potentially stacks with its counterpart on the opposite chain, and may also serve 
as a hydrogen donor to the backbone oxygen of C33. Lastly, Q48 can potentially 
hydrogen bond with its opposite. 
 
Figure 6-1. Selected residues for mutation and their interaction partners in the 
TNFR1 PLAD. 
6.3.2 Selected mutants in the PLAD reduce dimer affinity 
To determine whether selected polymorphisms of interacting PLAD 
residues can reduce the dimerization affinity of TNFR1, we tested our mutants 
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using a previously established photobleaching FRET assay (60). We first 
subcloned plasmids for each TNFR1 mutant in which an ECFP or EYFP 
fluorophore was inserted in place of its death domain. The plasmids were then 
cotransfected in a 4:1 EYFP:ECFP ratio to increase the percentage of donors 
fluorophores that would dimerize with acceptors. Normalized ECFP-enhancement 
was plotted against EYFP depletion and the intercept where EYFP would be fully 
bleached was taken as FD (fluorescence in absence of acceptor). The initial ECFP 
was normalized to unity and taken as FDA (fluorescence in presence of acceptor). 
FRET efficiency was calculated as FRET = 1-(FDA/FD) (252). All mutants displayed 
an essentially linear donor-enhancement vs. acceptor-depletion profile, indicating 
that our FRET constructs, and by extension, our TNFR1 mutants are dimeric (91). 
The plot of FRET efficiency vs. EYFP for each cell can be fit to a two-
parameter saturable binding curve to extract dissociation constant (Kd) and 
FRETmax (an indicator of how near the fluorophores are when dimerized) (Figure 
6-4) (82, 90). In the case of our mutants, we expect an increase in Kd, which 
corresponds to reduced dimer affinity and a larger monomer population. FRETmax 
is not expected to change. We observed (Figure 6-2) a nearly 5-fold increase in Kd 
for K19A and H34A and more than a 5-fold increase in Kd for Q48A compared to 
wild type. The Q17A mutation did not substantially affect Kd. This indicates that we 
can modulate the proportion of TNFR1 dimers by rationally selected point 
mutations. However, this assay cannot rule out the possibility that misfolding of 
receptors is interrupting dimerization. 
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Figure 6-2. Kd as determined from fitting acceptor-selective photobleaching FRET 
data to a two-parameter binding curve. Q17A dimerizes with roughly the same 
affinity as WT. All other mutants (Q17A, K19A, H34A, Q48A, and the triple mutant 
Q17AK19AQ48A) result in a > 3-fold increase in Kd. 
 
6.3.3 Reduced dimer affinity does not necessarily prevent ligand binding 
We co-immunoprecipitated TNFR1 with its ligand, LTα, to indicate whether 
TNFR1 mutants are properly folded and to show that mutations reducing dimer 
affinity do not necessarily ablate ligand-binding. Previous studies have suggested 
that receptor dimerization is necessary for ligand binding, however this hypothesis 
does not resonate with analysis of the TNFR1 structures, which clearly shows the 
ligand-binding and dimerization motifs to be distinct. This is the first study that 
rationally targets the PLAD while trying to preserve receptor conformation and 
especially ligand-binding affinity. None of the selected mutants is directly involved 
in ligand binding or stabilizing the monomer architecture. 
Co-immunoprecipitation of LTα with transiently transfected full-length 
(death domain included) TNFR1 mutants revealed that ligand-binding and 
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dimerization affinity are not strictly correlated (Figure 6-3). Endogenous expression 
levels of TNFR1 were not detectable, therefore the visible bands on the Western 
Blots are the transfected mutants. H34 is included in the binding epitope of 
Ab19139, thus it did not appear on the IP or WCE blot and we cannot conclude 
whether it binds ligand. W107A was previously shown to reduce ligand binding 
(43) and is included here as a control. Other than H34A, all mutants were 
confirmed to bind ligand. Q17A appears to bind less LTα. K19A appears to bind 
more ligand, but this may be a consequence of slightly greater protein load on the 
gel (see whole cell extract, WCE). Q48A also appears to bind ligand more avidly. 
Our mutants do not completely abolish dimerization, however a loss in dimer 
affinity should correspond to a smaller number of TNFR1 dimers on the membrane 
and would produce a commensurate loss in ligand-binding if the latter 
phenomenon were directly dependent on receptor self-association. Therefore, 
these data reject the hypothesis that dimerization is required for ligand binding. 
 
Figure 6-3. Co-Immunoprecipitation of TNFR1 mutants with FLAG-tagged LTα.  
Q17A, K19A, Q48A, and W107A all bind to LTα. Binding efficiency was reduced with 
Q17A and W107A (as we have previously shown (175)). Binding to Q48A is 
enhanced. H34 is in the binding epitope of Ab19139 and its mutant was not labeled. 
TNFR1 in untransfected (UT) cells was undetectable. 
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6.4. Concluding remarks 
We have shown that dimerization affinity of TNFR1 can be modulated by 
introducing rationally selected mutants to the PLAD in the extracellular domain. 
Moreover, we are the first to show that TNFR1 self-assembly and ligand binding 
ability are not necessarily tied in live cells – that is, our data suggest that TNFR1 
monomers are able to bind to ligand. This agrees with a study that first determined 
the stoichiometry of binding between soluble TNFR1 ECD monomers and LTα 
(58).  
Our data deal exclusively with the extracellular domain and do not address 
the potential influence of death domain (94, 95) or transmembrane self-
interactions. The transmembrane domain does not contain any obvious 
dimerization motifs, except for a cysteine at its midpoint that has thus far not been 
shown to form disulfide bonds (55). However, death domain aggregation is a noted 
finding across the death receptor family (94). Our FRET constructs do not contain 
death domains, and it is not known how reduced dimerization affinity in the ECD 
will balance with the dimerization affinity of the whole protein. Previous studies 
have shown TNFR1 signaling to be sensitive to extracellular mutations (253), 
therefore cytosolic interactions are not expected to dominate receptor self-
association. 
Lastly, the goal of this research is to demonstrate whether the TNFR1 dimer 
is a potential target for modulating its activity. No currently available drug acts on 
the TNFR1 dimer, although this strategy has been proposed as early as 2000 (254) 
and has proven successful in animal models (27). However, in that study, 
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ligand/receptor binding was also prevented, leading to doubt as to whether the 
observed effects were due to receptor dissociation or ligand blockade. This is an 
important distinction if we are to fully understand activation/inhibition mechanisms 
for TNFR1 and generalize to other TNFRs, for which there is therapeutic interest 
in both agonistic and antagonistic drugs. To explore whether receptor dissociation 
can be exploited for potential therapeutic applications, ongoing work will determine 
whether dimer ablation correlates to a loss of both ligand-independent and ligand-
induced signaling of the NF-κB pathway. Lastly, future efforts will work towards 
identifying small-molecule drugs to affect self-association of TNFR1, DR5, and 
other death receptors. 
 
6.5. Supplementary Figures 
 
Figure 6-4. Individual plots of FRET vs. EYFP intensity for wild type TNFR1 (A), 
Q17A (B), K19A (C), H34A (D), Q48A (E), and Q17A K19A Q48A (F). Each fit to a two-
parameter saturable binding curve is shown. 
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Chapter 7 – Concluding remarks and future work 
The work here represents only a single facet of the broader goal of the 
Sachs lab of fully characterizing ligand/receptor networks formed by members of 
the TNFR superfamily. We show that in the cases of TNFR1 and DR5-L, 
conformational change occurs at the level of the receptor dimer which is subsumed 
within a networks. However, we still only have a model of what these networks look 
like. They certainly contain receptor/receptor and ligand/receptor interactions, but 
several features have yet to be characterized including network size, binding site 
saturation, kinetics of their formation, stability, and of course, definitive proof of 
their arrangements. Certainly a crystal structure of the pre-ligand DR5 (a dimer 
based on the TM domain, a trimer based on cross-linking studies, or perhaps both 
exist) would help illuminate the arrangement of those networks. After TNFR1 and 
DR5, there remain the 27 other members of the TNFR superfamily, not to mention 
all possible arrangements with ligands. At least for TNFR1, all evidence points to 
hexagonal lattices, but this has yet to be seen. Unfortunately, the feature size lies 
below the diffraction limit and traditional light microscopy will provide little more 
utility than it already has. Super-resolution methods have recently advanced and 
hold promise, with precision in the range of tens of nanometers, but significant 
improvement must still occur before we can observe network structure. 
As far as translating our findings for therapeutic use, there is still much 
insight to be gained as to the functional significance of ligand/receptor networks. 
The crystal structure of the LTα-TNFR1 trimer complex was solved in 1993 and 
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experimental evidence for trimerization had emerged shortly before that, however 
these described only the binding stoichiometry of the TNFR1 extracellular domain. 
Francis Chan’s crosslinking studies showed that in live cells, networks are found, 
not trimer complexes. So in functional cell studies, we always observe network-
induced activation, not ligand-induced activation. This dissertation provides 
evidence that receptor dimers are the minimal functional subunit for activation, 
however we cannot rule out that receptor aggregation due to ligand binding would 
similarly induce some activation. Networks likely also create synergistic effects due 
to elevated local concentrations of signaling components. This could amplify 
signals in both the extracellular and cytosolic spaces through phenomena such as 
ligand passing. Thus, there is still interest in determining the functional potency of 
individual ligand/receptor trimer complexes and what bioactivity is gained by 
network-induced change in local concentration. 
We have also begun to further characterize the functional significance of 
TNFR1 dimerization, both in the absence of ligand and when ligand bound, 
following the lead set up in chapter 6. Ongoing efforts hope to show that disruption 
of TNFR1 dimerization results in a concomitant loss in TNFR1 function. This will 
prove the TNFR1 PLAD as a viable site for inhibitory binding of small molecules or 
antibodies. We have tested several mutants that reduce dimerization affinity, but 
do not fully abolish it. Combining mutants and introducing more may accomplish 
this. We expect that total ablation of TNFR1 dimers would result in the dissociation 
of ligand/receptor networks and the difference may be observable by confocal 
microscopy. 
  160 
Disrupting TNFR1 dimers is one approach for inhibiting TNFR1 activity. The 
other strategy is to lock TNFR1 in its closed, inactive conformation (although 
TNFR1 antagonists and agonists are both of interest). We have developed a FRET 
assay for activation as detailed in Chapter 2 and 6 and can determine a FRETmax 
proportional to the distance between the donor and acceptor fluorophores and a 
KD, which provides a measure of binding kinetics. Fluorescent lifetime detection 
provides both of these pieces of information with a single measurement and in a 
high-throughput format. Thus, our lab is currently screening for small molecules 
that modulate TNFR1 dimerization kinetics, cytosolic domain separation, or both. 
This strategy is being extended to DR5 with the hope of finding agonists that 
entirely bypass network formation and might better overcome TRAIL resistance. 
Identified agonists and antagonists will then be subjected to the usual IκBα or 
caspase 8 detection assays to determine whether they are also functionally 
effective. Small molecule modulators of TNFR activity represent a novel approach 
and we hope that this strategy will provide safer and more effective drugs for 
inflammatory disease and cancer.  
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